In addition , PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned $T1$ , thereby excluding the possibility that the p76 $T2$ is a previously undescribed splice variant of the cloned IL-7R .
IL-7R
IL-7R
0
These analyses showed that the ability of PBMC to proliferate to $T1$ correlated with expression of the $T2$ IL-7R , and not with expression of the p90 IL-7R .
IL-7
p76
0
These analyses showed that the ability of PBMC to proliferate to $T1$ correlated with expression of the p76 $T2$ , and not with expression of the p90 IL-7R .
IL-7
IL-7R
0
These analyses showed that the ability of PBMC to proliferate to $T1$ correlated with expression of the p76 IL-7R , and not with expression of the $T2$ IL-7R .
IL-7
p90
0
These analyses showed that the ability of PBMC to proliferate to $T1$ correlated with expression of the p76 IL-7R , and not with expression of the p90 $T2$ .
IL-7
IL-7R
0
These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the $T1$ $T2$ , and not with expression of the p90 IL-7R .
p76
IL-7R
0
These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the $T1$ IL-7R , and not with expression of the $T2$ IL-7R .
p76
p90
0
These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the $T1$ IL-7R , and not with expression of the p90 $T2$ .
p76
IL-7R
0
These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the p76 $T1$ , and not with expression of the $T2$ IL-7R .
IL-7R
p90
0
These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the p76 $T1$ , and not with expression of the p90 $T2$ .
IL-7R
IL-7R
0
In addition , PCR analysis of $T1$-expressing cells could not detect splicing of the extracellular domain of the cloned IL-7R , thereby excluding the possibility that the $T2$ IL-7R is a previously undescribed splice variant of the cloned IL-7R .
p76
p76
0
In addition , PCR analysis of $T1$-expressing cells could not detect splicing of the extracellular domain of the cloned $T2$ , thereby excluding the possibility that the p76 IL-7R is a previously undescribed splice variant of the cloned IL-7R .
p76
IL-7R
0
These analyses showed that the ability of PBMC to proliferate to IL-7 correlated with expression of the p76 IL-7R , and not with expression of the $T1$ $T2$ .
p90
IL-7R
0
These antibodies also immunoprecipitated the cloned $T1$ as a 90-kDa species from both 125-I-surface-labeled resting and activated T cells , but were unable to precipitate the 76-kDa $T2$ .
IL-7R
IL-7R
0
In addition , PCR analysis of p76-expressing cells could not detect splicing of the extracellular domain of the cloned $T1$ , thereby excluding the possibility that the $T2$ IL-7R is a previously undescribed splice variant of the cloned IL-7R .
IL-7R
p76
0
$T1$-driven proliferation is mediated via high affinity $T2$ , and accordingly , Scatchard analysis revealed that , like the p90 IL-7R , the p76 IL-7R bound IL-7 with dual ( high ; Kd 38 pM and low ; Kd 360 pM ) affinity .
IL-7
IL-7R
0
$T1$-driven proliferation is mediated via high affinity IL-7R , and accordingly , Scatchard analysis revealed that , like the $T2$ IL-7R , the p76 IL-7R bound IL-7 with dual ( high ; Kd 38 pM and low ; Kd 360 pM ) affinity .
IL-7
p90
0
IL-7-driven proliferation is mediated via high affinity $T1$ , and accordingly , Scatchard analysis revealed that , like the $T2$ IL-7R , the p76 IL-7R bound IL-7 with dual ( high ; Kd 38 pM and low ; Kd 360 pM ) affinity .
IL-7R
p90
0
In agreement , mAb to the previously cloned IL-7R were found to stain unstimulated T cells that express only the p90 IL-7R but not T-cell clones that express predominantly the $T1$ $T2$ .
p76
IL-7R
0
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , FADD/MORT , RIP , FLICE/$T1$ , and TRAFs ) associated with both of the $T2$ and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .
MACH
p60
1
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , FADD/MORT , RIP , FLICE/$T1$ , and TRAFs ) associated with both of the p60 and $T2$ forms of the TNF receptor and with other members of the TNF receptor superfamily .
MACH
p80
1
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , FADD/MORT , RIP , $T1$/MACH , and TRAFs ) associated with both of the $T2$ and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .
FLICE
p60
1
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , FADD/MORT , RIP , $T1$/MACH , and TRAFs ) associated with both of the p60 and $T2$ forms of the TNF receptor and with other members of the TNF receptor superfamily .
FLICE
p80
1
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , FADD/$T1$ , RIP , FLICE/MACH , and TRAFs ) associated with both of the $T2$ and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .
MORT
p60
1
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , FADD/$T1$ , RIP , FLICE/MACH , and TRAFs ) associated with both of the p60 and $T2$ forms of the TNF receptor and with other members of the TNF receptor superfamily .
MORT
p80
1
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( $T1$ , FADD/MORT , RIP , FLICE/MACH , and TRAFs ) associated with both of the p60 and $T2$ forms of the TNF receptor and with other members of the TNF receptor superfamily .
TRADD
p80
1
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , $T1$/MORT , RIP , FLICE/MACH , and TRAFs ) associated with both of the $T2$ and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .
FADD
p60
1
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( $T1$ , FADD/MORT , RIP , FLICE/MACH , and TRAFs ) associated with both of the $T2$ and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .
TRADD
p60
1
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , FADD/MORT , $T1$ , FLICE/$T2$ , and TRAFs ) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .
RIP
MACH
0
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , FADD/MORT , RIP , $T1$/$T2$ , and TRAFs ) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .
FLICE
MACH
0
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( $T1$ , FADD/MORT , RIP , FLICE/$T2$ , and TRAFs ) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .
TRADD
MACH
0
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , FADD/$T1$ , RIP , FLICE/$T2$ , and TRAFs ) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .
MORT
MACH
0
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , $T1$/MORT , RIP , FLICE/$T2$ , and TRAFs ) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .
FADD
MACH
0
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , FADD/MORT , $T1$ , FLICE/MACH , and TRAFs ) associated with both of the $T2$ and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .
RIP
p60
0
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , FADD/MORT , RIP , FLICE/MACH , and TRAFs ) associated with both of the $T1$ and $T2$ forms of the TNF receptor and with other members of the TNF receptor superfamily .
p60
p80
0
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , FADD/MORT , $T1$ , $T2$/MACH , and TRAFs ) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .
RIP
FLICE
0
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , FADD/MORT , $T1$ , FLICE/MACH , and TRAFs ) associated with both of the p60 and $T2$ forms of the TNF receptor and with other members of the TNF receptor superfamily .
RIP
p80
0
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( $T1$ , FADD/MORT , $T2$ , FLICE/MACH , and TRAFs ) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .
TRADD
RIP
0
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , FADD/$T1$ , $T2$ , FLICE/MACH , and TRAFs ) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .
MORT
RIP
0
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , $T1$/MORT , $T2$ , FLICE/MACH , and TRAFs ) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .
FADD
RIP
0
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( $T1$ , FADD/MORT , RIP , $T2$/MACH , and TRAFs ) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .
TRADD
FLICE
0
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , FADD/$T1$ , RIP , $T2$/MACH , and TRAFs ) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .
MORT
FLICE
0
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , $T1$/MORT , RIP , $T2$/MACH , and TRAFs ) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .
FADD
FLICE
0
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , $T1$/MORT , RIP , FLICE/MACH , and TRAFs ) associated with both of the p60 and $T2$ forms of the TNF receptor and with other members of the TNF receptor superfamily .
FADD
p80
0
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( $T1$ , FADD/$T2$ , RIP , FLICE/MACH , and TRAFs ) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .
TRADD
MORT
0
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( $T1$ , $T2$/MORT , RIP , FLICE/MACH , and TRAFs ) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .
TRADD
FADD
0
The cloning of members of these gene families and the identification of the protein-interaction motifs found within their gene products has initiated the molecular identity of factors ( TRADD , $T1$/$T2$ , RIP , FLICE/MACH , and TRAFs ) associated with both of the p60 and p80 forms of the TNF receptor and with other members of the TNF receptor superfamily .
FADD
MORT
0
We postulate that the mechanism of bone induction is based on the secretion of bone morphogenetic proteins $T1$ and $T2$ by the grafted HeLa cells .
BMP-4
BMP-6
0
$T1$ and $T2$ involvement in the osteogenic properties of the HeLa cell line .
BMP-4
BMP-6
0
A protein , sorting nexin-1 ( $T1$ ) , was identified in a human cell line that bound to a region of the epidermal growth factor receptor ( $T2$ ) containing the lysosomal targeting code .
SNX1
EGFR
1
A protein , $T1$ ( SNX1 ) , was identified in a human cell line that bound to a region of the epidermal growth factor receptor ( $T2$ ) containing the lysosomal targeting code .
sorting nexin-1
EGFR
1
A protein , sorting nexin-1 ( $T1$ ) , was identified in a human cell line that bound to a region of the $T2$ ( EGFR ) containing the lysosomal targeting code .
SNX1
epidermal growth factor receptor
1
A protein , $T1$ ( SNX1 ) , was identified in a human cell line that bound to a region of the $T2$ ( EGFR ) containing the lysosomal targeting code .
sorting nexin-1
epidermal growth factor receptor
1
A protein , sorting nexin-1 ( SNX1 ) , was identified in a human cell line that bound to a region of the $T1$ ( $T2$ ) containing the lysosomal targeting code .
epidermal growth factor receptor
EGFR
0
A protein , $T1$ ( $T2$ ) , was identified in a human cell line that bound to a region of the epidermal growth factor receptor ( EGFR ) containing the lysosomal targeting code .
sorting nexin-1
SNX1
0
$T1$ contains a region of homology to a yeast vacuolar sorting protein , and overexpression of SNX1 decreased the amount of $T2$ on the cell surface as a result of enhanced rates of constitutive and ligand-induced degradation .
SNX1
EGFR
0
SNX1 contains a region of homology to a yeast vacuolar sorting protein , and overexpression of $T1$ decreased the amount of $T2$ on the cell surface as a result of enhanced rates of constitutive and ligand-induced degradation .
SNX1
EGFR
0
Thus , $T1$ is likely to play a role in sorting $T2$ to lysosomes .
SNX1
EGFR
0
$T1$ contains a region of homology to a yeast vacuolar sorting protein , and overexpression of $T2$ decreased the amount of EGFR on the cell surface as a result of enhanced rates of constitutive and ligand-induced degradation .
SNX1
SNX1
0
Enhanced degradation of $T1$ receptors by a sorting nexin , $T2$ .
EGF
SNX1
0
Enhanced degradation of $T1$ receptors by a sorting $T2$ , SNX1 .
EGF
nexin
0
Enhanced degradation of EGF receptors by a sorting $T1$ , $T2$ .
nexin
SNX1
0
In addition , a possible role for $T1$ , the product of $T2$ , in atherosclerotic lesion development is put into perspective .
Gas6
growth arrest-specific gene 6
0
This overview summarizes the current knowledge on $T1$ ( $T2$ ) in the progression of atherosclerosis and the influence of MMPs in aneurysm formation .
plasminogen activator inhibitor-1
PAI-1
0
The splicing factor U2AF ( U2 snRNP auxiliary factor ) is a heterodimer with subunits of 65 and 35 kD ( $T1$ and $T2$ ) .
U2AF65
U2AF35
1
Nuclear extracts deficient in $T1$ were inactive ; however , both constitutive and enhancer-dependent splicing could be restored by the addition of purified recombinant $T2$ .
U2AF35
U2AF35
0
$T1$ binds specifically to 3 ' splice sites , but previous studies failed to demonstrate a function for $T2$ .
U2AF65
U2AF35
0
In vitro protein-RNA interaction studies with pre-mRNAs containing either a constitutive or regulated splicing enhancer revealed that $T1$ directly mediates interactions between $T2$ and proteins bound to the enhancers .
U2AF35
U2AF65
0
Thus , $T1$ functions as a bridge between $T2$ and the enhancer complex to recruit U2AF65 to the adjacent intron .
U2AF35
U2AF65
0
Thus , $T1$ functions as a bridge between U2AF65 and the enhancer complex to recruit $T2$ to the adjacent intron .
U2AF35
U2AF65
0
Thus , U2AF35 functions as a bridge between $T1$ and the enhancer complex to recruit $T2$ to the adjacent intron .
U2AF65
U2AF65
0
Furthermore , p21 blocks the ability of $T1$ to activate $T2$ , the principal replicative DNA polymerase .
PCNA
DNA polymerase delta
1
This regulation results from a direct interaction between $T1$ and $T2$ .
p21
PCNA
1
Here we use simian virus 40 DNA replication in vitro to show than $T1$ directly inhibits $T2$-dependent DNA replication in the absence of a cyclin/CDK .
p21
PCNA
1
Furthermore , $T1$ blocks the ability of $T2$ to activate DNA polymerase delta , the principal replicative DNA polymerase .
p21
PCNA
1
In normal human cells , but not in many tumour cells , $T1$ exists in a quaternary complex with a cyclin , a CDK , and the $T2$ ( PCNA ) .
p21
proliferating-cell nuclear antigen
1
In normal human cells , but not in many tumour cells , $T1$ exists in a quaternary complex with a cyclin , a CDK , and the proliferating-cell nuclear antigen ( $T2$ ) .
p21
PCNA
1
The $T1$ inhibitor of cyclin-dependent kinases controls DNA replication by interaction with $T2$ .
p21
PCNA
1
The $T1$ tumour-suppressor protein controls the expression of a gene encoding the $T2$ cyclin-dependent protein kinase ( CDK ) regulator .
p53
p21
0
Levels of $T1$ protein are increased in senescent cells and $T2$ overexpression blocks the growth of tumour cells .
p21
p21
0
$T1$ controls CDK activity , thereby affecting cell-cycle control , whereas $T2$ functions in both DNA replication and repair .
p21
PCNA
0
In normal human cells , but not in many tumour cells , p21 exists in a quaternary complex with a cyclin , a CDK , and the $T1$ ( $T2$ ) .
proliferating-cell nuclear antigen
PCNA
0
Furthermore , $T1$ blocks the ability of PCNA to activate $T2$ , the principal replicative DNA polymerase .
p21
DNA polymerase delta
0
Thus , during $T1$-mediated suppression of cell proliferation , p21 and $T2$ may be important for coordinating cell-cycle progression , DNA replication and repair of damaged DNA .
p53
PCNA
0
Thus , during p53-mediated suppression of cell proliferation , $T1$ and $T2$ may be important for coordinating cell-cycle progression , DNA replication and repair of damaged DNA .
p21
PCNA
0
Thus , during $T1$-mediated suppression of cell proliferation , $T2$ and PCNA may be important for coordinating cell-cycle progression , DNA replication and repair of damaged DNA .
p53
p21
0
Several genes are involved in this process , and two have been the focus of recent interest : the $T1$ ( NRAMP1 ) gene and the genes coding for the $T2$ .
natural resistance-associated protein
vitamin D receptor
0
Several genes are involved in this process , and two have been the focus of recent interest : the $T1$ ( $T2$ ) gene and the genes coding for the vitamin D receptor .
natural resistance-associated protein
NRAMP1
0
Several genes are involved in this process , and two have been the focus of recent interest : the natural resistance-associated protein ( $T1$ ) gene and the genes coding for the $T2$ .
NRAMP1
vitamin D receptor
0
Positive inotropic responses mediated by endothelin $T1$ and $T2$ receptors in human myocardial trabeculae .
ET(A)
ET(B)
0
The aim of the present study was to determine possible inotropic effects mediated by endothelin $T1$ and $T2$ receptors in human myocardial trabeculae from the right atrium and the left ventricle .
ET(A)
ET(B)
0
Endothelin-1 ( $T1$ ) and $T2$ had a strong positive inotropic effect in all trabeculae .
ET-1
ET-3
0
$T1$ ( $T2$ ) and ET-3 had a strong positive inotropic effect in all trabeculae .
Endothelin-1
ET-1
0
$T1$ ( ET-1 ) and $T2$ had a strong positive inotropic effect in all trabeculae .
Endothelin-1
ET-3
0
Preincubation with the $T1$ antagonist FR139317 ( 1 microM ) decreased significantly ( P < 0.005 ) the potency of $T2$ in both atrial and ventricular trabeculae , without any significant changes in Emax ( maximum effect obtained with an agonist ) .
ET(A) receptor
ET- I
0
The $T1$ agonist IRL 1620 had a positive inotropic effect only in some trabeculae , and the $T2$ antagonist BQ 788 ( 1 microM ) almost completely blocked this effect .
ET(B) receptor
ET(B) receptor
0
$T1$ was significantly more potent than $T2$ in both atrial ( P < 0.001 ) and ventricular ( P < 0.05 ) trabeculae .
ET-1
ET-3
0
These results suggest that both $T1$ and $T2$ receptors mediate positive inotropic responses at both the atrial and ventricular level in the human heart .
ET(A)
ET(B)
0
Some $T1$ substitution mutants , which had severely impaired transacting activity , exhibited reduced binding affinity with either TFIIB or $T2$ in a mutually exclusive manner , suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB .
HBx
RPB5
1
Some HBx substitution mutants , which had severely impaired transacting activity , exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner , suggesting that $T1$ transactivation requires the interactions of both $T2$ and TFIIB .
HBx
RPB5
1
Our finding that $T1$ directly interacts with RNA polymerase II subunit 5 ( $T2$ ) , a common subunit of RNA polymerases , implies that HBx directly modulates the function of RNA polymerase ( Cheong , J. H. , Yi , M. , Lin , Y. , and Murakami , S. ( 1995 ) EMBO J .
HBx
RPB5
1
Delineation of the binding regions of these three proteins revealed that $T1$ , $T2$ , and TFIIB each has two binding regions for the other two proteins .
HBx
RPB5
1
Our finding that $T1$ directly interacts with $T2$ ( RPB5 ) , a common subunit of RNA polymerases , implies that HBx directly modulates the function of RNA polymerase ( Cheong , J. H. , Yi , M. , Lin , Y. , and Murakami , S. ( 1995 ) EMBO J .
HBx
RNA polymerase II subunit 5
1
Our finding that $T1$ directly interacts with RNA polymerase II subunit 5 ( RPB5 ) , a common subunit of RNA polymerases , implies that $T2$ directly modulates the function of RNA polymerase ( Cheong , J. H. , Yi , M. , Lin , Y. , and Murakami , S. ( 1995 ) EMBO J .
HBx
HBx
0
Our finding that HBx directly interacts with $T1$ ( $T2$ ) , a common subunit of RNA polymerases , implies that HBx directly modulates the function of RNA polymerase ( Cheong , J. H. , Yi , M. , Lin , Y. , and Murakami , S. ( 1995 ) EMBO J .
RNA polymerase II subunit 5
RPB5
0
Our finding that HBx directly interacts with $T1$ ( RPB5 ) , a common subunit of RNA polymerases , implies that $T2$ directly modulates the function of RNA polymerase ( Cheong , J. H. , Yi , M. , Lin , Y. , and Murakami , S. ( 1995 ) EMBO J .
RNA polymerase II subunit 5
HBx
0
Hepatitis B virus X protein is a transcriptional modulator that communicates with transcription factor IIB and the RNA polymerase II subunit 5. $T1$n ( $T2$ ) transactivates viral and cellular genes through a wide variety of cis-elements .
Hepatitis B virus X protei
HBx
0
These results indicated that HBx is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and TFIIB through communication with $T1$ and $T2$ .
RPB5
TFIIB
0
These results indicated that HBx is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and $T1$ through communication with RPB5 and $T2$ .
TFIIB
TFIIB
0
These results indicated that $T1$ is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and TFIIB through communication with RPB5 and $T2$ .
HBx
TFIIB
0
These results indicated that HBx is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and $T1$ through communication with $T2$ and TFIIB .
TFIIB
RPB5
0
These results indicated that $T1$ is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and TFIIB through communication with $T2$ and TFIIB .
HBx
RPB5
0
These results indicated that $T1$ is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and $T2$ through communication with RPB5 and TFIIB .
HBx
TFIIB
0
Our finding that HBx directly interacts with RNA polymerase II subunit 5 ( $T1$ ) , a common subunit of RNA polymerases , implies that $T2$ directly modulates the function of RNA polymerase ( Cheong , J. H. , Yi , M. , Lin , Y. , and Murakami , S. ( 1995 ) EMBO J .
RPB5
HBx
0
Some HBx substitution mutants , which had severely impaired transacting activity , exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner , suggesting that HBx transactivation requires the interactions of both $T1$ and $T2$ .
RPB5
TFIIB
0
Some HBx substitution mutants , which had severely impaired transacting activity , exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner , suggesting that $T1$ transactivation requires the interactions of both RPB5 and $T2$ .
HBx
TFIIB
0
Some HBx substitution mutants , which had severely impaired transacting activity , exhibited reduced binding affinity with either TFIIB or $T1$ in a mutually exclusive manner , suggesting that HBx transactivation requires the interactions of both RPB5 and $T2$ .
RPB5
TFIIB
0
Some HBx substitution mutants , which had severely impaired transacting activity , exhibited reduced binding affinity with either $T1$ or RPB5 in a mutually exclusive manner , suggesting that HBx transactivation requires the interactions of both RPB5 and $T2$ .
TFIIB
TFIIB
0
Some $T1$ substitution mutants , which had severely impaired transacting activity , exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner , suggesting that HBx transactivation requires the interactions of both RPB5 and $T2$ .
HBx
TFIIB
0
Some HBx substitution mutants , which had severely impaired transacting activity , exhibited reduced binding affinity with either TFIIB or $T1$ in a mutually exclusive manner , suggesting that HBx transactivation requires the interactions of both $T2$ and TFIIB .
RPB5
RPB5
0
Some HBx substitution mutants , which had severely impaired transacting activity , exhibited reduced binding affinity with either $T1$ or RPB5 in a mutually exclusive manner , suggesting that HBx transactivation requires the interactions of both $T2$ and TFIIB .
TFIIB
RPB5
0
Some $T1$ substitution mutants , which had severely impaired transacting activity , exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner , suggesting that HBx transactivation requires the interactions of both $T2$ and TFIIB .
HBx
RPB5
0
Some HBx substitution mutants , which had severely impaired transacting activity , exhibited reduced binding affinity with either TFIIB or $T1$ in a mutually exclusive manner , suggesting that $T2$ transactivation requires the interactions of both RPB5 and TFIIB .
RPB5
HBx
0
Some HBx substitution mutants , which had severely impaired transacting activity , exhibited reduced binding affinity with either $T1$ or RPB5 in a mutually exclusive manner , suggesting that $T2$ transactivation requires the interactions of both RPB5 and TFIIB .
TFIIB
HBx
0
Some $T1$ substitution mutants , which had severely impaired transacting activity , exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner , suggesting that $T2$ transactivation requires the interactions of both RPB5 and TFIIB .
HBx
HBx
0
Some HBx substitution mutants , which had severely impaired transacting activity , exhibited reduced binding affinity with either $T1$ or $T2$ in a mutually exclusive manner , suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB .
TFIIB
RPB5
0
Some $T1$ substitution mutants , which had severely impaired transacting activity , exhibited reduced binding affinity with either $T2$ or RPB5 in a mutually exclusive manner , suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB .
HBx
TFIIB
0
$T1$ is a transcriptional modulator that communicates with transcription factor IIB and the $T2$ .
Hepatitis B virus X protein
RNA polymerase II subunit 5
0
$T1$ is a transcriptional modulator that communicates with $T2$ and the RNA polymerase II subunit 5 .
Hepatitis B virus X protein
transcription factor IIB
0
Hepatitis B virus X protein is a transcriptional modulator that communicates with $T1$ and the $T2$ .
transcription factor IIB
RNA polymerase II subunit 5
0
In this context , we examined the possibility that $T1$ and $T2$ interact with other general transcription factors .
HBx
RPB5
0
$T1$ and $T2$ specifically bound to transcription factor IIB ( TFIIB ) in vitro , both of which were detected by either far-Western blotting or the glutathione S-transferase-resin pull-down assay .
HBx
RPB5
0
$T1$ and RPB5 specifically bound to $T2$ ( TFIIB ) in vitro , both of which were detected by either far-Western blotting or the glutathione S-transferase-resin pull-down assay .
HBx
transcription factor IIB
0
$T1$ and RPB5 specifically bound to transcription factor IIB ( $T2$ ) in vitro , both of which were detected by either far-Western blotting or the glutathione S-transferase-resin pull-down assay .
HBx
TFIIB
0
HBx and $T1$ specifically bound to $T2$ ( TFIIB ) in vitro , both of which were detected by either far-Western blotting or the glutathione S-transferase-resin pull-down assay .
RPB5
transcription factor IIB
0
HBx and $T1$ specifically bound to transcription factor IIB ( $T2$ ) in vitro , both of which were detected by either far-Western blotting or the glutathione S-transferase-resin pull-down assay .
RPB5
TFIIB
0
HBx and RPB5 specifically bound to $T1$ ( $T2$ ) in vitro , both of which were detected by either far-Western blotting or the glutathione S-transferase-resin pull-down assay .
transcription factor IIB
TFIIB
0
Delineation of the binding regions of these three proteins revealed that $T1$ , RPB5 , and $T2$ each has two binding regions for the other two proteins .
HBx
TFIIB
0
Delineation of the binding regions of these three proteins revealed that HBx , $T1$ , and $T2$ each has two binding regions for the other two proteins .
RPB5
TFIIB
0
Cross-family dimerization of transcription factors Fos/Jun and $T1$/$T2$ alters DNA binding specificity .
ATF
CREB
1
Cross-family dimerization of transcription factors $T1$/$T2$ and ATF/CREB alters DNA binding specificity .
Fos
Jun
1
Cross-family dimerization of transcription factors $T1$/Jun and $T2$/CREB alters DNA binding specificity .
Fos
ATF
0
Cross-family dimerization of transcription factors $T1$/Jun and ATF/$T2$ alters DNA binding specificity .
Fos
CREB
0
Cross-family dimerization of transcription factors Fos/$T1$ and $T2$/CREB alters DNA binding specificity .
Jun
ATF
0
Cross-family dimerization of transcription factors Fos/$T1$ and ATF/$T2$ alters DNA binding specificity .
Jun
CREB
0
The Fos/$T1$ and $T2$/CREB families of transcription factors function in coupling extracellular signals to alterations in expression of specific target genes .
Jun
ATF
0
The $T1$/$T2$ and ATF/CREB families of transcription factors function in coupling extracellular signals to alterations in expression of specific target genes .
Fos
Jun
0
The Fos/$T1$ and ATF/$T2$ families of transcription factors function in coupling extracellular signals to alterations in expression of specific target genes .
Jun
CREB
0
The $T1$/Jun and $T2$/CREB families of transcription factors function in coupling extracellular signals to alterations in expression of specific target genes .
Fos
ATF
0
The Fos/Jun and $T1$/$T2$ families of transcription factors function in coupling extracellular signals to alterations in expression of specific target genes .
ATF
CREB
0
The $T1$/Jun and ATF/$T2$ families of transcription factors function in coupling extracellular signals to alterations in expression of specific target genes .
Fos
CREB
0
Although Fos/$T1$ and $T2$/CREB were previously thought to interact preferentially with different DNA regulatory elements ( the AP-1/TRE and ATF/CRE sites , respectively ) , we find that members of these two families form selective cross-family heterodimers .
Jun
ATF
0
Although Fos/$T1$ and ATF/$T2$ were previously thought to interact preferentially with different DNA regulatory elements ( the AP-1/TRE and ATF/CRE sites , respectively ) , we find that members of these two families form selective cross-family heterodimers .
Jun
CREB
0
Although $T1$/$T2$ and ATF/CREB were previously thought to interact preferentially with different DNA regulatory elements ( the AP-1/TRE and ATF/CRE sites , respectively ) , we find that members of these two families form selective cross-family heterodimers .
Fos
Jun
0
Although Fos/Jun and $T1$/$T2$ were previously thought to interact preferentially with different DNA regulatory elements ( the AP-1/TRE and ATF/CRE sites , respectively ) , we find that members of these two families form selective cross-family heterodimers .
ATF
CREB
0
Although $T1$/Jun and $T2$/CREB were previously thought to interact preferentially with different DNA regulatory elements ( the AP-1/TRE and ATF/CRE sites , respectively ) , we find that members of these two families form selective cross-family heterodimers .
Fos
ATF
0
Although $T1$/Jun and ATF/$T2$ were previously thought to interact preferentially with different DNA regulatory elements ( the AP-1/TRE and ATF/CRE sites , respectively ) , we find that members of these two families form selective cross-family heterodimers .
Fos
CREB
0
These findings indicate that the $T1$/$T2$ and ATF/CREB families of transcription factors are not as distinct as was previously thought .
Fos
Jun
0
These findings indicate that the $T1$/Jun and $T2$/CREB families of transcription factors are not as distinct as was previously thought .
Fos
ATF
0
These findings indicate that the $T1$/Jun and ATF/$T2$ families of transcription factors are not as distinct as was previously thought .
Fos
CREB
0
These findings indicate that the Fos/$T1$ and $T2$/CREB families of transcription factors are not as distinct as was previously thought .
Jun
ATF
0
These findings indicate that the Fos/$T1$ and ATF/$T2$ families of transcription factors are not as distinct as was previously thought .
Jun
CREB
0
These findings indicate that the Fos/Jun and $T1$/$T2$ families of transcription factors are not as distinct as was previously thought .
ATF
CREB
0
This last observation was confirmed by affinity chromatography and immunoprecipitation , which demonstrated an interaction between $T1$ and $T2$ .
Rb
UBF
1
Here we report that ( 1 ) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription ; ( 2 ) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I ; ( 3 ) this inhibition requires a functional Rb pocket ; and ( 4 ) $T1$ specifically inhibits the activity of the RNA polymerase I transcription factor $T2$ ( upstream binding factor ) in vitro .
Rb
UBF
1
Here we report that ( 1 ) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription ; ( 2 ) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I ; ( 3 ) this inhibition requires a functional Rb pocket ; and ( 4 ) $T1$ specifically inhibits the activity of the RNA polymerase I transcription factor UBF ( $T2$ ) in vitro .
Rb
upstream binding factor
1
Activity of RNA polymerase I transcription factor $T1$ blocked by $T2$ gene product .
UBF
Rb
1
The protein encoded by the $T1$ ( $T2$ ) functions as a tumour suppressor and negative growth regulator .
retinoblastoma susceptibility gene
Rb
0
Here we report that ( 1 ) there is an accumulation of $T1$ protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription ; ( 2 ) addition of $T2$ to an in vitro transcription system inhibits transcription by RNA polymerase I ; ( 3 ) this inhibition requires a functional Rb pocket ; and ( 4 ) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF ( upstream binding factor ) in vitro .
Rb
Rb
0
Here we report that ( 1 ) there is an accumulation of $T1$ protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription ; ( 2 ) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I ; ( 3 ) this inhibition requires a functional Rb pocket ; and ( 4 ) Rb specifically inhibits the activity of the RNA polymerase I transcription factor $T2$ ( upstream binding factor ) in vitro .
Rb
UBF
0
Here we report that ( 1 ) there is an accumulation of $T1$ protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription ; ( 2 ) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I ; ( 3 ) this inhibition requires a functional Rb pocket ; and ( 4 ) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF ( $T2$ ) in vitro .
Rb
upstream binding factor
0
Here we report that ( 1 ) there is an accumulation of $T1$ protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription ; ( 2 ) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I ; ( 3 ) this inhibition requires a functional $T2$ pocket ; and ( 4 ) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF ( upstream binding factor ) in vitro .
Rb
Rb
0
Here we report that ( 1 ) there is an accumulation of $T1$ protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription ; ( 2 ) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I ; ( 3 ) this inhibition requires a functional Rb pocket ; and ( 4 ) $T2$ specifically inhibits the activity of the RNA polymerase I transcription factor UBF ( upstream binding factor ) in vitro .
Rb
Rb
0
Here we report that ( 1 ) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription ; ( 2 ) addition of $T1$ to an in vitro transcription system inhibits transcription by RNA polymerase I ; ( 3 ) this inhibition requires a functional Rb pocket ; and ( 4 ) Rb specifically inhibits the activity of the RNA polymerase I transcription factor $T2$ ( upstream binding factor ) in vitro .
Rb
UBF
0
Here we report that ( 1 ) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription ; ( 2 ) addition of $T1$ to an in vitro transcription system inhibits transcription by RNA polymerase I ; ( 3 ) this inhibition requires a functional Rb pocket ; and ( 4 ) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF ( $T2$ ) in vitro .
Rb
upstream binding factor
0
Here we report that ( 1 ) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription ; ( 2 ) addition of $T1$ to an in vitro transcription system inhibits transcription by RNA polymerase I ; ( 3 ) this inhibition requires a functional $T2$ pocket ; and ( 4 ) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF ( upstream binding factor ) in vitro .
Rb
Rb
0
Here we report that ( 1 ) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription ; ( 2 ) addition of $T1$ to an in vitro transcription system inhibits transcription by RNA polymerase I ; ( 3 ) this inhibition requires a functional Rb pocket ; and ( 4 ) $T2$ specifically inhibits the activity of the RNA polymerase I transcription factor UBF ( upstream binding factor ) in vitro .
Rb
Rb
0
Here we report that ( 1 ) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription ; ( 2 ) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I ; ( 3 ) this inhibition requires a functional Rb pocket ; and ( 4 ) Rb specifically inhibits the activity of the RNA polymerase I transcription factor $T1$ ( $T2$ ) in vitro .
UBF
upstream binding factor
0
Here we report that ( 1 ) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription ; ( 2 ) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I ; ( 3 ) this inhibition requires a functional $T1$ pocket ; and ( 4 ) Rb specifically inhibits the activity of the RNA polymerase I transcription factor $T2$ ( upstream binding factor ) in vitro .
Rb
UBF
0
Here we report that ( 1 ) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription ; ( 2 ) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I ; ( 3 ) this inhibition requires a functional $T1$ pocket ; and ( 4 ) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF ( $T2$ ) in vitro .
Rb
upstream binding factor
0
Here we report that ( 1 ) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription ; ( 2 ) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I ; ( 3 ) this inhibition requires a functional $T1$ pocket ; and ( 4 ) $T2$ specifically inhibits the activity of the RNA polymerase I transcription factor UBF ( upstream binding factor ) in vitro .
Rb
Rb
0
These results indicate that there is an additional mechanism by which $T1$ suppresses cell growth , namely that $T2$ directly represses transcription of the rRNA genes .
Rb
Rb
0
As $T1$ forms complexes with beta 1 integrins and the integrins are known to regulate keratinocyte behaviour , we investigated $T2$ expression and function in human epidermal keratinocytes .
CD9
CD9
0
There was extensive co-localisation of $T1$ and beta 1 integrins on microvilli and at cell-cell borders of basal keratinocytes ; however , in contrast to the integrins , $T2$ was not found in focal adhesions .
CD9
CD9
0
$T1$ was detected in beta 1 integrin immunoprecipitates and also in immunoprecipitates of CD44 and $T2$ , but not of cadherins .
CD9
syndecan
0
CD9 was detected in beta 1 integrin immunoprecipitates and also in immunoprecipitates of $T1$ and $T2$ , but not of cadherins .
CD44
syndecan
0
$T1$ was associated with alpha 3 beta 1 but not alpha 5 beta 1 ; small amounts of $T2$ also co-immunoprecipitated with antibodies to alpha 2 beta 1 and alpha 6 beta 4 .
CD9
CD9
0
$T1$ was detected in beta 1 integrin immunoprecipitates and also in immunoprecipitates of $T2$ and syndecan , but not of cadherins .
CD9
CD44
0
Antibodies to $T1$ did not affect the proportion of keratinocytes that adhered to $T2$ , type IV collagen and fibronectin , but did inhibit motility of keratinocytes on tissue culture plastic .
CD9
laminin 1
0
Antibodies to $T1$ did not affect the proportion of keratinocytes that adhered to laminin 1 , $T2$ and fibronectin , but did inhibit motility of keratinocytes on tissue culture plastic .
CD9
type IV collagen
0
Antibodies to $T1$ did not affect the proportion of keratinocytes that adhered to laminin 1 , type IV collagen and $T2$ , but did inhibit motility of keratinocytes on tissue culture plastic .
CD9
fibronectin
0
Antibodies to CD9 did not affect the proportion of keratinocytes that adhered to $T1$ , $T2$ and fibronectin , but did inhibit motility of keratinocytes on tissue culture plastic .
laminin 1
type IV collagen
0
Antibodies to CD9 did not affect the proportion of keratinocytes that adhered to $T1$ , type IV collagen and $T2$ , but did inhibit motility of keratinocytes on tissue culture plastic .
laminin 1
fibronectin
0
Antibodies to CD9 did not affect the proportion of keratinocytes that adhered to laminin 1 , $T1$ and $T2$ , but did inhibit motility of keratinocytes on tissue culture plastic .
type IV collagen
fibronectin
0
Like antibodies to the $T1$ subunit , anti-$T2$ inhibited suspension-induced terminal differentiation .
beta 1 integrin
CD9
0
The crystal structure of the homodimeric $T1$ ( $T2$ ) has been determined by X-ray analysis to 3.0 A resolution .
BB isoform of human recombinant platelet-derived growth factor
PDGF-BB
0
Other NH2-terminal residues directly modulate the affinity of $T1$ dimers for the $T2$ tethering site .
RII beta
AKAP75
1
Replacement of Val20-Leu21 with Ala-Ala produced a dimeric $T1$ protein that binds $T2$ approximately 4 % as avidly as wild-type RII beta .
RII beta
AKAP75
1
Mutagenesis , recombinant protein expression , and physicochemical characterization were used to investigate the structural basis for the homodimerization and $T1$ binding activities of $T2$ .
AKAP75
RII beta
1
Evidently , large hydrophobic side chains of Leu13 and Phe36 play pivotal roles in stabilizing $T1$-$T2$ interactions .
RII beta
RII beta
1
The prototypic neuronal anchor protein $T1$ has a COOH-terminal 22-residue $T2$ binding ( tethering ) site .
AKAP75
RII beta
1
In neurons cAMP-dependent protein kinase II beta ( $T1$ ) is sequestered in the dendritic cytoskeleton because the regulatory subunit ( $T2$ ) of the enzyme is tightly bound by A Kinase Anchor Proteins ( AKAPs ) .
PKAII beta
RII beta
0
In neurons $T1$ ( $T2$ ) is sequestered in the dendritic cytoskeleton because the regulatory subunit ( RII beta ) of the enzyme is tightly bound by A Kinase Anchor Proteins ( AKAPs ) .
cAMP-dependent protein kinase II beta
PKAII beta
0
In neurons $T1$ ( PKAII beta ) is sequestered in the dendritic cytoskeleton because the regulatory subunit ( $T2$ ) of the enzyme is tightly bound by A Kinase Anchor Proteins ( AKAPs ) .
cAMP-dependent protein kinase II beta
RII beta
0
Mutagenesis of the regulatory subunit ( $T1$ ) of cAMP-dependent protein kinase II beta reveals hydrophobic amino acids that are essential for RII beta dimerization and/or anchoring $T2$ to the cytoskeleton .
RII beta
RII beta
0
Mutagenesis of the regulatory subunit ( RII beta ) of cAMP-dependent protein kinase II beta reveals hydrophobic amino acids that are essential for $T1$ dimerization and/or anchoring $T2$ to the cytoskeleton .
RII beta
RII beta
0
Mutagenesis of the regulatory subunit ( RII beta ) of $T1$ reveals hydrophobic amino acids that are essential for RII beta dimerization and/or anchoring $T2$ to the cytoskeleton .
cAMP-dependent protein kinase II beta
RII beta
0
Replacement of Val20-Leu21 with Ala-Ala produced a dimeric RII beta protein that binds $T1$ approximately 4 % as avidly as wild-type $T2$ .
AKAP75
RII beta
0
Replacement of Val20-Leu21 with Ala-Ala produced a dimeric $T1$ protein that binds AKAP75 approximately 4 % as avidly as wild-type $T2$ .
RII beta
RII beta
0
A secondary consequence of destabilizing $T1$ dimers is the loss of intracellular targeting/anchoring capacity because monomers fail to bind $T2$ .
RII beta
AKAP75
0
Mutagenesis of the regulatory subunit ( $T1$ ) of cAMP-dependent protein kinase II beta reveals hydrophobic amino acids that are essential for $T2$ dimerization and/or anchoring RII beta to the cytoskeleton .
RII beta
RII beta
0
Mutagenesis of the regulatory subunit ( $T1$ ) of $T2$ reveals hydrophobic amino acids that are essential for RII beta dimerization and/or anchoring RII beta to the cytoskeleton .
RII beta
cAMP-dependent protein kinase II beta
0
Mutagenesis of the regulatory subunit ( RII beta ) of $T1$ reveals hydrophobic amino acids that are essential for $T2$ dimerization and/or anchoring RII beta to the cytoskeleton .
cAMP-dependent protein kinase II beta
RII beta
0
Substitution of Ala for Leu13 or Phe36 generates monomeric $T1$ subunits that can not bind $T2$ .
RII beta
AKAP75
0
The results are not due to general misfolding since mutant $T1$ monomers bind cAMP and inhibit the catalytic subunit of $T2$ with the same affinity and efficacy as wild-type RII beta dimers .
RII beta
PKAII beta
0
The results are not due to general misfolding since mutant $T1$ monomers bind cAMP and inhibit the catalytic subunit of PKAII beta with the same affinity and efficacy as wild-type $T2$ dimers .
RII beta
RII beta
0
The results are not due to general misfolding since mutant RII beta monomers bind cAMP and inhibit the catalytic subunit of $T1$ with the same affinity and efficacy as wild-type $T2$ dimers .
PKAII beta
RII beta
0
Levels of p16 ( $T1$ ) and $T2$ ( KIP2 ) rise in HUCs during progressive passages , whereas only p16 increases in HPEC cultures .
INK4a
p57
0
Levels of $T1$ ( $T2$ ) and p57 ( KIP2 ) rise in HUCs during progressive passages , whereas only p16 increases in HPEC cultures .
p16
INK4a
0
Levels of p16 ( $T1$ ) and p57 ( $T2$ ) rise in HUCs during progressive passages , whereas only p16 increases in HPEC cultures .
INK4a
KIP2
0
Levels of p16 ( $T1$ ) and p57 ( KIP2 ) rise in HUCs during progressive passages , whereas only $T2$ increases in HPEC cultures .
INK4a
p16
0
Levels of $T1$ ( INK4a ) and $T2$ ( KIP2 ) rise in HUCs during progressive passages , whereas only p16 increases in HPEC cultures .
p16
p57
0
Levels of p16 ( INK4a ) and $T1$ ( $T2$ ) rise in HUCs during progressive passages , whereas only p16 increases in HPEC cultures .
p57
KIP2
0
Levels of p16 ( INK4a ) and $T1$ ( KIP2 ) rise in HUCs during progressive passages , whereas only $T2$ increases in HPEC cultures .
p57
p16
0
Temporally following this growth arrest , the cells develop a senescence morphology and express $T1$ ( $T2$ ) .
senescence-associated beta-galactosidase
SA-beta-gal
0
Temporally following this growth arrest , the cells develop a senescence morphology and express senescence-associated $T1$ ( $T2$ ) .
beta-galactosidase
SA-beta-gal
0
Levels of $T1$ ( INK4a ) and p57 ( $T2$ ) rise in HUCs during progressive passages , whereas only p16 increases in HPEC cultures .
p16
KIP2
0
Levels of $T1$ ( INK4a ) and p57 ( KIP2 ) rise in HUCs during progressive passages , whereas only $T2$ increases in HPEC cultures .
p16
p16
0
Analysis of p53 , p21 ( CIP1 ) , p15 ( INK4b ) , $T1$ ( $T2$ ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .
p16
INK4a
0
Analysis of p53 , p21 ( CIP1 ) , p15 ( $T1$ ) , p16 ( $T2$ ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .
INK4b
INK4a
0
Analysis of p53 , p21 ( CIP1 ) , $T1$ ( INK4b ) , p16 ( $T2$ ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .
p15
INK4a
0
Analysis of p53 , p21 ( $T1$ ) , p15 ( INK4b ) , p16 ( $T2$ ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .
CIP1
INK4a
0
Analysis of p53 , $T1$ ( CIP1 ) , p15 ( INK4b ) , p16 ( $T2$ ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .
p21
INK4a
0
Analysis of $T1$ , p21 ( CIP1 ) , p15 ( INK4b ) , p16 ( $T2$ ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .
p53
INK4a
0
Analysis of p53 , p21 ( CIP1 ) , p15 ( INK4b ) , p16 ( $T1$ ) , and $T2$ ( KIP2 ) reveals altered expression in immortalized , non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .
INK4a
p57
0
Analysis of p53 , p21 ( CIP1 ) , p15 ( INK4b ) , p16 ( $T1$ ) , and p57 ( $T2$ ) reveals altered expression in immortalized , non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .
INK4a
KIP2
0
Analysis of p53 , p21 ( CIP1 ) , p15 ( $T1$ ) , $T2$ ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .
INK4b
p16
0
Analysis of p53 , p21 ( CIP1 ) , $T1$ ( INK4b ) , $T2$ ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .
p15
p16
0
Analysis of p53 , p21 ( $T1$ ) , p15 ( INK4b ) , $T2$ ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .
CIP1
p16
0
Analysis of p53 , $T1$ ( CIP1 ) , p15 ( INK4b ) , $T2$ ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .
p21
p16
0
Analysis of $T1$ , p21 ( CIP1 ) , p15 ( INK4b ) , $T2$ ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .
p53
p16
0
Analysis of p53 , p21 ( CIP1 ) , p15 ( INK4b ) , $T1$ ( INK4a ) , and $T2$ ( KIP2 ) reveals altered expression in immortalized , non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .
p16
p57
0
Analysis of p53 , p21 ( CIP1 ) , p15 ( INK4b ) , $T1$ ( INK4a ) , and p57 ( $T2$ ) reveals altered expression in immortalized , non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .
p16
KIP2
0
Analysis of p53 , p21 ( CIP1 ) , $T1$ ( $T2$ ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .
p15
INK4b
0
Analysis of p53 , p21 ( $T1$ ) , p15 ( $T2$ ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .
CIP1
INK4b
0
Analysis of p53 , $T1$ ( CIP1 ) , p15 ( $T2$ ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .
p21
INK4b
0
Analysis of $T1$ , p21 ( CIP1 ) , p15 ( $T2$ ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .
p53
INK4b
0
Analysis of p53 , p21 ( CIP1 ) , p15 ( $T1$ ) , p16 ( INK4a ) , and $T2$ ( KIP2 ) reveals altered expression in immortalized , non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .
INK4b
p57
0
Analysis of p53 , p21 ( CIP1 ) , p15 ( $T1$ ) , p16 ( INK4a ) , and p57 ( $T2$ ) reveals altered expression in immortalized , non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .
INK4b
KIP2
0
Levels of p16 ( INK4a ) and p57 ( $T1$ ) rise in HUCs during progressive passages , whereas only $T2$ increases in HPEC cultures .
KIP2
p16
0
Analysis of p53 , p21 ( $T1$ ) , $T2$ ( INK4b ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .
CIP1
p15
0
Analysis of p53 , $T1$ ( CIP1 ) , $T2$ ( INK4b ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .
p21
p15
0
Analysis of $T1$ , p21 ( CIP1 ) , $T2$ ( INK4b ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .
p53
p15
0
Analysis of p53 , p21 ( CIP1 ) , $T1$ ( INK4b ) , p16 ( INK4a ) , and $T2$ ( KIP2 ) reveals altered expression in immortalized , non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .
p15
p57
0
Analysis of p53 , p21 ( CIP1 ) , $T1$ ( INK4b ) , p16 ( INK4a ) , and p57 ( $T2$ ) reveals altered expression in immortalized , non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .
p15
KIP2
0
Analysis of p53 , $T1$ ( $T2$ ) , p15 ( INK4b ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .
p21
CIP1
0
Analysis of $T1$ , p21 ( $T2$ ) , p15 ( INK4b ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .
p53
CIP1
0
Analysis of p53 , p21 ( $T1$ ) , p15 ( INK4b ) , p16 ( INK4a ) , and $T2$ ( KIP2 ) reveals altered expression in immortalized , non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .
CIP1
p57
0
Analysis of p53 , p21 ( $T1$ ) , p15 ( INK4b ) , p16 ( INK4a ) , and p57 ( $T2$ ) reveals altered expression in immortalized , non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .
CIP1
KIP2
0
Analysis of $T1$ , $T2$ ( CIP1 ) , p15 ( INK4b ) , p16 ( INK4a ) , and p57 ( KIP2 ) reveals altered expression in immortalized , non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .
p53
p21
0
Analysis of p53 , $T1$ ( CIP1 ) , p15 ( INK4b ) , p16 ( INK4a ) , and $T2$ ( KIP2 ) reveals altered expression in immortalized , non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .
p21
p57
0
Analysis of p53 , $T1$ ( CIP1 ) , p15 ( INK4b ) , p16 ( INK4a ) , and p57 ( $T2$ ) reveals altered expression in immortalized , non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .
p21
KIP2
0
Analysis of $T1$ , p21 ( CIP1 ) , p15 ( INK4b ) , p16 ( INK4a ) , and $T2$ ( KIP2 ) reveals altered expression in immortalized , non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .
p53
p57
0
Analysis of $T1$ , p21 ( CIP1 ) , p15 ( INK4b ) , p16 ( INK4a ) , and p57 ( $T2$ ) reveals altered expression in immortalized , non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .
p53
KIP2
0
We find that p53 , p21 ( CIP1 ) and $T1$ ( $T2$ ) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest , then return to low proliferating levels at terminal senescence .
p15
INK4b
0
We find that p53 , p21 ( $T1$ ) and p15 ( $T2$ ) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest , then return to low proliferating levels at terminal senescence .
CIP1
INK4b
0
We find that $T1$ , p21 ( CIP1 ) and p15 ( $T2$ ) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest , then return to low proliferating levels at terminal senescence .
p53
INK4b
0
We find that p53 , $T1$ ( CIP1 ) and p15 ( $T2$ ) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest , then return to low proliferating levels at terminal senescence .
p21
INK4b
0
We find that p53 , p21 ( $T1$ ) and $T2$ ( INK4b ) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest , then return to low proliferating levels at terminal senescence .
CIP1
p15
0
We find that $T1$ , p21 ( CIP1 ) and $T2$ ( INK4b ) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest , then return to low proliferating levels at terminal senescence .
p53
p15
0
We find that p53 , $T1$ ( CIP1 ) and $T2$ ( INK4b ) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest , then return to low proliferating levels at terminal senescence .
p21
p15
0
We find that $T1$ , p21 ( $T2$ ) and p15 ( INK4b ) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest , then return to low proliferating levels at terminal senescence .
p53
CIP1
0
We find that p53 , $T1$ ( $T2$ ) and p15 ( INK4b ) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest , then return to low proliferating levels at terminal senescence .
p21
CIP1
0
Temporally following this growth arrest , the cells develop a senescence morphology and express $T1$$T2$ ( SA-beta-gal ) .
senescence-associated beta-galactosidase
beta-galactosidase
0
The induced expression of $T1$ , similar to $T2$ , produces a senescent-like phenotype .
p57
p16
0
$T1$ , $T2$ , p19 ( INK4d ) and p27 ( KIP1 ) decrease in both cell types .
pRB
cyclin D
0
$T1$ , cyclin D , $T2$ ( INK4d ) and p27 ( KIP1 ) decrease in both cell types .
pRB
p19
0
$T1$ , cyclin D , p19 ( $T2$ ) and p27 ( KIP1 ) decrease in both cell types .
pRB
INK4d
0
$T1$ , cyclin D , p19 ( INK4d ) and $T2$ ( KIP1 ) decrease in both cell types .
pRB
p27
0
$T1$ , cyclin D , p19 ( INK4d ) and p27 ( $T2$ ) decrease in both cell types .
pRB
KIP1
0
pRB , $T1$ , $T2$ ( INK4d ) and p27 ( KIP1 ) decrease in both cell types .
cyclin D
p19
0
pRB , $T1$ , p19 ( $T2$ ) and p27 ( KIP1 ) decrease in both cell types .
cyclin D
INK4d
0
pRB , $T1$ , p19 ( INK4d ) and $T2$ ( KIP1 ) decrease in both cell types .
cyclin D
p27
0
pRB , $T1$ , p19 ( INK4d ) and p27 ( $T2$ ) decrease in both cell types .
cyclin D
KIP1
0
pRB , cyclin D , $T1$ ( $T2$ ) and p27 ( KIP1 ) decrease in both cell types .
p19
INK4d
0
pRB , cyclin D , $T1$ ( INK4d ) and $T2$ ( KIP1 ) decrease in both cell types .
p19
p27
0
pRB , cyclin D , $T1$ ( INK4d ) and p27 ( $T2$ ) decrease in both cell types .
p19
KIP1
0
pRB , cyclin D , p19 ( $T1$ ) and $T2$ ( KIP1 ) decrease in both cell types .
INK4d
p27
0
pRB , cyclin D , p19 ( $T1$ ) and p27 ( $T2$ ) decrease in both cell types .
INK4d
KIP1
0
pRB , cyclin D , p19 ( INK4d ) and $T1$ ( $T2$ ) decrease in both cell types .
p27
KIP1
0
We find that $T1$ , $T2$ ( CIP1 ) and p15 ( INK4b ) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest , then return to low proliferating levels at terminal senescence .
p53
p21
0
Analysis of p53 , p21 ( CIP1 ) , p15 ( INK4b ) , p16 ( INK4a ) , and $T1$ ( $T2$ ) reveals altered expression in immortalized , non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells .
p57
KIP2
0
The protein $T1$ , a key mediator of mitogenesis and differentiation , associates with $T2$ ( refs 1-3 ) .
Raf-1
p21ras
1
These proteins , $T1$ ( $T2$ ) and 14-3-3 beta ( HS1 ) , are members of the 14-3-3 family of proteins .
14-3-3 zeta
PLA2
0
These proteins , $T1$ ( PLA2 ) and $T2$ ( HS1 ) , are members of the 14-3-3 family of proteins .
14-3-3 zeta
14-3-3 beta
0
These proteins , $T1$ ( PLA2 ) and 14-3-3 beta ( $T2$ ) , are members of the 14-3-3 family of proteins .
14-3-3 zeta
HS1
0
These proteins , 14-3-3 zeta ( $T1$ ) and $T2$ ( HS1 ) , are members of the 14-3-3 family of proteins .
PLA2
14-3-3 beta
0
These proteins , 14-3-3 zeta ( $T1$ ) and 14-3-3 beta ( $T2$ ) , are members of the 14-3-3 family of proteins .
PLA2
HS1
0
Expression of 14-3-3 proteins in Xenopus oocytes enhanced $T1$ activity and promoted $T2$-dependent oocyte maturation .
Raf-1
Raf-1
0
These proteins , 14-3-3 zeta ( PLA2 ) and $T1$ ( $T2$ ) , are members of the 14-3-3 family of proteins .
14-3-3 beta
HS1
0
For the calibration , we used two sets of proteins , the $T1$-Max-$T2$ helix-loop-helix proteins , and wild-type and dimerization-defective versions of the lambda cI repressor .
Myc
Mxi1
0
For the calibration , we used two sets of proteins , the $T1$-$T2$-Mxi1 helix-loop-helix proteins , and wild-type and dimerization-defective versions of the lambda cI repressor .
Myc
Max
0
For the calibration , we used two sets of proteins , the Myc-$T1$-$T2$ helix-loop-helix proteins , and wild-type and dimerization-defective versions of the lambda cI repressor .
Max
Mxi1
0
The native and reconstituted $T1$-$T2$ complexes have similar thermal stability and , like steroid receptor heterocomplexes , they are stabilized by molybdate .
pp60src
hsp90
1
As previously shown with reticulocyte lysate-reconstituted steroid receptor heteroprotein complexes , the reconstituted $T1$ multiprotein complex contains $T2$ , which is a major candidate for providing the protein unfoldase activity required for hsp90 association .
pp60src
hsp70
1
In addition , $T1$ in the lysate complexes with wild-type $T2$ , of which only a small portion is normally recovered in cytosol in the native multiprotein complex , and with the cellular homolog , pp60c-src , which has never been recovered in cytosol in the form of a native multiprotein complex with hsp90 .
hsp90
pp60v-src
1
In addition , $T1$ in the lysate complexes with wild-type pp60v-src , of which only a small portion is normally recovered in cytosol in the native multiprotein complex , and with the cellular homolog , $T2$ , which has never been recovered in cytosol in the form of a native multiprotein complex with hsp90 .
hsp90
pp60c-src
1
A rabbit reticulocyte lysate system that has been used to reconstitute functional complexes between steroid receptors and the 90-kDa heat shock protein ( hsp90 ) has been used here to form complexes between the $T1$ tyrosine kinase and $T2$ .
pp60src
hsp90
1
Reticulocyte lysate forms complexes between $T1$ and a temperature-sensitive mutant of Rous sarcoma virus $T2$ , which is normally present in cytosol virtually entirely in the multiprotein complex form .
hsp90
pp60v-src
1
Reconstitution of the multiprotein complex of $T1$ , $T2$ , and p50 in a cell-free system .
pp60src
hsp90
1
Reconstitution of the multiprotein complex of $T1$ , hsp90 , and $T2$ in a cell-free system .
pp60src
p50
0
Reconstitution of the multiprotein complex of pp60src , $T1$ , and $T2$ in a cell-free system .
hsp90
p50
0
A rabbit reticulocyte lysate system that has been used to reconstitute functional complexes between steroid receptors and the 90-kDa heat shock protein ( $T1$ ) has been used here to form complexes between the pp60src tyrosine kinase and $T2$ .
hsp90
hsp90
0
A rabbit reticulocyte lysate system that has been used to reconstitute functional complexes between steroid receptors and the 90-kDa heat shock protein ( $T1$ ) has been used here to form complexes between the $T2$ tyrosine kinase and hsp90 .
hsp90
pp60src
0
In addition , hsp90 in the lysate complexes with wild-type $T1$ , of which only a small portion is normally recovered in cytosol in the native multiprotein complex , and with the cellular homolog , $T2$ , which has never been recovered in cytosol in the form of a native multiprotein complex with hsp90 .
pp60v-src
pp60c-src
0
In addition , hsp90 in the lysate complexes with wild-type $T1$ , of which only a small portion is normally recovered in cytosol in the native multiprotein complex , and with the cellular homolog , pp60c-src , which has never been recovered in cytosol in the form of a native multiprotein complex with $T2$ .
pp60v-src
hsp90
0
In addition , hsp90 in the lysate complexes with wild-type pp60v-src , of which only a small portion is normally recovered in cytosol in the native multiprotein complex , and with the cellular homolog , $T1$ , which has never been recovered in cytosol in the form of a native multiprotein complex with $T2$ .
pp60c-src
hsp90
0
In addition , $T1$ in the lysate complexes with wild-type pp60v-src , of which only a small portion is normally recovered in cytosol in the native multiprotein complex , and with the cellular homolog , pp60c-src , which has never been recovered in cytosol in the form of a native multiprotein complex with $T2$ .
hsp90
hsp90
0
As previously shown with reticulocyte lysate-reconstituted steroid receptor heteroprotein complexes , the reconstituted $T1$ multiprotein complex contains hsp70 , which is a major candidate for providing the protein unfoldase activity required for $T2$ association .
pp60src
hsp90
0
As previously shown with reticulocyte lysate-reconstituted steroid receptor heteroprotein complexes , the reconstituted pp60src multiprotein complex contains $T1$ , which is a major candidate for providing the protein unfoldase activity required for $T2$ association .
hsp70
hsp90
0
Here , we show that TRADD interacts strongly with $T1$ , another death domain protein that was shown previously to associate with $T2$ antigen .
RIP
Fas
1
The death domain of tumor necrosis factor ( TNF ) receptor-1 ( $T1$ ) triggers distinct signaling pathways leading to apoptosis and NF-kappa B activation through its interaction with the death domain protein $T2$ .
TNFR1
TRADD
1
Here , we show that $T1$ interacts strongly with $T2$ , another death domain protein that was shown previously to associate with Fas antigen .
TRADD
RIP
1
The death domain of $T1$ ( TNFR1 ) triggers distinct signaling pathways leading to apoptosis and NF-kappa B activation through its interaction with the death domain protein $T2$ .
tumor necrosis factor (TNF) receptor-1
TRADD
1
TNF-dependent recruitment of the protein kinase $T1$ to the $T2$ signaling complex .
RIP
TNF receptor-1
0
The death domain of $T1$ ( $T2$ ) triggers distinct signaling pathways leading to apoptosis and NF-kappa B activation through its interaction with the death domain protein TRADD .
tumor necrosis factor (TNF) receptor-1
TNFR1
0
The death domain of $T1$ ( TNFR1 ) triggers distinct signaling pathways leading to apoptosis and $T2$ activation through its interaction with the death domain protein TRADD .
tumor necrosis factor (TNF) receptor-1
NF-kappa B
0
The death domain of tumor necrosis factor ( TNF ) receptor-1 ( TNFR1 ) triggers distinct signaling pathways leading to apoptosis and $T1$ activation through its interaction with the death domain protein $T2$ .
NF-kappa B
TRADD
0
Here , we show that $T1$ interacts strongly with RIP , another death domain protein that was shown previously to associate with $T2$ antigen .
TRADD
Fas
0
The death domain of tumor necrosis factor ( TNF ) receptor-1 ( $T1$ ) triggers distinct signaling pathways leading to apoptosis and $T2$ activation through its interaction with the death domain protein TRADD .
TNFR1
NF-kappa B
0
We also show that $T1$ is a serine-threonine kinase that is recruited by $T2$ to TNFR1 in a TNF-dependent process .
RIP
TRADD
0
We also show that $T1$ is a serine-threonine kinase that is recruited by TRADD to $T2$ in a TNF-dependent process .
RIP
TNFR1
0
We also show that RIP is a serine-threonine kinase that is recruited by $T1$ to $T2$ in a TNF-dependent process .
TRADD
TNFR1
0
Overexpression of the intact $T1$ protein induces both $T2$ activation and apoptosis .
RIP
NF-kappa B
0
However , expression of the death domain of $T1$ Induces apoptosis , but potently inhibits $T2$ activation by TNF .
RIP
NF-kappa B
0
These results suggest that distinct domains of $T1$ participate in the TNF signaling cascades leading to apoptosis and $T2$ activation .
RIP
NF-kappa B
0
Using the human RAD52 protein as the `` bait '' in a yeast two-hybrid system , we have identified a human homolog of yeast UBC9 , designated $T1$ , that interacts with RAD52 , RAD51 , p53 , and a ubiquitin-like protein $T2$ .
UBE2I
UBL1
1
The interaction of $T1$ with $T2$ is mediated by RAD52 's self-association region .
UBE2I
RAD52
1
Using the human RAD52 protein as the `` bait '' in a yeast two-hybrid system , we have identified a human homolog of yeast UBC9 , designated $T1$ , that interacts with RAD52 , $T2$ , p53 , and a ubiquitin-like protein UBL1 .
UBE2I
RAD51
1
Using the human RAD52 protein as the `` bait '' in a yeast two-hybrid system , we have identified a human homolog of yeast UBC9 , designated $T1$ , that interacts with RAD52 , RAD51 , $T2$ , and a ubiquitin-like protein UBL1 .
UBE2I
p53
1
Associations of $T1$ with RAD52 , UBL1 , p53 , and $T2$ proteins in a yeast two-hybrid system .
UBE2I
RAD51
1
Using the human RAD52 protein as the `` bait '' in a yeast two-hybrid system , we have identified a human homolog of yeast UBC9 , designated $T1$ , that interacts with $T2$ , RAD51 , p53 , and a ubiquitin-like protein UBL1 .
UBE2I
RAD52
1
Associations of $T1$ with RAD52 , $T2$ , p53 , and RAD51 proteins in a yeast two-hybrid system .
UBE2I
UBL1
1
Associations of $T1$ with RAD52 , UBL1 , $T2$ , and RAD51 proteins in a yeast two-hybrid system .
UBE2I
p53
1
Associations of $T1$ with $T2$ , UBL1 , p53 , and RAD51 proteins in a yeast two-hybrid system .
UBE2I
RAD52
1
Associations of UBE2I with $T1$ , $T2$ , p53 , and RAD51 proteins in a yeast two-hybrid system .
RAD52
UBL1
0
Associations of UBE2I with RAD52 , $T1$ , $T2$ , and RAD51 proteins in a yeast two-hybrid system .
UBL1
p53
0
Associations of UBE2I with RAD52 , $T1$ , p53 , and $T2$ proteins in a yeast two-hybrid system .
UBL1
RAD51
0
Associations of UBE2I with $T1$ , UBL1 , $T2$ , and RAD51 proteins in a yeast two-hybrid system .
RAD52
p53
0
Associations of UBE2I with $T1$ , UBL1 , p53 , and $T2$ proteins in a yeast two-hybrid system .
RAD52
RAD51
0
Associations of UBE2I with RAD52 , UBL1 , $T1$ , and $T2$ proteins in a yeast two-hybrid system .
p53
RAD51
0
Using the human $T1$ protein as the `` bait '' in a yeast two-hybrid system , we have identified a human homolog of yeast UBC9 , designated $T2$ , that interacts with RAD52 , RAD51 , p53 , and a ubiquitin-like protein UBL1 .
RAD52
UBE2I
0
Using the human RAD52 protein as the `` bait '' in a yeast two-hybrid system , we have identified a human homolog of yeast $T1$ , designated $T2$ , that interacts with RAD52 , RAD51 , p53 , and a ubiquitin-like protein UBL1 .
UBC9
UBE2I
0
Using the human RAD52 protein as the `` bait '' in a yeast two-hybrid system , we have identified a human homolog of yeast UBC9 , designated UBE2I , that interacts with $T1$ , $T2$ , p53 , and a ubiquitin-like protein UBL1 .
RAD52
RAD51
0
Using the human $T1$ protein as the `` bait '' in a yeast two-hybrid system , we have identified a human homolog of yeast UBC9 , designated UBE2I , that interacts with $T2$ , RAD51 , p53 , and a ubiquitin-like protein UBL1 .
RAD52
RAD52
0
Using the human RAD52 protein as the `` bait '' in a yeast two-hybrid system , we have identified a human homolog of yeast UBC9 , designated UBE2I , that interacts with $T1$ , RAD51 , $T2$ , and a ubiquitin-like protein UBL1 .
RAD52
p53
0
Using the human RAD52 protein as the `` bait '' in a yeast two-hybrid system , we have identified a human homolog of yeast UBC9 , designated UBE2I , that interacts with $T1$ , RAD51 , p53 , and a ubiquitin-like protein $T2$ .
RAD52
UBL1
0
Using the human RAD52 protein as the `` bait '' in a yeast two-hybrid system , we have identified a human homolog of yeast $T1$ , designated UBE2I , that interacts with $T2$ , RAD51 , p53 , and a ubiquitin-like protein UBL1 .
UBC9
RAD52
0
Using the human $T1$ protein as the `` bait '' in a yeast two-hybrid system , we have identified a human homolog of yeast UBC9 , designated UBE2I , that interacts with RAD52 , $T2$ , p53 , and a ubiquitin-like protein UBL1 .
RAD52
RAD51
0
Using the human RAD52 protein as the `` bait '' in a yeast two-hybrid system , we have identified a human homolog of yeast UBC9 , designated UBE2I , that interacts with RAD52 , $T1$ , $T2$ , and a ubiquitin-like protein UBL1 .
RAD51
p53
0
Using the human RAD52 protein as the `` bait '' in a yeast two-hybrid system , we have identified a human homolog of yeast UBC9 , designated UBE2I , that interacts with RAD52 , $T1$ , p53 , and a ubiquitin-like protein $T2$ .
RAD51
UBL1
0
Using the human RAD52 protein as the `` bait '' in a yeast two-hybrid system , we have identified a human homolog of yeast $T1$ , designated UBE2I , that interacts with RAD52 , $T2$ , p53 , and a ubiquitin-like protein UBL1 .
UBC9
RAD51
0
Using the human $T1$ protein as the `` bait '' in a yeast two-hybrid system , we have identified a human homolog of yeast UBC9 , designated UBE2I , that interacts with RAD52 , RAD51 , $T2$ , and a ubiquitin-like protein UBL1 .
RAD52
p53
0
Using the human $T1$ protein as the `` bait '' in a yeast two-hybrid system , we have identified a human homolog of yeast UBC9 , designated UBE2I , that interacts with RAD52 , RAD51 , p53 , and a ubiquitin-like protein $T2$ .
RAD52
UBL1
0
Using the human $T1$ protein as the `` bait '' in a yeast two-hybrid system , we have identified a human homolog of yeast $T2$ , designated UBE2I , that interacts with RAD52 , RAD51 , p53 , and a ubiquitin-like protein UBL1 .
RAD52
UBC9
0
Using the human RAD52 protein as the `` bait '' in a yeast two-hybrid system , we have identified a human homolog of yeast UBC9 , designated UBE2I , that interacts with RAD52 , RAD51 , $T1$ , and a ubiquitin-like protein $T2$ .
p53
UBL1
0
Using the human RAD52 protein as the `` bait '' in a yeast two-hybrid system , we have identified a human homolog of yeast $T1$ , designated UBE2I , that interacts with RAD52 , RAD51 , $T2$ , and a ubiquitin-like protein UBL1 .
UBC9
p53
0
Using the human RAD52 protein as the `` bait '' in a yeast two-hybrid system , we have identified a human homolog of yeast $T1$ , designated UBE2I , that interacts with RAD52 , RAD51 , p53 , and a ubiquitin-like protein $T2$ .
UBC9
UBL1
0
These interactions are $T1$-specific , since another DNA repair-related ubiquitin-conjugating enzyme , $T2$ ( UBC2 ) , does not interact with these proteins .
UBE2I
RAD6
0
These interactions are $T1$-specific , since another DNA repair-related ubiquitin-conjugating enzyme , RAD6 ( $T2$ ) , does not interact with these proteins .
UBE2I
UBC2
0
These interactions are UBE2I-specific , since another DNA repair-related ubiquitin-conjugating enzyme , $T1$ ( $T2$ ) , does not interact with these proteins .
RAD6
UBC2
0
These results suggest that the RAD52-dependent processes , cell cycle control , $T1$-mediated pathway ( s ) , and ubiquitination interact through human $T2$ .
p53
UBE2I
0
These results suggest that the $T1$-dependent processes , cell cycle control , p53-mediated pathway ( s ) , and ubiquitination interact through human $T2$ .
RAD52
UBE2I
0
These results suggest that the $T1$-dependent processes , cell cycle control , $T2$-mediated pathway ( s ) , and ubiquitination interact through human UBE2I .
RAD52
p53
0
The interaction of $T1$ with RAD52 is mediated by $T2$ 's self-association region .
UBE2I
RAD52
0
The interaction of UBE2I with $T1$ is mediated by $T2$ 's self-association region .
RAD52
RAD52
0
We demonstrate that $T1$ forms a specific complex with the cytoplasmic domain of the $T2$ when both are expressed as hybrid proteins in yeast cells .
IRS-1
insulin receptor
1
Although $T1$ is thought to interact with the $T2$ , the nature of the interaction has not been defined .
IRS-1
insulin receptor
1
In this study , we used the two-hybrid assay of protein-protein interaction in the yeast Saccharomyces cerevisiae to study the interaction between human $T1$ and the $T2$ .
IRS-1
insulin receptor
1
$T1$ ( IRS-1 ) is a major substrate of the $T2$ and has been implicated in insulin signaling .
Insulin receptor substrate 1
insulin receptor
1
Insulin receptor substrate 1 ( $T1$ ) is a major substrate of the $T2$ and has been implicated in insulin signaling .
IRS-1
insulin receptor
1
Characterization of an interaction between $T1$ and the $T2$ by using the two-hybrid system .
insulin receptor substrate 1
insulin receptor
1
$T1$ ( IRS-1 ) is a major substrate of the insulin receptor and has been implicated in $T2$ signaling .
Insulin receptor substrate 1
insulin
0
$T1$ ( $T2$ ) is a major substrate of the insulin receptor and has been implicated in insulin signaling .
Insulin receptor substrate 1
IRS-1
0
Insulin receptor substrate 1 ( $T1$ ) is a major substrate of the insulin receptor and has been implicated in $T2$ signaling .
IRS-1
insulin
0
Insulin receptor substrate 1 ( IRS-1 ) is a major substrate of the $T1$ and has been implicated in $T2$ signaling .
insulin receptor
insulin
0
Although $T1$ is thought to interact with the $T2$ receptor , the nature of the interaction has not been defined .
IRS-1
insulin
0
In this study , we used the two-hybrid assay of protein-protein interaction in the yeast Saccharomyces cerevisiae to study the interaction between human $T1$ and the $T2$ receptor .
IRS-1
insulin
0
In this study , we used the two-hybrid assay of protein-protein interaction in the yeast Saccharomyces cerevisiae to study the interaction between human IRS-1 and the $T1$$T2$ .
insulin
insulin receptor
0
Although IRS-1 is thought to interact with the $T1$$T2$ , the nature of the interaction has not been defined .
insulin
insulin receptor
0
Lastly , in agreement with our findings for yeast cells , we show that the $T1$ is unable to phosphorylate an $T2$ protein containing a deletion of amino acids 45 to 516 when expressed in COS cells .
insulin receptor
IRS-1
0
Using a genetic selection based on protein-protein interaction in yeast , we have identified two gene products that associate with the intracellular domain of $T1$ : Fas itself , and a novel 74 kDa protein we have named RIP , for $T2$ .
Fas
receptor interacting protein
1
$T1$ also interacts weakly with the p55 tumor necrosis factor receptor ( $T2$ ) intracellular domain , but not with a mutant version of Fas corresponding to the murine lprcg mutation .
RIP
TNFR1
1
Using a genetic selection based on protein-protein interaction in yeast , we have identified two gene products that associate with the intracellular domain of $T1$ : $T2$ itself , and a novel 74 kDa protein we have named RIP , for receptor interacting protein .
Fas
Fas
1
Using a genetic selection based on protein-protein interaction in yeast , we have identified two gene products that associate with the intracellular domain of $T1$ : Fas itself , and a novel 74 kDa protein we have named $T2$ , for receptor interacting protein .
Fas
RIP
1
$T1$ : a novel protein containing a death domain that interacts with Fas/$T2$ ( CD95 ) in yeast and causes cell death .
RIP
APO-1
1
$T1$ : a novel protein containing a death domain that interacts with Fas/APO-1 ( $T2$ ) in yeast and causes cell death .
RIP
CD95
1
$T1$ : a novel protein containing a death domain that interacts with $T2$/APO-1 ( CD95 ) in yeast and causes cell death .
RIP
Fas
1
RIP : a novel protein containing a death domain that interacts with $T1$/$T2$ ( CD95 ) in yeast and causes cell death .
Fas
APO-1
0
RIP : a novel protein containing a death domain that interacts with Fas/$T1$ ( $T2$ ) in yeast and causes cell death .
APO-1
CD95
0
RIP : a novel protein containing a death domain that interacts with $T1$/APO-1 ( $T2$ ) in yeast and causes cell death .
Fas
CD95
0
Ligation of the extracellular domain of the cell surface receptor Fas/$T1$ ( $T2$ ) elicits a characteristic programmed death response in susceptible cells .
APO-1
CD95
0
Ligation of the extracellular domain of the cell surface receptor $T1$/$T2$ ( CD95 ) elicits a characteristic programmed death response in susceptible cells .
Fas
APO-1
0
Ligation of the extracellular domain of the cell surface receptor $T1$/APO-1 ( $T2$ ) elicits a characteristic programmed death response in susceptible cells .
Fas
CD95
0
Using a genetic selection based on protein-protein interaction in yeast , we have identified two gene products that associate with the intracellular domain of Fas : Fas itself , and a novel 74 kDa protein we have named $T1$ , for $T2$ .
RIP
receptor interacting protein
0
Using a genetic selection based on protein-protein interaction in yeast , we have identified two gene products that associate with the intracellular domain of Fas : $T1$ itself , and a novel 74 kDa protein we have named $T2$ , for receptor interacting protein .
Fas
RIP
0
Using a genetic selection based on protein-protein interaction in yeast , we have identified two gene products that associate with the intracellular domain of Fas : $T1$ itself , and a novel 74 kDa protein we have named RIP , for $T2$ .
Fas
receptor interacting protein
0
$T1$ also interacts weakly with the $T2$ tumor necrosis factor receptor ( TNFR1 ) intracellular domain , but not with a mutant version of Fas corresponding to the murine lprcg mutation .
RIP
p55
0
$T1$ also interacts weakly with the p55 tumor necrosis factor receptor ( TNFR1 ) intracellular domain , but not with a mutant version of $T2$ corresponding to the murine lprcg mutation .
RIP
Fas
0
RIP also interacts weakly with the $T1$ tumor necrosis factor receptor ( $T2$ ) intracellular domain , but not with a mutant version of Fas corresponding to the murine lprcg mutation .
p55
TNFR1
0
RIP also interacts weakly with the $T1$ tumor necrosis factor receptor ( TNFR1 ) intracellular domain , but not with a mutant version of $T2$ corresponding to the murine lprcg mutation .
p55
Fas
0
RIP also interacts weakly with the p55 tumor necrosis factor receptor ( $T1$ ) intracellular domain , but not with a mutant version of $T2$ corresponding to the murine lprcg mutation .
TNFR1
Fas
0
$T1$ contains an N-terminal region with homology to protein kinases and a C-terminal region containing a cytoplasmic motif ( death domain ) present in the $T2$ and TNFR1 intracellular domains .
RIP
Fas
0
$T1$ contains an N-terminal region with homology to protein kinases and a C-terminal region containing a cytoplasmic motif ( death domain ) present in the Fas and $T2$ intracellular domains .
RIP
TNFR1
0
RIP contains an N-terminal region with homology to protein kinases and a C-terminal region containing a cytoplasmic motif ( death domain ) present in the $T1$ and $T2$ intracellular domains .
Fas
TNFR1
0
Interestingly , the $T1$ binding site overlaps the largest continuous hydrophobic patch on $T2$ .
ifnar2
IFNalpha2
1
Here , we quantitatively mapped the complete binding region of $T1$ on $T2$ by 35 individual mutations to alanine and isosteric residues .
ifnar2
interferon (IFN)alpha2
1
Relating the anti-viral and anti-proliferative activity of the various interferon mutants with their affinity toward $T1$ results in linear function over the whole range of affinities investigated , suggesting that $T2$ binding is the rate-determining step in cellular activation .
ifnar2
ifnar2
0
Type I interferons bind to two cell surface receptors , $T1$ and $T2$ , as the first step in the activation of several signal transduction pathways that elicit an anti-viral state and an anti-proliferative response .
ifnar1
ifnar2
0
We previously have shown that $T1$ purified from human HeLa cells is a multisubunit complex of four polypeptides designated $T2$ , -beta , -gamma , and -delta .
PTF
PTF alpha
0
We previously have shown that PTF purified from human HeLa cells is a multisubunit complex of four polypeptides designated $T1$$T2$ alpha , -beta , -gamma , and -delta .
PTF alpha
PTF
0
We now report the isolation and expression of cDNAs encoding $T1$ gamma and $T2$ delta , as well as functional studies with cognate antibodies that recognize the native PTF complex in HeLa extracts .
PTF
PTF
0
We now report the isolation and expression of cDNAs encoding $T1$ gamma and PTF delta , as well as functional studies with cognate antibodies that recognize the native $T2$ complex in HeLa extracts .
PTF
PTF
0
We previously have shown that $T1$ purified from human HeLa cells is a multisubunit complex of four polypeptides designated $T2$ alpha , -beta , -gamma , and -delta .
PTF
PTF
0
In addition , we show that in extracts depleted of $T1$ and TBP-associated factors , transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB , indicating that transcription of class II snRNA genes requires a $T2$ complex different from the one used for mRNA-encoding genes .
TBP
TBP
0
In addition , we show that in extracts depleted of $T1$ and TBP-associated factors , transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or $T2$ , indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes .
TBP
TFIIIB
0
In addition , we show that in extracts depleted of $T1$ and $T2$-associated factors , transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB , indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes .
TBP
TBP
0
In addition , we show that in extracts depleted of $T1$ and TBP-associated factors , transcription from the U1 promoter is restored by recombinant TBP but not by $T2$ or TFIIIB , indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes .
TBP
TFIID
0
In addition , we show that in extracts depleted of $T1$ and TBP-associated factors , transcription from the U1 promoter is restored by recombinant $T2$ but not by TFIID or TFIIIB , indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes .
TBP
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound $T1$ and TATA-bound $T2$ during promoter activation .
PTF
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP-$T1$-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound $T2$ during promoter activation .
TBP
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable $T1$-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound $T2$ during promoter activation .
TBP
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with $T1$ in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound $T2$ during promoter activation .
PTF
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of $T1$ with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound $T2$ during promoter activation .
TBP
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with $T1$ , consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound $T2$ during promoter activation .
TBP
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and $T1$ delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound $T2$ during promoter activation .
PTF
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant $T1$ gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound $T2$ during promoter activation .
PTF
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP-$T1$-associated factor complex or with possible functional interactions between PSE-bound $T2$ and TATA-bound TBP during promoter activation .
TBP
PTF
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable $T1$-TBP-associated factor complex or with possible functional interactions between PSE-bound $T2$ and TATA-bound TBP during promoter activation .
TBP
PTF
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with $T1$ in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound $T2$ and TATA-bound TBP during promoter activation .
PTF
PTF
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of $T1$ with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound $T2$ and TATA-bound TBP during promoter activation .
TBP
PTF
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with $T1$ , consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound $T2$ and TATA-bound TBP during promoter activation .
TBP
PTF
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and $T1$ delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound $T2$ and TATA-bound TBP during promoter activation .
PTF
PTF
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant $T1$ gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound $T2$ and TATA-bound TBP during promoter activation .
PTF
PTF
0
We now report the isolation and expression of cDNAs encoding PTF gamma and $T1$ delta , as well as functional studies with cognate antibodies that recognize the native $T2$ complex in HeLa extracts .
PTF
PTF
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable $T1$-$T2$-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation .
TBP
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with $T1$ in a semistable TBP-$T2$-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation .
PTF
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of $T1$ with PTF in a semistable TBP-$T2$-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation .
TBP
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with $T1$ , consistent either with the natural association of TBP with PTF in a semistable TBP-$T2$-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation .
TBP
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and $T1$ delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP-$T2$-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation .
PTF
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant $T1$ gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP-$T2$-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation .
PTF
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of TBP with $T1$ in a semistable $T2$-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation .
PTF
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of $T1$ with PTF in a semistable $T2$-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation .
TBP
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with $T1$ , consistent either with the natural association of TBP with PTF in a semistable $T2$-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation .
TBP
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and $T1$ delta with TBP , consistent either with the natural association of TBP with PTF in a semistable $T2$-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation .
PTF
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant $T1$ gamma and PTF delta with TBP , consistent either with the natural association of TBP with PTF in a semistable $T2$-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation .
PTF
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with TBP , consistent either with the natural association of $T1$ with $T2$ in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation .
TBP
PTF
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with $T1$ , consistent either with the natural association of TBP with $T2$ in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation .
TBP
PTF
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and $T1$ delta with TBP , consistent either with the natural association of TBP with $T2$ in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation .
PTF
PTF
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant $T1$ gamma and PTF delta with TBP , consistent either with the natural association of TBP with $T2$ in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation .
PTF
PTF
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and PTF delta with $T1$ , consistent either with the natural association of $T2$ with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation .
TBP
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and $T1$ delta with TBP , consistent either with the natural association of $T2$ with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation .
PTF
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant $T1$ gamma and PTF delta with TBP , consistent either with the natural association of $T2$ with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation .
PTF
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant PTF gamma and $T1$ delta with $T2$ , consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation .
PTF
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant $T1$ gamma and PTF delta with $T2$ , consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation .
PTF
TBP
0
Glutathione S-transferase pulldown assays further indicate relatively strong direct interactions of both recombinant $T1$ gamma and $T2$ delta with TBP , consistent either with the natural association of TBP with PTF in a semistable TBP-TBP-associated factor complex or with possible functional interactions between PSE-bound PTF and TATA-bound TBP during promoter activation .
PTF
PTF
0
The $T1$ ( $T2$ ) specifically recognizes the PSEs of both RNA polymerase II- and RNA polymerase III-transcribed small nuclear RNA ( snRNA ) genes .
proximal sequence element (PSE)-binding transcription factor
PTF
0
Immunoprecipitation studies confirm that the four $T1$ subunits originally found to copurify during conventional chromatography indeed form a tightly associated complex ; they further show that the $T2$ so defined , including the gamma and delta subunits specifically , is essential for transcription of both class II and class III snRNA genes .
PTF
PTF
0
Immunoprecipitation assays also show a weak substoichiometric association of the $T1$ ( $T2$ ) with PTF , consistent with the previous report of a PTF-related complex ( SNAPc ) containing substoichiometric levels of TBP and a component ( SNAPc43 ) identical in sequence to the PTF gamma reported here .
TATA-binding protein
TBP
0
Immunoprecipitation assays also show a weak substoichiometric association of the $T1$ ( TBP ) with $T2$ , consistent with the previous report of a PTF-related complex ( SNAPc ) containing substoichiometric levels of TBP and a component ( SNAPc43 ) identical in sequence to the PTF gamma reported here .
TATA-binding protein
PTF
0
Immunoprecipitation assays also show a weak substoichiometric association of the $T1$ ( TBP ) with PTF , consistent with the previous report of a $T2$-related complex ( SNAPc ) containing substoichiometric levels of TBP and a component ( SNAPc43 ) identical in sequence to the PTF gamma reported here .
TATA-binding protein
PTF
0
Immunoprecipitation assays also show a weak substoichiometric association of the $T1$ ( TBP ) with PTF , consistent with the previous report of a PTF-related complex ( $T2$ ) containing substoichiometric levels of TBP and a component ( SNAPc43 ) identical in sequence to the PTF gamma reported here .
TATA-binding protein
SNAPc
0
Immunoprecipitation assays also show a weak substoichiometric association of the $T1$ ( TBP ) with PTF , consistent with the previous report of a PTF-related complex ( SNAPc ) containing substoichiometric levels of $T2$ and a component ( SNAPc43 ) identical in sequence to the PTF gamma reported here .
TATA-binding protein
TBP
0
Immunoprecipitation assays also show a weak substoichiometric association of the $T1$ ( TBP ) with PTF , consistent with the previous report of a PTF-related complex ( SNAPc ) containing substoichiometric levels of TBP and a component ( $T2$ ) identical in sequence to the PTF gamma reported here .
TATA-binding protein
SNAPc43
0
Immunoprecipitation assays also show a weak substoichiometric association of the $T1$ ( TBP ) with PTF , consistent with the previous report of a PTF-related complex ( SNAPc ) containing substoichiometric levels of TBP and a component ( SNAPc43 ) identical in sequence to the $T2$ gamma reported here .
TATA-binding protein
PTF
0
Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein ( $T1$ ) with $T2$ , consistent with the previous report of a PTF-related complex ( SNAPc ) containing substoichiometric levels of TBP and a component ( SNAPc43 ) identical in sequence to the PTF gamma reported here .
TBP
PTF
0
Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein ( $T1$ ) with PTF , consistent with the previous report of a $T2$-related complex ( SNAPc ) containing substoichiometric levels of TBP and a component ( SNAPc43 ) identical in sequence to the PTF gamma reported here .
TBP
PTF
0
Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein ( $T1$ ) with PTF , consistent with the previous report of a PTF-related complex ( $T2$ ) containing substoichiometric levels of TBP and a component ( SNAPc43 ) identical in sequence to the PTF gamma reported here .
TBP
SNAPc
0
Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein ( $T1$ ) with PTF , consistent with the previous report of a PTF-related complex ( SNAPc ) containing substoichiometric levels of $T2$ and a component ( SNAPc43 ) identical in sequence to the PTF gamma reported here .
TBP
TBP
0
Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein ( $T1$ ) with PTF , consistent with the previous report of a PTF-related complex ( SNAPc ) containing substoichiometric levels of TBP and a component ( $T2$ ) identical in sequence to the PTF gamma reported here .
TBP
SNAPc43
0
Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein ( $T1$ ) with PTF , consistent with the previous report of a PTF-related complex ( SNAPc ) containing substoichiometric levels of TBP and a component ( SNAPc43 ) identical in sequence to the $T2$ gamma reported here .
TBP
PTF
0
Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein ( TBP ) with $T1$ , consistent with the previous report of a $T2$-related complex ( SNAPc ) containing substoichiometric levels of TBP and a component ( SNAPc43 ) identical in sequence to the PTF gamma reported here .
PTF
PTF
0
Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein ( TBP ) with $T1$ , consistent with the previous report of a PTF-related complex ( $T2$ ) containing substoichiometric levels of TBP and a component ( SNAPc43 ) identical in sequence to the PTF gamma reported here .
PTF
SNAPc
0
Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein ( TBP ) with $T1$ , consistent with the previous report of a PTF-related complex ( SNAPc ) containing substoichiometric levels of $T2$ and a component ( SNAPc43 ) identical in sequence to the PTF gamma reported here .
PTF
TBP
0
Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein ( TBP ) with $T1$ , consistent with the previous report of a PTF-related complex ( SNAPc ) containing substoichiometric levels of TBP and a component ( $T2$ ) identical in sequence to the PTF gamma reported here .
PTF
SNAPc43
0
Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein ( TBP ) with $T1$ , consistent with the previous report of a PTF-related complex ( SNAPc ) containing substoichiometric levels of TBP and a component ( SNAPc43 ) identical in sequence to the $T2$ gamma reported here .
PTF
PTF
0
In addition , we show that in extracts depleted of TBP and TBP-associated factors , transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or $T1$ , indicating that transcription of class II snRNA genes requires a $T2$ complex different from the one used for mRNA-encoding genes .
TFIIIB
TBP
0
In addition , we show that in extracts depleted of TBP and $T1$-associated factors , transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or TFIIIB , indicating that transcription of class II snRNA genes requires a $T2$ complex different from the one used for mRNA-encoding genes .
TBP
TBP
0
In addition , we show that in extracts depleted of TBP and TBP-associated factors , transcription from the U1 promoter is restored by recombinant TBP but not by $T1$ or TFIIIB , indicating that transcription of class II snRNA genes requires a $T2$ complex different from the one used for mRNA-encoding genes .
TFIID
TBP
0
In addition , we show that in extracts depleted of TBP and TBP-associated factors , transcription from the U1 promoter is restored by recombinant $T1$ but not by TFIID or TFIIIB , indicating that transcription of class II snRNA genes requires a $T2$ complex different from the one used for mRNA-encoding genes .
TBP
TBP
0
Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein ( TBP ) with PTF , consistent with the previous report of a $T1$-related complex ( $T2$ ) containing substoichiometric levels of TBP and a component ( SNAPc43 ) identical in sequence to the PTF gamma reported here .
PTF
SNAPc
0
Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein ( TBP ) with PTF , consistent with the previous report of a $T1$-related complex ( SNAPc ) containing substoichiometric levels of $T2$ and a component ( SNAPc43 ) identical in sequence to the PTF gamma reported here .
PTF
TBP
0
Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein ( TBP ) with PTF , consistent with the previous report of a $T1$-related complex ( SNAPc ) containing substoichiometric levels of TBP and a component ( $T2$ ) identical in sequence to the PTF gamma reported here .
PTF
SNAPc43
0
Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein ( TBP ) with PTF , consistent with the previous report of a $T1$-related complex ( SNAPc ) containing substoichiometric levels of TBP and a component ( SNAPc43 ) identical in sequence to the $T2$ gamma reported here .
PTF
PTF
0
In addition , we show that in extracts depleted of TBP and $T1$-associated factors , transcription from the U1 promoter is restored by recombinant TBP but not by TFIID or $T2$ , indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes .
TBP
TFIIIB
0
In addition , we show that in extracts depleted of TBP and TBP-associated factors , transcription from the U1 promoter is restored by recombinant TBP but not by $T1$ or $T2$ , indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes .
TFIID
TFIIIB
0
In addition , we show that in extracts depleted of TBP and TBP-associated factors , transcription from the U1 promoter is restored by recombinant $T1$ but not by TFIID or $T2$ , indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes .
TBP
TFIIIB
0
Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein ( TBP ) with PTF , consistent with the previous report of a PTF-related complex ( $T1$ ) containing substoichiometric levels of $T2$ and a component ( SNAPc43 ) identical in sequence to the PTF gamma reported here .
SNAPc
TBP
0
Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein ( TBP ) with PTF , consistent with the previous report of a PTF-related complex ( $T1$ ) containing substoichiometric levels of TBP and a component ( $T2$ ) identical in sequence to the PTF gamma reported here .
SNAPc
SNAPc43
0
Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein ( TBP ) with PTF , consistent with the previous report of a PTF-related complex ( $T1$ ) containing substoichiometric levels of TBP and a component ( SNAPc43 ) identical in sequence to the $T2$ gamma reported here .
SNAPc
PTF
0
Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein ( TBP ) with PTF , consistent with the previous report of a PTF-related complex ( SNAPc ) containing substoichiometric levels of $T1$ and a component ( $T2$ ) identical in sequence to the PTF gamma reported here .
TBP
SNAPc43
0
Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein ( TBP ) with PTF , consistent with the previous report of a PTF-related complex ( SNAPc ) containing substoichiometric levels of $T1$ and a component ( SNAPc43 ) identical in sequence to the $T2$ gamma reported here .
TBP
PTF
0
Immunoprecipitation assays also show a weak substoichiometric association of the TATA-binding protein ( TBP ) with PTF , consistent with the previous report of a PTF-related complex ( SNAPc ) containing substoichiometric levels of TBP and a component ( $T1$ ) identical in sequence to the $T2$ gamma reported here .
SNAPc43
PTF
0
In addition , we show that in extracts depleted of TBP and $T1$-associated factors , transcription from the U1 promoter is restored by recombinant TBP but not by $T2$ or TFIIIB , indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes .
TBP
TFIID
0
In addition , we show that in extracts depleted of TBP and $T1$-associated factors , transcription from the U1 promoter is restored by recombinant $T2$ but not by TFIID or TFIIIB , indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes .
TBP
TBP
0
In addition , we show that in extracts depleted of TBP and TBP-associated factors , transcription from the U1 promoter is restored by recombinant $T1$ but not by $T2$ or TFIIIB , indicating that transcription of class II snRNA genes requires a TBP complex different from the one used for mRNA-encoding genes .
TBP
TFIID
0
Present data concerning the $T1$-$T2$ system of extrarenal origin .
renin
angiotensin
0
After a brief historical incursion regarding $T1$ of renal origin , we present the main extrarenal angiotensin-forming enzymes , starting with isorenin , $T2$ , D and G cathepsin and ending with the conversion enzyme and chymase .
RAS
tonin
0
After a brief historical incursion regarding $T1$ of renal origin , we present the main extrarenal angiotensin-forming enzymes , starting with isorenin , tonin , D and $T2$ and ending with the conversion enzyme and chymase .
RAS
G cathepsin
0
After a brief historical incursion regarding $T1$ of renal origin , we present the main extrarenal $T2$-forming enzymes , starting with isorenin , tonin , D and G cathepsin and ending with the conversion enzyme and chymase .
RAS
angiotensin
0
After a brief historical incursion regarding $T1$ of renal origin , we present the main extrarenal angiotensin-forming enzymes , starting with $T2$ , tonin , D and G cathepsin and ending with the conversion enzyme and chymase .
RAS
isorenin
0
After a brief historical incursion regarding $T1$ of renal origin , we present the main extrarenal angiotensin-forming enzymes , starting with isorenin , tonin , D and G cathepsin and ending with the conversion enzyme and $T2$ .
RAS
chymase
0
After a brief historical incursion regarding RAS of renal origin , we present the main extrarenal angiotensin-forming enzymes , starting with isorenin , $T1$ , D and $T2$ and ending with the conversion enzyme and chymase .
tonin
G cathepsin
0
After a brief historical incursion regarding RAS of renal origin , we present the main extrarenal $T1$-forming enzymes , starting with isorenin , $T2$ , D and G cathepsin and ending with the conversion enzyme and chymase .
angiotensin
tonin
0
After a brief historical incursion regarding RAS of renal origin , we present the main extrarenal angiotensin-forming enzymes , starting with $T1$ , $T2$ , D and G cathepsin and ending with the conversion enzyme and chymase .
isorenin
tonin
0
After a brief historical incursion regarding RAS of renal origin , we present the main extrarenal angiotensin-forming enzymes , starting with isorenin , $T1$ , D and G cathepsin and ending with the conversion enzyme and $T2$ .
tonin
chymase
0
After a brief historical incursion regarding RAS of renal origin , we present the main extrarenal $T1$-forming enzymes , starting with isorenin , tonin , D and $T2$ and ending with the conversion enzyme and chymase .
angiotensin
G cathepsin
0
After a brief historical incursion regarding RAS of renal origin , we present the main extrarenal angiotensin-forming enzymes , starting with $T1$ , tonin , D and $T2$ and ending with the conversion enzyme and chymase .
isorenin
G cathepsin
0
After a brief historical incursion regarding RAS of renal origin , we present the main extrarenal angiotensin-forming enzymes , starting with isorenin , tonin , D and $T1$ and ending with the conversion enzyme and $T2$ .
G cathepsin
chymase
0
After a brief historical incursion regarding RAS of renal origin , we present the main extrarenal $T1$-forming enzymes , starting with $T2$ , tonin , D and G cathepsin and ending with the conversion enzyme and chymase .
angiotensin
isorenin
0
After a brief historical incursion regarding RAS of renal origin , we present the main extrarenal $T1$-forming enzymes , starting with isorenin , tonin , D and G cathepsin and ending with the conversion enzyme and $T2$ .
angiotensin
chymase
0
After a brief historical incursion regarding RAS of renal origin , we present the main extrarenal angiotensin-forming enzymes , starting with $T1$ , tonin , D and G cathepsin and ending with the conversion enzyme and $T2$ .
isorenin
chymase
0
In the end we refer to the relations between circulating $T1$ of renal origin and the extrarenal $T2$ specific to tissue underlying the fact that the two RAS components cooperate and constitute a unitary hormonal system , regulating the major functions of the organism and maintaining the main homeostatic equilibria .
RAS
RAS
0
In the end we refer to the relations between circulating $T1$ of renal origin and the extrarenal RAS specific to tissue underlying the fact that the two $T2$ components cooperate and constitute a unitary hormonal system , regulating the major functions of the organism and maintaining the main homeostatic equilibria .
RAS
RAS
0
In the end we refer to the relations between circulating RAS of renal origin and the extrarenal $T1$ specific to tissue underlying the fact that the two $T2$ components cooperate and constitute a unitary hormonal system , regulating the major functions of the organism and maintaining the main homeostatic equilibria .
RAS
RAS
0
While the circulating $T1$ of renal origin is acutely activated to contribute to the accomplishment of short term homeostatic reactions , tissue $T2$ , in paracrine or autocrine ways , exerts local-regional adaptive actions of long duration .
RAS
RAS
0
$T1$ ( neuromodulin , B-50 , F1 ) , a $T2$ ( PKC ) substrate important for the growth and plasticity of neuronal connections , has been implicated in vitro in several signal transduction pathways .
GAP-43
protein kinase C
1
Surprisingly , the N-terminal third of GAP-43 alone bound $T1$ more strongly than did intact $T2$ , suggesting that the protein 's C-terminus may play a role in modulating the interaction with CaM .
CaM
GAP-43
1
These results , along with other recent findings , suggest a novel role for the interaction between $T1$ and $T2$ .
GAP-43
CaM
1
$T1$ phosphorylates $T2$ on serine 41 .
PKC
GAP-43
1
Surprisingly , the N-terminal third of $T1$ alone bound $T2$ more strongly than did intact GAP-43 , suggesting that the protein 's C-terminus may play a role in modulating the interaction with CaM .
GAP-43
CaM
1
In the yeast-based cloning system , the only strong interaction that was detected between $T1$ and the calcium effector protein , calmodulin ( $T2$ ) .
GAP-43
CaM
1
GAP-43 ( neuromodulin , B-50 , $T1$ ) , a protein kinase C ( $T2$ ) substrate important for the growth and plasticity of neuronal connections , has been implicated in vitro in several signal transduction pathways .
F1
PKC
1
In the yeast-based cloning system , the only strong interaction that was detected between $T1$ and the calcium effector protein , $T2$ ( CaM ) .
GAP-43
calmodulin
1
GAP-43 ( neuromodulin , $T1$ , F1 ) , a protein kinase C ( $T2$ ) substrate important for the growth and plasticity of neuronal connections , has been implicated in vitro in several signal transduction pathways .
B-50
PKC
1
GAP-43 ( neuromodulin , B-50 , $T1$ ) , a $T2$ ( PKC ) substrate important for the growth and plasticity of neuronal connections , has been implicated in vitro in several signal transduction pathways .
F1
protein kinase C
1
GAP-43 ( $T1$ , B-50 , F1 ) , a protein kinase C ( $T2$ ) substrate important for the growth and plasticity of neuronal connections , has been implicated in vitro in several signal transduction pathways .
neuromodulin
PKC
1
GAP-43 ( neuromodulin , $T1$ , F1 ) , a $T2$ ( PKC ) substrate important for the growth and plasticity of neuronal connections , has been implicated in vitro in several signal transduction pathways .
B-50
protein kinase C
1
$T1$ ( neuromodulin , B-50 , F1 ) , a protein kinase C ( $T2$ ) substrate important for the growth and plasticity of neuronal connections , has been implicated in vitro in several signal transduction pathways .
GAP-43
PKC
1
GAP-43 ( $T1$ , B-50 , F1 ) , a $T2$ ( PKC ) substrate important for the growth and plasticity of neuronal connections , has been implicated in vitro in several signal transduction pathways .
neuromodulin
protein kinase C
1
$T1$ ( neuromodulin , B-50 , $T2$ ) , a protein kinase C ( PKC ) substrate important for the growth and plasticity of neuronal connections , has been implicated in vitro in several signal transduction pathways .
GAP-43
F1
0
$T1$ ( $T2$ , B-50 , F1 ) , a protein kinase C ( PKC ) substrate important for the growth and plasticity of neuronal connections , has been implicated in vitro in several signal transduction pathways .
GAP-43
neuromodulin
0
$T1$ ( neuromodulin , $T2$ , F1 ) , a protein kinase C ( PKC ) substrate important for the growth and plasticity of neuronal connections , has been implicated in vitro in several signal transduction pathways .
GAP-43
B-50
0
GAP-43 ( $T1$ , B-50 , $T2$ ) , a protein kinase C ( PKC ) substrate important for the growth and plasticity of neuronal connections , has been implicated in vitro in several signal transduction pathways .
neuromodulin
F1
0
GAP-43 ( neuromodulin , $T1$ , $T2$ ) , a protein kinase C ( PKC ) substrate important for the growth and plasticity of neuronal connections , has been implicated in vitro in several signal transduction pathways .
B-50
F1
0
GAP-43 ( neuromodulin , B-50 , F1 ) , a $T1$ ( $T2$ ) substrate important for the growth and plasticity of neuronal connections , has been implicated in vitro in several signal transduction pathways .
protein kinase C
PKC
0
GAP-43 ( $T1$ , $T2$ , F1 ) , a protein kinase C ( PKC ) substrate important for the growth and plasticity of neuronal connections , has been implicated in vitro in several signal transduction pathways .
neuromodulin
B-50
0
In the yeast-based cloning system , the only strong interaction that was detected between GAP-43 and the $T1$ , $T2$ ( CaM ) .
calcium effector protein
calmodulin
0
In the yeast-based cloning system , the only strong interaction that was detected between GAP-43 and the $T1$ , calmodulin ( $T2$ ) .
calcium effector protein
CaM
0
In the yeast-based cloning system , the only strong interaction that was detected between $T1$ and the $T2$ , calmodulin ( CaM ) .
GAP-43
calcium effector protein
0
In the yeast-based cloning system , the only strong interaction that was detected between GAP-43 and the calcium effector protein , $T1$ ( $T2$ ) .
calmodulin
CaM
0
Surprisingly , the N-terminal third of $T1$ alone bound CaM more strongly than did intact $T2$ , suggesting that the protein 's C-terminus may play a role in modulating the interaction with CaM .
GAP-43
GAP-43
0
Surprisingly , the N-terminal third of $T1$ alone bound CaM more strongly than did intact GAP-43 , suggesting that the protein 's C-terminus may play a role in modulating the interaction with $T2$ .
GAP-43
CaM
0
Surprisingly , the N-terminal third of GAP-43 alone bound $T1$ more strongly than did intact GAP-43 , suggesting that the protein 's C-terminus may play a role in modulating the interaction with $T2$ .
CaM
CaM
0
Surprisingly , the N-terminal third of GAP-43 alone bound CaM more strongly than did intact $T1$ , suggesting that the protein 's C-terminus may play a role in modulating the interaction with $T2$ .
GAP-43
CaM
0
The specificity of intehraction between $T1$ and $T2$ was confirmed by an in vitro binding assay using recombinant proteins .
G alpha i2
nucleobindin
1
Interaction of the protein $T1$ with $T2$ , as revealed by the yeast two-hybrid system .
nucleobindin
G alpha i2
1
Transfection of $T1$ and $T2$ in COS cells increased G alpha i2 expression relative to cells transfected with G alpha i2 and mock vector .
G alpha i2
nucleobindin
0
Transfection of $T1$ and nucleobindin in COS cells increased $T2$ expression relative to cells transfected with G alpha i2 and mock vector .
G alpha i2
G alpha i2
0
Transfection of $T1$ and nucleobindin in COS cells increased G alpha i2 expression relative to cells transfected with $T2$ and mock vector .
G alpha i2
G alpha i2
0
Transfection of G alpha i2 and $T1$ in COS cells increased $T2$ expression relative to cells transfected with G alpha i2 and mock vector .
nucleobindin
G alpha i2
0
Transfection of G alpha i2 and $T1$ in COS cells increased G alpha i2 expression relative to cells transfected with $T2$ and mock vector .
nucleobindin
G alpha i2
0
Transfection of G alpha i2 and nucleobindin in COS cells increased $T1$ expression relative to cells transfected with $T2$ and mock vector .
G alpha i2
G alpha i2
0
The results show that $T1$ heterodimerizes with E12 and $T2$ in vivo , but it does not homodimerize to a measurable extent .
myogenin
E47
1
$T1$ is a muscle-specific HLH protein that binds DNA in vitro as a heterodimer with several widely expressed HLH proteins , such as the E2A gene products E12 and $T2$ .
Myogenin
E47
1
The results show that $T1$ heterodimerizes with $T2$ and E47 in vivo , but it does not homodimerize to a measurable extent .
myogenin
E12
1
$T1$ is a muscle-specific HLH protein that binds DNA in vitro as a heterodimer with several widely expressed HLH proteins , such as the E2A gene products $T2$ and E47 .
Myogenin
E12
1
Analysis of the oligomerization of $T1$ and $T2$ products in vivo using a two-hybrid assay system .
myogenin
E2A
0
$T1$ is a muscle-specific HLH protein that binds DNA in vitro as a heterodimer with several widely expressed HLH proteins , such as the $T2$ gene products E12 and E47 .
Myogenin
E2A
0
Myogenin is a muscle-specific HLH protein that binds DNA in vitro as a heterodimer with several widely expressed HLH proteins , such as the $T1$ gene products E12 and $T2$ .
E2A
E47
0
Myogenin is a muscle-specific HLH protein that binds DNA in vitro as a heterodimer with several widely expressed HLH proteins , such as the E2A gene products $T1$ and $T2$ .
E12
E47
0
Myogenin is a muscle-specific HLH protein that binds DNA in vitro as a heterodimer with several widely expressed HLH proteins , such as the $T1$ gene products $T2$ and E47 .
E2A
E12
0
The results show that myogenin heterodimerizes with $T1$ and $T2$ in vivo , but it does not homodimerize to a measurable extent .
E12
E47
0
Peptide growth factors , as well as the immediate early gene products $T1$ , $T2$ , and c-Myc , inhibit the activity of myogenin through a mechanism independent of its association with E2A products .
c-Jun
v-Fos
0
Peptide growth factors , as well as the immediate early gene products $T1$ , v-Fos , and $T2$ , inhibit the activity of myogenin through a mechanism independent of its association with E2A products .
c-Jun
c-Myc
0
Peptide growth factors , as well as the immediate early gene products $T1$ , v-Fos , and c-Myc , inhibit the activity of myogenin through a mechanism independent of its association with $T2$ products .
c-Jun
E2A
0
Peptide growth factors , as well as the immediate early gene products c-Jun , $T1$ , and $T2$ , inhibit the activity of myogenin through a mechanism independent of its association with E2A products .
v-Fos
c-Myc
0
Peptide growth factors , as well as the immediate early gene products c-Jun , $T1$ , and c-Myc , inhibit the activity of myogenin through a mechanism independent of its association with $T2$ products .
v-Fos
E2A
0
Peptide growth factors , as well as the immediate early gene products c-Jun , v-Fos , and $T1$ , inhibit the activity of myogenin through a mechanism independent of its association with $T2$ products .
c-Myc
E2A
0
When human embryonic kidney cells ( cell line 293 ) over-expressing IL-1RI or HeLa cells were exposed to IL-1 , $T1$ rapidly associated with the $T2$ complex and was phosphorylated .
IRAK
IL-1RI
1
The pleiotropic biological activities of $T1$ ( IL-1 ) are mediated by its type I receptor ( $T2$ ) .
interleukin-1
IL-1RI
1
The pleiotropic biological activities of interleukin-1 ( $T1$ ) are mediated by its type I receptor ( $T2$ ) .
IL-1
IL-1RI
1
$T1$ : a kinase associated with the $T2$ .
IRAK
interleukin-1 receptor
1
The pleiotropic biological activities of $T1$ ( $T2$ ) are mediated by its type I receptor ( IL-1RI ) .
interleukin-1
IL-1
0
When the ligand binds , $T1$ initiates a signaling cascade that results in the activation of the transcription regulator $T2$ ( NF-kappa B ) .
IL-1RI
nuclear factor kappa B
0
When the ligand binds , $T1$ initiates a signaling cascade that results in the activation of the transcription regulator nuclear factor kappa B ( $T2$ ) .
IL-1RI
NF-kappa B
0
When the ligand binds , IL-1RI initiates a signaling cascade that results in the activation of the transcription regulator $T1$ ( $T2$ ) .
nuclear factor kappa B
NF-kappa B
0
A protein kinase designated IRAK ( $T1$$T2$ ) was purified , and its complementary DNA was molecularly cloned .
IL-1
IL-1 receptor-associated kinase
0
A protein kinase designated $T1$ ( $T2$ receptor-associated kinase ) was purified , and its complementary DNA was molecularly cloned .
IRAK
IL-1
0
A protein kinase designated $T1$ ( $T2$ ) was purified , and its complementary DNA was molecularly cloned .
IRAK
IL-1 receptor-associated kinase
0
When human embryonic kidney cells ( cell line 293 ) over-expressing $T1$ or HeLa cells were exposed to $T2$ , IRAK rapidly associated with the IL-1RI complex and was phosphorylated .
IL-1RI
IL-1
0
When human embryonic kidney cells ( cell line 293 ) over-expressing $T1$ or HeLa cells were exposed to IL-1 , $T2$ rapidly associated with the IL-1RI complex and was phosphorylated .
IL-1RI
IRAK
0
When human embryonic kidney cells ( cell line 293 ) over-expressing $T1$ or HeLa cells were exposed to IL-1 , IRAK rapidly associated with the $T2$ complex and was phosphorylated .
IL-1RI
IL-1RI
0
When human embryonic kidney cells ( cell line 293 ) over-expressing IL-1RI or HeLa cells were exposed to $T1$ , $T2$ rapidly associated with the IL-1RI complex and was phosphorylated .
IL-1
IRAK
0
When human embryonic kidney cells ( cell line 293 ) over-expressing IL-1RI or HeLa cells were exposed to $T1$ , IRAK rapidly associated with the $T2$ complex and was phosphorylated .
IL-1
IL-1RI
0
The primary amino acid sequence of $T1$ shares similarity with that of pelle , a protein kinase that is essential for the activation of a $T2$ homolog in Drosophila .
IRAK
NF-kappa B
0
Assaying of $T1$ , complement factors , and $T2$ in the diagnosis of malignant serous effusions .
tumor necrosis factor alpha
alpha-1-antitrypsin
0
The objective of this study was to measure the concentrations of $T1$ ( TNFalpha ) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha , $T2$ ( alpha1AT ) , and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion .
tumor necrosis factor-alpha
alpha-1-antitrypsin
0
The objective of this study was to measure the concentrations of $T1$ ( TNFalpha ) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha , alpha-1-antitrypsin ( $T2$ ) , and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion .
tumor necrosis factor-alpha
alpha1AT
0
The objective of this study was to measure the concentrations of $T1$ ( $T2$ ) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha , alpha-1-antitrypsin ( alpha1AT ) , and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion .
tumor necrosis factor-alpha
TNFalpha
0
The objective of this study was to measure the concentrations of $T1$ ( TNFalpha ) in pleural and peritoneal effusions of different causes and to verify whether $T2$ , alpha-1-antitrypsin ( alpha1AT ) , and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion .
tumor necrosis factor-alpha
TNFalpha
0
The objective of this study was to measure the concentrations of $T1$ ( TNFalpha ) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha , alpha-1-antitrypsin ( alpha1AT ) , and complement factors $T2$ and C4 can be used in the differential diagnosis of serous effusion .
tumor necrosis factor-alpha
C3
0
The objective of this study was to measure the concentrations of $T1$ ( TNFalpha ) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha , alpha-1-antitrypsin ( alpha1AT ) , and complement factors C3 and $T2$ can be used in the differential diagnosis of serous effusion .
tumor necrosis factor-alpha
C4
0
The objective of this study was to measure the concentrations of tumor necrosis factor-alpha ( TNFalpha ) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha , $T1$ ( $T2$ ) , and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion .
alpha-1-antitrypsin
alpha1AT
0
The objective of this study was to measure the concentrations of tumor necrosis factor-alpha ( $T1$ ) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha , $T2$ ( alpha1AT ) , and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion .
TNFalpha
alpha-1-antitrypsin
0
The objective of this study was to measure the concentrations of tumor necrosis factor-alpha ( TNFalpha ) in pleural and peritoneal effusions of different causes and to verify whether $T1$ , $T2$ ( alpha1AT ) , and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion .
TNFalpha
alpha-1-antitrypsin
0
The objective of this study was to measure the concentrations of tumor necrosis factor-alpha ( TNFalpha ) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha , $T1$ ( alpha1AT ) , and complement factors $T2$ and C4 can be used in the differential diagnosis of serous effusion .
alpha-1-antitrypsin
C3
0
The objective of this study was to measure the concentrations of tumor necrosis factor-alpha ( TNFalpha ) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha , $T1$ ( alpha1AT ) , and complement factors C3 and $T2$ can be used in the differential diagnosis of serous effusion .
alpha-1-antitrypsin
C4
0
The objective of this study was to measure the concentrations of tumor necrosis factor-alpha ( $T1$ ) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha , alpha-1-antitrypsin ( $T2$ ) , and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion .
TNFalpha
alpha1AT
0
The objective of this study was to measure the concentrations of tumor necrosis factor-alpha ( TNFalpha ) in pleural and peritoneal effusions of different causes and to verify whether $T1$ , alpha-1-antitrypsin ( $T2$ ) , and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion .
TNFalpha
alpha1AT
0
The objective of this study was to measure the concentrations of tumor necrosis factor-alpha ( TNFalpha ) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha , alpha-1-antitrypsin ( $T1$ ) , and complement factors $T2$ and C4 can be used in the differential diagnosis of serous effusion .
alpha1AT
C3
0
The objective of this study was to measure the concentrations of tumor necrosis factor-alpha ( TNFalpha ) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha , alpha-1-antitrypsin ( $T1$ ) , and complement factors C3 and $T2$ can be used in the differential diagnosis of serous effusion .
alpha1AT
C4
0
The objective of this study was to measure the concentrations of tumor necrosis factor-alpha ( $T1$ ) in pleural and peritoneal effusions of different causes and to verify whether $T2$ , alpha-1-antitrypsin ( alpha1AT ) , and complement factors C3 and C4 can be used in the differential diagnosis of serous effusion .
TNFalpha
TNFalpha
0
The objective of this study was to measure the concentrations of tumor necrosis factor-alpha ( $T1$ ) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha , alpha-1-antitrypsin ( alpha1AT ) , and complement factors $T2$ and C4 can be used in the differential diagnosis of serous effusion .
TNFalpha
C3
0
The objective of this study was to measure the concentrations of tumor necrosis factor-alpha ( $T1$ ) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha , alpha-1-antitrypsin ( alpha1AT ) , and complement factors C3 and $T2$ can be used in the differential diagnosis of serous effusion .
TNFalpha
C4
0
The objective of this study was to measure the concentrations of tumor necrosis factor-alpha ( TNFalpha ) in pleural and peritoneal effusions of different causes and to verify whether $T1$ , alpha-1-antitrypsin ( alpha1AT ) , and complement factors $T2$ and C4 can be used in the differential diagnosis of serous effusion .
TNFalpha
C3
0
The objective of this study was to measure the concentrations of tumor necrosis factor-alpha ( TNFalpha ) in pleural and peritoneal effusions of different causes and to verify whether $T1$ , alpha-1-antitrypsin ( alpha1AT ) , and complement factors C3 and $T2$ can be used in the differential diagnosis of serous effusion .
TNFalpha
C4
0
$T1$ , $T2$ , and complement factors C3 and C4 concentrations were measured simultaneously in blood and serous effusion using commercially available methods .
TNFalpha
alpha1AT
0
$T1$ , alpha1AT , and complement factors $T2$ and C4 concentrations were measured simultaneously in blood and serous effusion using commercially available methods .
TNFalpha
C3
0
$T1$ , alpha1AT , and complement factors C3 and $T2$ concentrations were measured simultaneously in blood and serous effusion using commercially available methods .
TNFalpha
C4
0
TNFalpha , $T1$ , and complement factors $T2$ and C4 concentrations were measured simultaneously in blood and serous effusion using commercially available methods .
alpha1AT
C3
0
TNFalpha , $T1$ , and complement factors C3 and $T2$ concentrations were measured simultaneously in blood and serous effusion using commercially available methods .
alpha1AT
C4
0
TNFalpha , alpha1AT , and complement factors $T1$ and $T2$ concentrations were measured simultaneously in blood and serous effusion using commercially available methods .
C3
C4
0
The objective of this study was to measure the concentrations of tumor necrosis factor-alpha ( TNFalpha ) in pleural and peritoneal effusions of different causes and to verify whether TNFalpha , alpha-1-antitrypsin ( alpha1AT ) , and complement factors $T1$ and $T2$ can be used in the differential diagnosis of serous effusion .
C3
C4
0
Their order of selection was $T1$ effusion , $T2$ serum , TNFalpha-effusion , and C3 effusion .
alpha1AT
C4
0
Their order of selection was $T1$ effusion , C4 serum , $T2$-effusion , and C3 effusion .
alpha1AT
TNFalpha
0
Their order of selection was $T1$ effusion , C4 serum , TNFalpha-effusion , and $T2$ effusion .
alpha1AT
C3
0
Their order of selection was alpha1AT effusion , $T1$ serum , $T2$-effusion , and C3 effusion .
C4
TNFalpha
0
Their order of selection was alpha1AT effusion , $T1$ serum , TNFalpha-effusion , and $T2$ effusion .
C4
C3
0
Their order of selection was alpha1AT effusion , C4 serum , $T1$-effusion , and $T2$ effusion .
TNFalpha
C3
0
Determination of $T1$ , complement factors C3 and C4 , and $T2$ may be a significant parameter in the differential diagnosis of serous effusions , particularly in those patients with malignant disease .
TNFalpha
alpha1AT
0
Determination of $T1$ , complement factors $T2$ and C4 , and alpha1AT may be a significant parameter in the differential diagnosis of serous effusions , particularly in those patients with malignant disease .
TNFalpha
C3
0
Determination of $T1$ , complement factors C3 and $T2$ , and alpha1AT may be a significant parameter in the differential diagnosis of serous effusions , particularly in those patients with malignant disease .
TNFalpha
C4
0
Determination of TNFalpha , complement factors $T1$ and C4 , and $T2$ may be a significant parameter in the differential diagnosis of serous effusions , particularly in those patients with malignant disease .
C3
alpha1AT
0
Determination of TNFalpha , complement factors C3 and $T1$ , and $T2$ may be a significant parameter in the differential diagnosis of serous effusions , particularly in those patients with malignant disease .
C4
alpha1AT
0
Determination of TNFalpha , complement factors $T1$ and $T2$ , and alpha1AT may be a significant parameter in the differential diagnosis of serous effusions , particularly in those patients with malignant disease .
C3
C4
0
Endogenous $T1$-$T2$ complexes were detected in human CSF by immunoprecipitation .
TTR
A beta
1
Using site-directed mutagenesis and computer-assisted modelling , we identified amino acid residues on the surface of the $T1$ monomer that interact with $T2$ .
TTR
A beta
1
$T1$ ( TTR ) , a second major CSF protein , formed SDS-stable complexes with $T2$ and significantly decreased the rate of A beta fibril formation .
Transthyretin
A beta
1
Transthyretin ( $T1$ ) , a second major CSF protein , formed SDS-stable complexes with $T2$ and significantly decreased the rate of A beta fibril formation .
TTR
A beta
1
Interaction of $T1$ with $T2$ : binding and inhibition of amyloid formation .
transthyretin
amyloid beta-protein
1
Aggregated $T1$ ( $T2$ ) is a key component of the amyloid depositions found in the brains of patients with Alzheimer 's disease .
amyloid beta-protein
A beta
0
The analysis of complexes of $T1$ with CSF proteins in a KBr gradient revealed an association of $T2$ only with free proteins and not with lipoprotein particles .
A beta
A beta
0
Transthyretin ( TTR ) , a second major CSF protein , formed SDS-stable complexes with $T1$ and significantly decreased the rate of $T2$ fibril formation .
A beta
A beta
0
$T1$ ( TTR ) , a second major CSF protein , formed SDS-stable complexes with A beta and significantly decreased the rate of $T2$ fibril formation .
Transthyretin
A beta
0
Transthyretin ( $T1$ ) , a second major CSF protein , formed SDS-stable complexes with A beta and significantly decreased the rate of $T2$ fibril formation .
TTR
A beta
0
In physiological buffers and CSF , $T1$ exclusively decreased the level of $T2$ pentamers .
TTR
A beta
0
$T1$ ( $T2$ ) , a second major CSF protein , formed SDS-stable complexes with A beta and significantly decreased the rate of A beta fibril formation .
Transthyretin
TTR
0
We propose that $T1$ binding proteins play a key role in the modulation of $T2$ aggregation and normally prevent amyloid formation in biological fluids and in the brain .
A beta
A beta
0
We report chemotaxis and competitive binding studies that show $T1$ binds to and activates CCR1 and $T2$ transfected HEK-293 cells .
LEC
CCR8
1
$T1$ induces chemotaxis and adhesion by interacting with CCR1 and $T2$ .
LEC
CCR8
1
We report chemotaxis and competitive binding studies that show $T1$ binds to and activates $T2$ and CCR8 transfected HEK-293 cells .
LEC
CCR1
1
$T1$ induces chemotaxis and adhesion by interacting with $T2$ and CCR8 .
LEC
CCR1
1
LEC induces chemotaxis and adhesion by interacting with $T1$ and $T2$ .
CCR1
CCR8
0
Liver-expressed chemokine ( LEC ) is an unusually large CC chemokine , which is also known as $T1$ , $T2$ , NCC-4 , and CCL16 .
LMC
HCC-4
0
$T1$ ( LEC ) is an unusually large CC chemokine , which is also known as $T2$ , HCC-4 , NCC-4 , and CCL16 .
Liver-expressed chemokine
LMC
0
Liver-expressed chemokine ( $T1$ ) is an unusually large CC chemokine , which is also known as $T2$ , HCC-4 , NCC-4 , and CCL16 .
LEC
LMC
0
Liver-expressed chemokine ( LEC ) is an unusually large CC chemokine , which is also known as $T1$ , HCC-4 , $T2$ , and CCL16 .
LMC
NCC-4
0
Liver-expressed chemokine ( LEC ) is an unusually large CC chemokine , which is also known as $T1$ , HCC-4 , NCC-4 , and $T2$ .
LMC
CCL16
0
$T1$ ( LEC ) is an unusually large CC chemokine , which is also known as LMC , $T2$ , NCC-4 , and CCL16 .
Liver-expressed chemokine
HCC-4
0
Liver-expressed chemokine ( $T1$ ) is an unusually large CC chemokine , which is also known as LMC , $T2$ , NCC-4 , and CCL16 .
LEC
HCC-4
0
Liver-expressed chemokine ( LEC ) is an unusually large CC chemokine , which is also known as LMC , $T1$ , $T2$ , and CCL16 .
HCC-4
NCC-4
0
Liver-expressed chemokine ( LEC ) is an unusually large CC chemokine , which is also known as LMC , $T1$ , NCC-4 , and $T2$ .
HCC-4
CCL16
0
$T1$ ( $T2$ ) is an unusually large CC chemokine , which is also known as LMC , HCC-4 , NCC-4 , and CCL16 .
Liver-expressed chemokine
LEC
0
$T1$ ( LEC ) is an unusually large CC chemokine , which is also known as LMC , HCC-4 , $T2$ , and CCL16 .
Liver-expressed chemokine
NCC-4
0
$T1$ ( LEC ) is an unusually large CC chemokine , which is also known as LMC , HCC-4 , NCC-4 , and $T2$ .
Liver-expressed chemokine
CCL16
0
Liver-expressed chemokine ( $T1$ ) is an unusually large CC chemokine , which is also known as LMC , HCC-4 , $T2$ , and CCL16 .
LEC
NCC-4
0
Liver-expressed chemokine ( $T1$ ) is an unusually large CC chemokine , which is also known as LMC , HCC-4 , NCC-4 , and $T2$ .
LEC
CCL16
0
We report chemotaxis and competitive binding studies that show LEC binds to and activates $T1$ and $T2$ transfected HEK-293 cells .
CCR1
CCR8
0
Liver-expressed chemokine ( LEC ) is an unusually large CC chemokine , which is also known as LMC , HCC-4 , $T1$ , and $T2$ .
NCC-4
CCL16
0
$T1$ induced maximal migration of $T2$ and CCR8 transfected cells at 89.3 nmol/L and cell adhesion at 5.6 nmol/L .
LEC
CCR1
0
$T1$ induced maximal migration of CCR1 and $T2$ transfected cells at 89.3 nmol/L and cell adhesion at 5.6 nmol/L .
LEC
CCR8
0
LEC induced maximal migration of $T1$ and $T2$ transfected cells at 89.3 nmol/L and cell adhesion at 5.6 nmol/L .
CCR1
CCR8
0
The molar concentration of $T1$ required to induce maximum cell migration is 20- to 200-fold greater than that required for $T2$ or I309 , respectively .
LEC
RANTES
0
The molar concentration of $T1$ required to induce maximum cell migration is 20- to 200-fold greater than that required for RANTES or $T2$ , respectively .
LEC
I309
0
A neutralizing polyclonal antibody to LEC was developed to demonstrate that the unusually high concentration of $T1$ required to induce chemotaxis was a property of $T2$ and not as a result of an irrelevant protein contamination .
LEC
LEC
0
A neutralizing polyclonal antibody to $T1$ was developed to demonstrate that the unusually high concentration of LEC required to induce chemotaxis was a property of $T2$ and not as a result of an irrelevant protein contamination .
LEC
LEC
0
The molar concentration of LEC required to induce maximum cell migration is 20- to 200-fold greater than that required for $T1$ or $T2$ , respectively .
RANTES
I309
0
A neutralizing polyclonal antibody to $T1$ was developed to demonstrate that the unusually high concentration of $T2$ required to induce chemotaxis was a property of LEC and not as a result of an irrelevant protein contamination .
LEC
LEC
0
$T1$ protein interacts with CSB protein and with $T2$ protein , a subunit of the human RNA polymerase II transcription factor IIH .
CSA
p44
1
$T1$ protein interacts with $T2$ protein and with p44 protein , a subunit of the human RNA polymerase II transcription factor IIH .
CSA
CSB
1
The cloned CSB gene encodes a member of a protein family that includes the yeast Snf2 protein , a component of the transcriptional regulator $T1$/$T2$ .
Swi
Snf
0
The cloned CSB gene encodes a member of a protein family that includes the yeast $T1$ protein , a component of the transcriptional regulator $T2$/Snf .
Snf2
Swi
0
The cloned $T1$ gene encodes a member of a protein family that includes the yeast Snf2 protein , a component of the transcriptional regulator $T2$/Snf .
CSB
Swi
0
These observations suggest that the products of the $T1$ and $T2$ genes are involved in transcription .
CSA
CSB
0
The cloned CSB gene encodes a member of a protein family that includes the yeast $T1$ protein , a component of the transcriptional regulator Swi/$T2$ .
Snf2
Snf
0
The cloned $T1$ gene encodes a member of a protein family that includes the yeast Snf2 protein , a component of the transcriptional regulator Swi/$T2$ .
CSB
Snf
0
CSA protein interacts with $T1$ protein and with $T2$ protein , a subunit of the human RNA polymerase II transcription factor IIH .
CSB
p44
0
The cloned $T1$ gene encodes a member of a protein family that includes the yeast $T2$ protein , a component of the transcriptional regulator Swi/Snf .
CSB
Snf2
0
Thus $T1$ is a cellular oncogene that targets PP2A and $T2$ , both of which are targets for oncogenic viruses and chemical tumour promoters .
HOX11
PP1
1
We observed that the protein $T1$ interacted with protein serine-threonine phosphatase 2A catalytic subunit ( PP2AC ) , as well as protein phosphatase 1 ( $T2$ ) in mammalian cells .
HOX11
PP1C
1
Thus $T1$ is a cellular oncogene that targets $T2$ and PP1 , both of which are targets for oncogenic viruses and chemical tumour promoters .
HOX11
PP2A
1
We observed that the protein $T1$ interacted with protein serine-threonine phosphatase 2A catalytic subunit ( $T2$ ) , as well as protein phosphatase 1 ( PP1C ) in mammalian cells .
HOX11
PP2AC
1
We observed that the protein $T1$ interacted with protein serine-threonine phosphatase 2A catalytic subunit ( PP2AC ) , as well as $T2$ ( PP1C ) in mammalian cells .
HOX11
protein phosphatase 1
1
$T1$ interacts with protein phosphatases PP2A and $T2$ and disrupts a G2/M cell-cycle checkpoint .
HOX11
PP1
1
We observed that the protein $T1$ interacted with protein $T2$ ( PP2AC ) , as well as protein phosphatase 1 ( PP1C ) in mammalian cells .
HOX11
serine-threonine phosphatase 2A catalytic subunit
1
$T1$ interacts with protein phosphatases $T2$ and PP1 and disrupts a G2/M cell-cycle checkpoint .
HOX11
PP2A
1
HOX11 interacts with protein phosphatases $T1$ and $T2$ and disrupts a G2/M cell-cycle checkpoint .
PP2A
PP1
0
We observed that the protein $T1$ interacted with protein $T2$ catalytic subunit ( PP2AC ) , as well as protein phosphatase 1 ( PP1C ) in mammalian cells .
HOX11
serine-threonine phosphatase 2A
0
We observed that the protein HOX11 interacted with protein serine-threonine phosphatase 2A catalytic subunit ( $T1$ ) , as well as $T2$ ( PP1C ) in mammalian cells .
PP2AC
protein phosphatase 1
0
We observed that the protein HOX11 interacted with protein serine-threonine phosphatase 2A catalytic subunit ( $T1$ ) , as well as protein phosphatase 1 ( $T2$ ) in mammalian cells .
PP2AC
PP1C
0
We observed that the protein HOX11 interacted with protein $T1$ catalytic subunit ( $T2$ ) , as well as protein phosphatase 1 ( PP1C ) in mammalian cells .
serine-threonine phosphatase 2A
PP2AC
0
We observed that the protein HOX11 interacted with protein $T1$ ( $T2$ ) , as well as protein phosphatase 1 ( PP1C ) in mammalian cells .
serine-threonine phosphatase 2A catalytic subunit
PP2AC
0
We observed that the protein HOX11 interacted with protein serine-threonine phosphatase 2A catalytic subunit ( PP2AC ) , as well as $T1$ ( $T2$ ) in mammalian cells .
protein phosphatase 1
PP1C
0
We observed that the protein HOX11 interacted with protein $T1$ catalytic subunit ( PP2AC ) , as well as $T2$ ( PP1C ) in mammalian cells .
serine-threonine phosphatase 2A
protein phosphatase 1
0
We observed that the protein HOX11 interacted with protein $T1$ ( PP2AC ) , as well as $T2$ ( PP1C ) in mammalian cells .
serine-threonine phosphatase 2A catalytic subunit
protein phosphatase 1
0
We observed that the protein HOX11 interacted with protein $T1$ catalytic subunit ( PP2AC ) , as well as protein phosphatase 1 ( $T2$ ) in mammalian cells .
serine-threonine phosphatase 2A
PP1C
0
We observed that the protein HOX11 interacted with protein $T1$ ( PP2AC ) , as well as protein phosphatase 1 ( $T2$ ) in mammalian cells .
serine-threonine phosphatase 2A catalytic subunit
PP1C
0
We observed that the protein HOX11 interacted with protein $T1$$T2$ ( PP2AC ) , as well as protein phosphatase 1 ( PP1C ) in mammalian cells .
serine-threonine phosphatase 2A
serine-threonine phosphatase 2A catalytic subunit
0
Thus HOX11 is a cellular oncogene that targets $T1$ and $T2$ , both of which are targets for oncogenic viruses and chemical tumour promoters .
PP2A
PP1
0
We report an interaction between the human PS1 or $T1$ hydrophilic loop and $T2$ , a small GTPase belonging to the Ras-related superfamily .
PS2
Rab11
1
Interaction domains were mapped to codons 374-400 for $T1$ and to codons 106-179 for $T2$ , a region including the fourth GTP-binding domain .
PS1
Rab11
1
We report an interaction between the human $T1$ or PS2 hydrophilic loop and $T2$ , a small GTPase belonging to the Ras-related superfamily .
PS1
Rab11
1
We report an interaction between the human $T1$ or $T2$ hydrophilic loop and Rab11 , a small GTPase belonging to the Ras-related superfamily .
PS1
PS2
0
$T1$ ( $T2$ ) mutations account for the majority of early-onset dominant cases of familial Alzheimer 's disease .
Presenilin 1
PS1
0
We have now isolated cDNA clones that contain the full-length coding sequence of two other proteins , RBP1 and $T1$ , cloned originally by their interaction with $T2$ .
RBP2
pRB
1
In addition we have been able to identify complexes of $T1$ and $T2$ in vivo that are dissociated in the presence of purified human papillomavirus E7 protein .
pRB
RBP1
1
Characterization of the $T1$ binding proteins RBP1 and $T2$ .
retinoblastoma
RBP2
1
We have now isolated cDNA clones that contain the full-length coding sequence of two other proteins , $T1$ and RBP2 , cloned originally by their interaction with $T2$ .
RBP1
pRB
1
Characterization of the $T1$ binding proteins $T2$ and RBP2 .
retinoblastoma
RBP1
1
Characterization of the retinoblastoma binding proteins $T1$ and $T2$ .
RBP1
RBP2
0
The $T1$ gene product , $T2$ , regulates cell proliferation by binding to and inhibiting the activity of key growth promoting proteins .
retinoblastoma
pRB
0
The products of the $T1$ and $T2$ genes are ubiquitously expressed , large ( 200 kDa for RBP1 and 195 kDa for RBP2 ) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation .
RBP1
RBP2
0
The products of the $T1$ and RBP2 genes are ubiquitously expressed , large ( 200 kDa for $T2$ and 195 kDa for RBP2 ) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation .
RBP1
RBP1
0
The products of the $T1$ and RBP2 genes are ubiquitously expressed , large ( 200 kDa for RBP1 and 195 kDa for $T2$ ) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation .
RBP1
RBP2
0
The products of the RBP1 and $T1$ genes are ubiquitously expressed , large ( 200 kDa for $T2$ and 195 kDa for RBP2 ) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation .
RBP2
RBP1
0
The products of the RBP1 and $T1$ genes are ubiquitously expressed , large ( 200 kDa for RBP1 and 195 kDa for $T2$ ) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation .
RBP2
RBP2
0
We have now isolated cDNA clones that contain the full-length coding sequence of two other proteins , $T1$ and $T2$ , cloned originally by their interaction with pRB .
RBP1
RBP2
0
The products of the RBP1 and RBP2 genes are ubiquitously expressed , large ( 200 kDa for $T1$ and 195 kDa for $T2$ ) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation .
RBP1
RBP2
0
In addition we have been able to identify complexes of $T1$ and RBP1 in vivo that are dissociated in the presence of purified human papillomavirus $T2$ protein .
pRB
E7
0
In addition we have been able to identify complexes of pRB and $T1$ in vivo that are dissociated in the presence of purified human papillomavirus $T2$ protein .
RBP1
E7
0
RANTES interacts with CCR5 and $T1$ with $T2$ receptors .
SDF-1
CXCR4
1
$T1$ interacts with $T2$ and SDF-1 with CXCR4 receptors .
RANTES
CCR5
1
RANTES interacts with $T1$ and $T2$ with CXCR4 receptors .
CCR5
SDF-1
0
RANTES interacts with $T1$ and SDF-1 with $T2$ receptors .
CCR5
CXCR4
0
$T1$ interacts with CCR5 and $T2$ with CXCR4 receptors .
RANTES
SDF-1
0
DCs express more $T1$ and $T2$ mRNA than T cells .
CCR5
CXCR4
0
$T1$ interacts with CCR5 and SDF-1 with $T2$ receptors .
RANTES
CXCR4
0
We now find that HIV-1 begins reverse transcription much more efficiently in DCs than T cells , even though T cells have higher levels of $T1$ and $T2$ binding .
CD4
gp120
0
A va n't Hoff plot of the change in Kd was linear between 10 and 37 degrees C and yielded values of DeltaH degrees = -12.9 kcal/mol and DeltaS degrees = -15.9 cal mol-1 deg-1 , suggesting that electrostatic forces play a prominent role in the interaction of $T1$ with $T2$ .
C8
C9
1
Native $T1$ also formed a heterodimer with $T2$ , and low concentrations of polyionic ligands such as protamine and suramin inhibited the interaction .
C8
C5
1
Native $T1$ and $T2$ formed a heterodimer in solution of physiological ionic strength with a free-energy change DeltaG degrees of -8.3 kcal/mol and a dissociation constant Kd of 0.6 microM ( at 20 degrees C ) that was ionic strength- and temperature-dependent .
C8
C9
1
Suramin induced high-affinity trimerization of $T1$ ( Kd = 0.10 microM at 20 degrees C ) and dimerization of $T2$ ( Kd = 0.86 microM at 20 degrees C ) .
C8
C9
0
Analysis of sedimentation equilibria and also of the fluorescence enhancement of suramin when bound to protein provided evidence for two suramin-binding sites on each $T1$ and three on each $T2$ in the oligomers .
C9
C8
0
In yeast , $T1$ interacts with cyclin-dependent kinases , including human Cdc2 , Cdk2 , and $T2$ , but not with Cdk4 .
Cdi1
Cdk3
1
In HeLa cells , $T1$ is expressed at the G1 to S transition , and the protein forms stable complexes with $T2$ .
Cdi1
Cdk2
1
In yeast , $T1$ interacts with cyclin-dependent kinases , including human $T2$ , Cdk2 , and Cdk3 , but not with Cdk4 .
Cdi1
Cdc2
1
In yeast , $T1$ interacts with cyclin-dependent kinases , including human Cdc2 , $T2$ , and Cdk3 , but not with Cdk4 .
Cdi1
Cdk2
1
$T1$ , a human G1 and S phase protein phosphatase that associates with $T2$ .
Cdi1
Cdk2
1
We used the interaction trap , a yeast genetic selection for interacting proteins , to isolate human $T1$ ( $T2$ ) .
cyclin-dependent kinase interactor 1
Cdi1
0
In yeast , Cdi1 interacts with cyclin-dependent kinases , including human $T1$ , $T2$ , and Cdk3 , but not with Cdk4 .
Cdc2
Cdk2
0
In yeast , Cdi1 interacts with cyclin-dependent kinases , including human $T1$ , Cdk2 , and $T2$ , but not with Cdk4 .
Cdc2
Cdk3
0
In yeast , Cdi1 interacts with cyclin-dependent kinases , including human $T1$ , Cdk2 , and Cdk3 , but not with $T2$ .
Cdc2
Cdk4
0
In yeast , Cdi1 interacts with cyclin-dependent kinases , including human Cdc2 , $T1$ , and $T2$ , but not with Cdk4 .
Cdk2
Cdk3
0
In yeast , Cdi1 interacts with cyclin-dependent kinases , including human Cdc2 , $T1$ , and Cdk3 , but not with $T2$ .
Cdk2
Cdk4
0
In yeast , $T1$ interacts with cyclin-dependent kinases , including human Cdc2 , Cdk2 , and Cdk3 , but not with $T2$ .
Cdi1
Cdk4
0
In yeast , Cdi1 interacts with cyclin-dependent kinases , including human Cdc2 , Cdk2 , and $T1$ , but not with $T2$ .
Cdk3
Cdk4
0
Overexpression of wild-type $T1$ delays progression through the cell cycle in yeast and HeLa cells ; delay is dependent on $T2$ phosphatase activity .
Cdi1
Cdi1
0
The $T1$-$T2$ complex suggests a binding site for transferrin on TfR and sheds light upon the function of HFE in regulating iron homeostasis .
HFE
TfR
1
On a cell membrane containing both proteins , HFE would 'lie down ' parallel to the membrane , such that the $T1$ helices that delineate the counterpart of the MHC peptide-binding groove make extensive contacts with helices in the $T2$ dimerization domain .
HFE
TfR
1
The structures of $T1$ alone and complexed with $T2$ differ in their domain arrangement and dimer interfaces , providing a mechanism for communicating binding events between TfR chains .
TfR
HFE
1
The 2.8 A crystal structure of a complex between the extracellular portions of $T1$ and $T2$ shows two HFE molecules which grasp each side of a twofold symmetric TfR dimer .
HFE
TfR
1
The 2.8 A crystal structure of a complex between the extracellular portions of HFE and TfR shows two $T1$ molecules which grasp each side of a twofold symmetric $T2$ dimer .
HFE
TfR
1
$T1$ binds to the $T2$ ( TfR ) , a receptor by which cells acquire iron-loaded transferrin .
HFE
transferrin receptor
1
$T1$ binds to the transferrin receptor ( $T2$ ) , a receptor by which cells acquire iron-loaded transferrin .
HFE
TfR
1
Crystal structure of the hereditary haemochromatosis protein $T1$ complexed with $T2$ .
HFE
transferrin receptor
1
Crystal structure of the hereditary haemochromatosis protein $T1$ complexed with $T2$ receptor .
HFE
transferrin
0
Crystal structure of the hereditary haemochromatosis protein HFE complexed with $T1$$T2$ receptor .
transferrin receptor
transferrin
0
HFE binds to the $T1$$T2$ ( TfR ) , a receptor by which cells acquire iron-loaded transferrin .
transferrin
transferrin receptor
0
$T1$ binds to the $T2$ receptor ( TfR ) , a receptor by which cells acquire iron-loaded transferrin .
HFE
transferrin
0
HFE binds to the $T1$ receptor ( $T2$ ) , a receptor by which cells acquire iron-loaded transferrin .
transferrin
TfR
0
HFE binds to the $T1$ receptor ( TfR ) , a receptor by which cells acquire iron-loaded $T2$ .
transferrin
transferrin
0
HFE binds to the $T1$ ( $T2$ ) , a receptor by which cells acquire iron-loaded transferrin .
transferrin receptor
TfR
0
HFE binds to the $T1$ ( TfR ) , a receptor by which cells acquire iron-loaded $T2$ .
transferrin receptor
transferrin
0
$T1$ binds to the transferrin receptor ( TfR ) , a receptor by which cells acquire iron-loaded $T2$ .
HFE
transferrin
0
The 2.8 A crystal structure of a complex between the extracellular portions of $T1$ and TfR shows two $T2$ molecules which grasp each side of a twofold symmetric TfR dimer .
HFE
HFE
0
The 2.8 A crystal structure of a complex between the extracellular portions of $T1$ and TfR shows two HFE molecules which grasp each side of a twofold symmetric $T2$ dimer .
HFE
TfR
0
The 2.8 A crystal structure of a complex between the extracellular portions of HFE and $T1$ shows two $T2$ molecules which grasp each side of a twofold symmetric TfR dimer .
TfR
HFE
0
The 2.8 A crystal structure of a complex between the extracellular portions of HFE and $T1$ shows two HFE molecules which grasp each side of a twofold symmetric $T2$ dimer .
TfR
TfR
0
HFE binds to the transferrin receptor ( $T1$ ) , a receptor by which cells acquire iron-loaded $T2$ .
TfR
transferrin
0
On a cell membrane containing both proteins , $T1$ would 'lie down ' parallel to the membrane , such that the $T2$ helices that delineate the counterpart of the MHC peptide-binding groove make extensive contacts with helices in the TfR dimerization domain .
HFE
HFE
0
On a cell membrane containing both proteins , $T1$ would 'lie down ' parallel to the membrane , such that the HFE helices that delineate the counterpart of the MHC peptide-binding groove make extensive contacts with helices in the $T2$ dimerization domain .
HFE
TfR
0
The HFE-TfR complex suggests a binding site for transferrin on $T1$ and sheds light upon the function of $T2$ in regulating iron homeostasis .
TfR
HFE
0
The HFE-$T1$ complex suggests a binding site for transferrin on TfR and sheds light upon the function of $T2$ in regulating iron homeostasis .
TfR
HFE
0
The $T1$-TfR complex suggests a binding site for transferrin on TfR and sheds light upon the function of $T2$ in regulating iron homeostasis .
HFE
HFE
0
The structures of $T1$ alone and complexed with HFE differ in their domain arrangement and dimer interfaces , providing a mechanism for communicating binding events between $T2$ chains .
TfR
TfR
0
The HFE-$T1$ complex suggests a binding site for transferrin on $T2$ and sheds light upon the function of HFE in regulating iron homeostasis .
TfR
TfR
0
The $T1$-TfR complex suggests a binding site for transferrin on $T2$ and sheds light upon the function of HFE in regulating iron homeostasis .
HFE
TfR
0
The structures of TfR alone and complexed with $T1$ differ in their domain arrangement and dimer interfaces , providing a mechanism for communicating binding events between $T2$ chains .
HFE
TfR
0
We found that deletion of the carboxyl-terminal 28 amino acids of PU.1 disrupted $T1$-$T2$ physical interaction .
PU.1
NF-IL6 beta
1
We have characterized the physical and functional interactions between $T1$ and $T2$ , a leucine zipper transcription factor implicated in inflammatory responses .
PU.1
NF-IL6 beta
1
Transcriptional synergy with $T1$ ( C/$T2$ , CRP3 ) .
NF-IL6 beta
EBP delta
0
Transcriptional synergy with NF-IL6 beta ( C/$T1$ , $T2$ ) .
EBP delta
CRP3
0
Transcriptional synergy with $T1$ ( C/EBP delta , $T2$ ) .
NF-IL6 beta
CRP3
0
Using radiolabeled $T1$ protein as a probe , we screened a B cell cDNA expression library and isolated a number of clones encoding $T2$ interacting proteins .
PU.1
PU.1
0
Three of these clones encode DNA binding proteins ( NF-IL6 beta , $T1$ , and $T2$ ) , one clone encodes a chaperone protein , and another clone encodes a multifunctional phosphatase .
HMG I/Y
SSRP
0
Three of these clones encode DNA binding proteins ( $T1$ , $T2$ , and SSRP ) , one clone encodes a chaperone protein , and another clone encodes a multifunctional phosphatase .
NF-IL6 beta
HMG I/Y
0
Three of these clones encode DNA binding proteins ( $T1$ , HMG I/Y , and $T2$ ) , one clone encodes a chaperone protein , and another clone encodes a multifunctional phosphatase .
NF-IL6 beta
SSRP
0
We found that deletion of the carboxyl-terminal 28 amino acids of $T1$ disrupted $T2$-NF-IL6 beta physical interaction .
PU.1
PU.1
0
We found that deletion of the carboxyl-terminal 28 amino acids of $T1$ disrupted PU.1-$T2$ physical interaction .
PU.1
NF-IL6 beta
0
Electrophoretic mobility shift assays showed that $T1$ and $T2$ can simultaneously bind to adjacent DNA binding sites , but apparently do not influence the kinetics or affinity of each other 's DNA binding .
PU.1
NF-IL6 beta
0
In transient expression assays , we found that $T1$ and $T2$ can functionally cooperate to synergistically activate transcription .
PU.1
NF-IL6 beta
0
The gamma chain of the $T1$$T2$ ) receptor is shared with the functional IL-4 receptor and is causatively related to X-linked severe combined immunodeficiency ( XSCID ) , which is ascribed to a profound T cell defect .
interleukin-2 (IL-2) receptor
IL-2
0
The gamma chain of the $T1$ ( $T2$ ) receptor is shared with the functional IL-4 receptor and is causatively related to X-linked severe combined immunodeficiency ( XSCID ) , which is ascribed to a profound T cell defect .
interleukin-2
IL-2
0
The gamma chain of the interleukin-2 ( $T1$ ) receptor is shared with the functional $T2$ receptor and is causatively related to X-linked severe combined immunodeficiency ( XSCID ) , which is ascribed to a profound T cell defect .
IL-2
IL-4
0
The gamma chain of the interleukin-2 ( $T1$ ) receptor is shared with the functional $T2$ and is causatively related to X-linked severe combined immunodeficiency ( XSCID ) , which is ascribed to a profound T cell defect .
IL-2
IL-4 receptor
0
The gamma chain of the $T1$$T2$ ( IL-2 ) receptor is shared with the functional IL-4 receptor and is causatively related to X-linked severe combined immunodeficiency ( XSCID ) , which is ascribed to a profound T cell defect .
interleukin-2 (IL-2) receptor
interleukin-2
0
The gamma chain of the $T1$ is shared with the functional $T2$ receptor and is causatively related to X-linked severe combined immunodeficiency ( XSCID ) , which is ascribed to a profound T cell defect .
interleukin-2 (IL-2) receptor
IL-4
0
The gamma chain of the $T1$ is shared with the functional $T2$ and is causatively related to X-linked severe combined immunodeficiency ( XSCID ) , which is ascribed to a profound T cell defect .
interleukin-2 (IL-2) receptor
IL-4 receptor
0
Functional participation of the $T1$ receptor gamma chain in $T2$ complexes .
IL-2
IL-7 receptor
0
Functional participation of the IL-2 receptor gamma chain in $T1$$T2$ receptor complexes .
IL-7 receptor
IL-7
0
Functional participation of the $T1$ chain in $T2$ complexes .
IL-2 receptor gamma
IL-7 receptor
0
Studies with monoclonal antibodies specific for the $T1$ receptor gamma chain showed that the gamma chain participates in the functional high-affinity receptor complexes for $T2$ that are involved in the differentiation of T and B cells .
IL-2
IL-7
0
The gamma chain of the $T1$ ( IL-2 ) receptor is shared with the functional $T2$ receptor and is causatively related to X-linked severe combined immunodeficiency ( XSCID ) , which is ascribed to a profound T cell defect .
interleukin-2
IL-4
0
The gamma chain of the $T1$ ( IL-2 ) receptor is shared with the functional $T2$ and is causatively related to X-linked severe combined immunodeficiency ( XSCID ) , which is ascribed to a profound T cell defect .
interleukin-2
IL-4 receptor
0
The gamma chain of the interleukin-2 ( IL-2 ) receptor is shared with the functional $T1$$T2$ and is causatively related to X-linked severe combined immunodeficiency ( XSCID ) , which is ascribed to a profound T cell defect .
IL-4
IL-4 receptor
0
Functional participation of the $T1$ receptor gamma chain in $T2$ receptor complexes .
IL-2
IL-7
0
Functional participation of the $T1$$T2$ chain in IL-7 receptor complexes .
IL-2
IL-2 receptor gamma
0
Functional participation of the $T1$ chain in $T2$ receptor complexes .
IL-2 receptor gamma
IL-7
0
A large epitope 1 for high-affinity $T1$ binding was detected spanning the interface of the $T2$ dimer .
BMPR-IA
BMP-2
1
The binding epitopes of $T1$ for BMPR-IA ( type I ) and $T2$ or ActR-II ( type II ) were characterized using BMP-2 mutant proteins for analysis of interactions with receptor ectodomains .
BMP-2
BMPR-II
1
The binding epitopes of $T1$ for BMPR-IA ( type I ) and BMPR-II or $T2$ ( type II ) were characterized using BMP-2 mutant proteins for analysis of interactions with receptor ectodomains .
BMP-2
ActR-II
1
The binding epitopes of $T1$ for $T2$ ( type I ) and BMPR-II or ActR-II ( type II ) were characterized using BMP-2 mutant proteins for analysis of interactions with receptor ectodomains .
BMP-2
BMPR-IA
1
$T1$ antagonists emerge from alterations in the low-affinity binding epitope for receptor $T2$ .
BMP-2
BMPR-II
0
$T1$ ( $T2$ ) induces bone formation and regeneration in adult vertebrates and regulates important developmental processes in all animals .
Bone morphogenetic protein-2
BMP-2
0
BMP-2 is a homodimeric cysteine knot protein that , as a member of the $T1$ ( $T2$ ) superfamily , signals by oligomerizing type I and type II receptor serine-kinases in the cell membrane .
transforming growth factor-beta
TGF-beta
0
$T1$ is a homodimeric cysteine knot protein that , as a member of the $T2$ ( TGF-beta ) superfamily , signals by oligomerizing type I and type II receptor serine-kinases in the cell membrane .
BMP-2
transforming growth factor-beta
0
$T1$ is a homodimeric cysteine knot protein that , as a member of the transforming growth factor-beta ( $T2$ ) superfamily , signals by oligomerizing type I and type II receptor serine-kinases in the cell membrane .
BMP-2
TGF-beta
0
The binding epitopes of BMP-2 for BMPR-IA ( type I ) and $T1$ or $T2$ ( type II ) were characterized using BMP-2 mutant proteins for analysis of interactions with receptor ectodomains .
BMPR-II
ActR-II
0
The binding epitopes of BMP-2 for BMPR-IA ( type I ) and $T1$ or ActR-II ( type II ) were characterized using $T2$ mutant proteins for analysis of interactions with receptor ectodomains .
BMPR-II
BMP-2
0
The binding epitopes of BMP-2 for $T1$ ( type I ) and $T2$ or ActR-II ( type II ) were characterized using BMP-2 mutant proteins for analysis of interactions with receptor ectodomains .
BMPR-IA
BMPR-II
0
The binding epitopes of BMP-2 for BMPR-IA ( type I ) and BMPR-II or $T1$ ( type II ) were characterized using $T2$ mutant proteins for analysis of interactions with receptor ectodomains .
ActR-II
BMP-2
0
The binding epitopes of BMP-2 for $T1$ ( type I ) and BMPR-II or $T2$ ( type II ) were characterized using BMP-2 mutant proteins for analysis of interactions with receptor ectodomains .
BMPR-IA
ActR-II
0
The binding epitopes of $T1$ for BMPR-IA ( type I ) and BMPR-II or ActR-II ( type II ) were characterized using $T2$ mutant proteins for analysis of interactions with receptor ectodomains .
BMP-2
BMP-2
0
The binding epitopes of BMP-2 for $T1$ ( type I ) and BMPR-II or ActR-II ( type II ) were characterized using $T2$ mutant proteins for analysis of interactions with receptor ectodomains .
BMPR-IA
BMP-2
0
The screen identified interactions involving $T1$ and two 14-3-3 isoforms , cytokeratin 18 , human unconventional myosin IC , and a recently identified SH3 domain containing protein , $T2$ .
c-Cbl
SH3 P17
1
The precise function of c-Cbl in these pathways is not clear , although a genetic analysis in Caenorhabditis elegans suggests that $T1$ is a negative regulator of the $T2$ .
c-Cbl
epidermal growth factor receptor
1
The screen identified interactions involving $T1$ and two 14-3-3 isoforms , $T2$ , human unconventional myosin IC , and a recently identified SH3 domain containing protein , SH3 P17 .
c-Cbl
cytokeratin 18
1
The protein product of $T1$ proto-oncogene is known to interact with several proteins , including Grb2 , $T2$ and PI3 kinase , and is thought to regulate signalling by many cell surface receptors .
c-cbl
Crk
1
The protein product of $T1$ proto-oncogene is known to interact with several proteins , including Grb2 , Crk and $T2$ , and is thought to regulate signalling by many cell surface receptors .
c-cbl
PI3 kinase
1
The protein product of $T1$ proto-oncogene is known to interact with several proteins , including $T2$ , Crk and PI3 kinase , and is thought to regulate signalling by many cell surface receptors .
c-cbl
Grb2
1
The protein product of c-cbl proto-oncogene is known to interact with several proteins , including $T1$ , $T2$ and PI3 kinase , and is thought to regulate signalling by many cell surface receptors .
Grb2
Crk
0
The protein product of c-cbl proto-oncogene is known to interact with several proteins , including $T1$ , Crk and $T2$ , and is thought to regulate signalling by many cell surface receptors .
Grb2
PI3 kinase
0
The precise function of $T1$ in these pathways is not clear , although a genetic analysis in Caenorhabditis elegans suggests that $T2$ is a negative regulator of the epidermal growth factor receptor .
c-Cbl
c-Cbl
0
The precise function of $T1$ in these pathways is not clear , although a genetic analysis in Caenorhabditis elegans suggests that c-Cbl is a negative regulator of the $T2$ receptor .
c-Cbl
epidermal growth factor
0
The precise function of $T1$ in these pathways is not clear , although a genetic analysis in Caenorhabditis elegans suggests that c-Cbl is a negative regulator of the $T2$ .
c-Cbl
epidermal growth factor receptor
0
The precise function of c-Cbl in these pathways is not clear , although a genetic analysis in Caenorhabditis elegans suggests that $T1$ is a negative regulator of the $T2$ receptor .
c-Cbl
epidermal growth factor
0
The protein product of c-cbl proto-oncogene is known to interact with several proteins , including Grb2 , $T1$ and $T2$ , and is thought to regulate signalling by many cell surface receptors .
Crk
PI3 kinase
0
The screen identified interactions involving c-Cbl and two 14-3-3 isoforms , $T1$ , human unconventional myosin IC , and a recently identified SH3 domain containing protein , $T2$ .
cytokeratin 18
SH3 P17
0
The precise function of c-Cbl in these pathways is not clear , although a genetic analysis in Caenorhabditis elegans suggests that c-Cbl is a negative regulator of the $T1$$T2$ .
epidermal growth factor
epidermal growth factor receptor
0
Moreover , a transcriptional activation signal was transduced by $T1$ in the presence of type I receptors after stimulation by $T2$/BMP-7 .
BMPR-II
OP-1
1
Moreover , a transcriptional activation signal was transduced by $T1$ in the presence of type I receptors after stimulation by OP-1/$T2$ .
BMPR-II
BMP-7
1
Binding of $T1$/BMP-7 to $T2$ was also observed in nontransfected cell lines .
OP-1
BMPR-II
1
Binding of OP-1/$T1$ to $T2$ was also observed in nontransfected cell lines .
BMP-7
BMPR-II
1
In transfected COS-1 cells , osteogenic protein ( OP ) -1/$T1$ , and less efficiently BMP-4 , bound to $T2$ .
BMP-7
BMPR-II
1
In transfected COS-1 cells , osteogenic protein ( OP ) -1/BMP-7 , and less efficiently $T1$ , bound to $T2$ .
BMP-4
BMPR-II
1
In transfected COS-1 cells , $T1$/BMP-7 , and less efficiently BMP-4 , bound to $T2$ .
osteogenic protein (OP)-1
BMPR-II
1
Here we report the cDNA cloning and characterization of a human type II receptor for BMPs ( $T1$ ) , which is distantly related to $T2$ , a BMP type II receptor from Caenorhabditis elegans .
BMPR-II
DAF-4
0
Here we report the cDNA cloning and characterization of a human type II receptor for BMPs ( BMPR-II ) , which is distantly related to $T1$ , a $T2$ from Caenorhabditis elegans .
DAF-4
BMP type II receptor
0
Here we report the cDNA cloning and characterization of a human type II receptor for BMPs ( $T1$ ) , which is distantly related to DAF-4 , a $T2$ from Caenorhabditis elegans .
BMPR-II
BMP type II receptor
0
In transfected COS-1 cells , osteogenic protein ( OP ) -1/$T1$ , and less efficiently $T2$ , bound to BMPR-II .
BMP-7
BMP-4
0
In transfected COS-1 cells , $T1$/$T2$ , and less efficiently BMP-4 , bound to BMPR-II .
osteogenic protein (OP)-1
BMP-7
0
In transfected COS-1 cells , $T1$/BMP-7 , and less efficiently $T2$ , bound to BMPR-II .
osteogenic protein (OP)-1
BMP-4
0
Binding of $T1$/$T2$ to BMPR-II was also observed in nontransfected cell lines .
OP-1
BMP-7
0
Moreover , a transcriptional activation signal was transduced by BMPR-II in the presence of type I receptors after stimulation by $T1$/$T2$ .
OP-1
BMP-7
0
The cell surface form of $T1$ is assembled during biosynthesis as a heteromeric complex with lymphotoxin-beta ( $T2$ ) , a type II transmembrane protein that is another member of the TNF ligand family .
LT-alpha
LT-beta
1
Secreted LT-alpha is a homotrimer that binds to distinct TNF receptors of 60 and 80 kilodaltons ; however , these receptors do not recognize the major cell surface $T1$-$T2$ complex .
LT-alpha
LT-beta
1
The cell surface form of $T1$ is assembled during biosynthesis as a heteromeric complex with $T2$ ( LT-beta ) , a type II transmembrane protein that is another member of the TNF ligand family .
LT-alpha
lymphotoxin-beta
1
The cell surface form of LT-alpha is assembled during biosynthesis as a heteromeric complex with $T1$ ( $T2$ ) , a type II transmembrane protein that is another member of the TNF ligand family .
lymphotoxin-beta
LT-beta
0
Secreted $T1$ is a homotrimer that binds to distinct TNF receptors of 60 and 80 kilodaltons ; however , these receptors do not recognize the major cell surface $T2$-LT-beta complex .
LT-alpha
LT-alpha
0
Secreted $T1$ is a homotrimer that binds to distinct TNF receptors of 60 and 80 kilodaltons ; however , these receptors do not recognize the major cell surface LT-alpha-$T2$ complex .
LT-alpha
LT-beta
0
A receptor specific for human $T1$ was identified , which suggests that cell surface LT may have functions that are distinct from those of secreted $T2$ .
LT-beta
LT-alpha
0
Tumor necrosis factor ( TNF ) and $T1$ ( $T2$ ) are members of a family of secreted and cell surface cytokines that participate in the regulation of immune and inflammatory responses .
lymphotoxin-alpha
LT-alpha
0
We employed both random and site-specific mutagenesis to determine the function of amino acid residues in the extracellular domain ( referred to as $T1$ binding protein , $T2$ ) of the EPOR .
EPO
EBP
1
Mutagenesis of the $T1$ receptor ( $T2$ ) permits analysis of the contribution that individual amino acid residues make to erythropoietin ( EPO ) binding .
erythropoietin
EPOR
1
Mutagenesis studies of the human $T1$$T2$ .
erythropoietin
erythropoietin receptor
0
Mutagenesis of the $T1$ receptor ( EPOR ) permits analysis of the contribution that individual amino acid residues make to $T2$ ( EPO ) binding .
erythropoietin
erythropoietin
0
Mutagenesis of the $T1$ receptor ( EPOR ) permits analysis of the contribution that individual amino acid residues make to erythropoietin ( $T2$ ) binding .
erythropoietin
EPO
0
Mutagenesis of the $T1$$T2$ ( EPOR ) permits analysis of the contribution that individual amino acid residues make to erythropoietin ( EPO ) binding .
erythropoietin
erythropoietin receptor
0
Mutagenesis of the erythropoietin receptor ( EPOR ) permits analysis of the contribution that individual amino acid residues make to $T1$ ( $T2$ ) binding .
erythropoietin
EPO
0
Mutagenesis of the $T1$ ( EPOR ) permits analysis of the contribution that individual amino acid residues make to $T2$ ( EPO ) binding .
erythropoietin receptor
erythropoietin
0
Mutagenesis of the erythropoietin receptor ( $T1$ ) permits analysis of the contribution that individual amino acid residues make to $T2$ ( EPO ) binding .
EPOR
erythropoietin
0
Mutagenesis of the $T1$ ( EPOR ) permits analysis of the contribution that individual amino acid residues make to erythropoietin ( $T2$ ) binding .
erythropoietin receptor
EPO
0
Mutagenesis of the erythropoietin receptor ( $T1$ ) permits analysis of the contribution that individual amino acid residues make to erythropoietin ( $T2$ ) binding .
EPOR
EPO
0
Mutagenesis of the $T1$ ( $T2$ ) permits analysis of the contribution that individual amino acid residues make to erythropoietin ( EPO ) binding .
erythropoietin receptor
EPOR
0
We employed both random and site-specific mutagenesis to determine the function of amino acid residues in the extracellular domain ( referred to as EPO binding protein , $T1$ ) of the $T2$ .
EBP
EPOR
0
We employed both random and site-specific mutagenesis to determine the function of amino acid residues in the extracellular domain ( referred to as $T1$ , $T2$ ) of the EPOR .
EPO binding protein
EBP
0
We employed both random and site-specific mutagenesis to determine the function of amino acid residues in the extracellular domain ( referred to as $T1$ binding protein , EBP ) of the $T2$ .
EPO
EPOR
0
We employed both random and site-specific mutagenesis to determine the function of amino acid residues in the extracellular domain ( referred to as $T1$ , EBP ) of the $T2$ .
EPO binding protein
EPOR
0
Site-specific mutants were expressed in Escherichia coli as soluble $T1$ and analyzed for $T2$ binding in several different assay formats .
EBP
EPO
0
We employed both random and site-specific mutagenesis to determine the function of amino acid residues in the extracellular domain ( referred to as $T1$$T2$ , EBP ) of the EPOR .
EPO
EPO binding protein
0
In addition , selected mutant proteins were expressed as full-length $T1$ on the surface of COS cells and analyzed for 125I-$T2$ binding in receptor binding assays .
EPOR
EPO
0
Using these methods , we have identified residues that appear to be involved in $T1$ binding as well as other residues , most of which are conserved in receptors of the cytokine receptor family , that appear to be necessary for the proper folding and/or stability of the $T2$ .
EPO
EPOR
0
The SH2/SH3 domain-containing protein $T1$ interacts with tyrosine-phosphorylated $T2$ and Shc : implications for insulin control of ras signalling .
GRB2
IRS1
1
We propose a model whereby insulin stimulation leads to formation of multiple protein -- protein interactions between $T1$ and the two targets IRS-1 and $T2$ .
GRB2
Shc
1
Interestingly , both GRB2 and $T1$ can simultaneously bind distinct tyrosine phosphorylated regions on the same $T2$ molecule , suggesting a mechanism whereby IRS-1 could provide the core for a large signalling complex .
phosphatidylinositol-3 (PI-3) kinase
IRS-1
1
We propose a model whereby insulin stimulation leads to formation of multiple protein -- protein interactions between $T1$ and the two targets $T2$ and Shc .
GRB2
IRS-1
1
Interestingly , both $T1$ and phosphatidylinositol-3 ( PI-3 ) kinase can simultaneously bind distinct tyrosine phosphorylated regions on the same $T2$ molecule , suggesting a mechanism whereby IRS-1 could provide the core for a large signalling complex .
GRB2
IRS-1
1
Furthermore , we have identified a short sequence motif ( YV/IN ) present in IRS-1 , $T1$ and Shc , which specifically binds the SH2 domain of $T2$ with high affinity .
EGFR
GRB2
1
Furthermore , we have identified a short sequence motif ( YV/IN ) present in IRS-1 , EGFR and $T1$ , which specifically binds the SH2 domain of $T2$ with high affinity .
Shc
GRB2
1
Although $T1$ associates with IRS-1 and $T2$ , it is not tyrosine-phosphorylated after insulin stimulation , implying that GRB2 is not a substrate for the insulin receptor .
GRB2
Shc
1
Furthermore , we have identified a short sequence motif ( YV/IN ) present in $T1$ , EGFR and Shc , which specifically binds the SH2 domain of $T2$ with high affinity .
IRS-1
GRB2
1
The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of $T1$ to phosphotyrosines on both IRS-1 and $T2$ .
GRB2
Shc
1
Although $T1$ associates with $T2$ and Shc , it is not tyrosine-phosphorylated after insulin stimulation , implying that GRB2 is not a substrate for the insulin receptor .
GRB2
IRS-1
1
The SH2/SH3 domain-containing protein $T1$ interacts with tyrosine-phosphorylated IRS1 and $T2$ : implications for insulin control of ras signalling .
GRB2
Shc
1
The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of $T1$ to phosphotyrosines on both $T2$ and Shc .
GRB2
IRS-1
1
$T1$ , a small protein comprising one SH2 domain and two SH3 domains , represents the human homologue of the Caenorhabditis elegans protein , $T2$ .
GRB2
sem-5
0
Both $T1$ and $T2$ have been implicated in a highly conserved mechanism that regulates p21ras signalling by receptor tyrosine kinases .
GRB2
sem-5
0
Both $T1$ and sem-5 have been implicated in a highly conserved mechanism that regulates $T2$ signalling by receptor tyrosine kinases .
GRB2
p21ras
0
The SH2/SH3 domain-containing protein $T1$ interacts with tyrosine-phosphorylated IRS1 and Shc : implications for insulin control of $T2$ signalling .
GRB2
ras
0
The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and $T1$ : implications for insulin control of $T2$ signalling .
Shc
ras
0
The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated $T1$ and Shc : implications for insulin control of $T2$ signalling .
IRS1
ras
0
Interestingly , both $T1$ and $T2$ can simultaneously bind distinct tyrosine phosphorylated regions on the same IRS-1 molecule , suggesting a mechanism whereby IRS-1 could provide the core for a large signalling complex .
GRB2
phosphatidylinositol-3 (PI-3) kinase
0
Interestingly , both GRB2 and $T1$ can simultaneously bind distinct tyrosine phosphorylated regions on the same IRS-1 molecule , suggesting a mechanism whereby $T2$ could provide the core for a large signalling complex .
phosphatidylinositol-3 (PI-3) kinase
IRS-1
0
Interestingly , both $T1$ and phosphatidylinositol-3 ( PI-3 ) kinase can simultaneously bind distinct tyrosine phosphorylated regions on the same IRS-1 molecule , suggesting a mechanism whereby $T2$ could provide the core for a large signalling complex .
GRB2
IRS-1
0
Both GRB2 and $T1$ have been implicated in a highly conserved mechanism that regulates $T2$ signalling by receptor tyrosine kinases .
sem-5
p21ras
0
Furthermore , we have identified a short sequence motif ( YV/IN ) present in IRS-1 , $T1$ and $T2$ , which specifically binds the SH2 domain of GRB2 with high affinity .
EGFR
Shc
0
Furthermore , we have identified a short sequence motif ( YV/IN ) present in $T1$ , EGFR and $T2$ , which specifically binds the SH2 domain of GRB2 with high affinity .
IRS-1
Shc
0
Furthermore , we have identified a short sequence motif ( YV/IN ) present in $T1$ , $T2$ and Shc , which specifically binds the SH2 domain of GRB2 with high affinity .
IRS-1
EGFR
0
Although GRB2 associates with IRS-1 and Shc , it is not tyrosine-phosphorylated after $T1$ stimulation , implying that $T2$ is not a substrate for the insulin receptor .
insulin
GRB2
0
Although GRB2 associates with IRS-1 and $T1$ , it is not tyrosine-phosphorylated after insulin stimulation , implying that $T2$ is not a substrate for the insulin receptor .
Shc
GRB2
0
Although GRB2 associates with $T1$ and Shc , it is not tyrosine-phosphorylated after insulin stimulation , implying that $T2$ is not a substrate for the insulin receptor .
IRS-1
GRB2
0
Although $T1$ associates with IRS-1 and Shc , it is not tyrosine-phosphorylated after insulin stimulation , implying that $T2$ is not a substrate for the insulin receptor .
GRB2
GRB2
0
Although GRB2 associates with IRS-1 and $T1$ , it is not tyrosine-phosphorylated after $T2$ stimulation , implying that GRB2 is not a substrate for the insulin receptor .
Shc
insulin
0
Although GRB2 associates with $T1$ and Shc , it is not tyrosine-phosphorylated after $T2$ stimulation , implying that GRB2 is not a substrate for the insulin receptor .
IRS-1
insulin
0
Although $T1$ associates with IRS-1 and Shc , it is not tyrosine-phosphorylated after $T2$ stimulation , implying that GRB2 is not a substrate for the insulin receptor .
GRB2
insulin
0
Although GRB2 associates with $T1$ and $T2$ , it is not tyrosine-phosphorylated after insulin stimulation , implying that GRB2 is not a substrate for the insulin receptor .
IRS-1
Shc
0
The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated $T1$ and $T2$ : implications for insulin control of ras signalling .
IRS1
Shc
0
In this report we show that in response to $T1$ , $T2$ forms a stable complex with two tyrosine-phosphorylated proteins .
insulin
GRB2
0
One protein is the major insulin receptor substrate $T1$ and the second is the SH2 domain-containing oncogenic protein , $T2$ .
IRS-1
Shc
0
The interactions between $T1$ and these two proteins require ligand activation of the $T2$ and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS-1 and Shc .
GRB2
insulin receptor
0
The interactions between $T1$ and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of $T2$ to phosphotyrosines on both IRS-1 and Shc .
GRB2
GRB2
0
The interactions between $T1$ and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both $T2$ and Shc .
GRB2
IRS-1
0
The interactions between $T1$ and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS-1 and $T2$ .
GRB2
Shc
0
We propose a model whereby insulin stimulation leads to formation of multiple protein -- protein interactions between GRB2 and the two targets $T1$ and $T2$ .
IRS-1
Shc
0
The interactions between GRB2 and these two proteins require ligand activation of the $T1$ and are mediated by the binding of the SH2 domain of $T2$ to phosphotyrosines on both IRS-1 and Shc .
insulin receptor
GRB2
0
The interactions between GRB2 and these two proteins require ligand activation of the $T1$ and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both $T2$ and Shc .
insulin receptor
IRS-1
0
The interactions between GRB2 and these two proteins require ligand activation of the $T1$ and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS-1 and $T2$ .
insulin receptor
Shc
0
The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both $T1$ and $T2$ .
IRS-1
Shc
0
Interestingly , both GRB2 and phosphatidylinositol-3 ( PI-3 ) kinase can simultaneously bind distinct tyrosine phosphorylated regions on the same $T1$ molecule , suggesting a mechanism whereby $T2$ could provide the core for a large signalling complex .
IRS-1
IRS-1
0
Recombinant $T1$ binds directly to $T2$ both in vitro and in yeast , and participates in the formation of the TFIID complex .
hTAFII250
TBP
1
Biochemical studies established that some coactivators are associated with the $T1$ ( $T2$ ) to form the TFIID complex .
TATA-binding protein
TBP
0
Biochemical studies established that some coactivators are associated with the $T1$ ( TBP ) to form the $T2$ complex .
TATA-binding protein
TFIID
0
Biochemical studies established that some coactivators are associated with the TATA-binding protein ( $T1$ ) to form the $T2$ complex .
TBP
TFIID
0
Recombinant $T1$ binds directly to TBP both in vitro and in yeast , and participates in the formation of the $T2$ complex .
hTAFII250
TFIID
0
Recombinant hTAFII250 binds directly to $T1$ both in vitro and in yeast , and participates in the formation of the $T2$ complex .
TBP
TFIID
0
The $T1$ gene is identical to a gene , $T2$ , ( ref 7,8 ) , implicated in cell-cycle progression .
hTAFII250
CCG1
0
This largest TAF may therefore play a central role in $T1$ assembly by interacting with both $T2$ and other TAFs , as well as serving to link the control of transcription to the cell cycle .
TFIID
TBP
0
Based on the structure of the closely related lymphotoxin alpha-tumor necrosis factor receptor I complex , a molecular model of the $T1$ homotrimer bound to three $T2$ molecules was generated using knowledge-based protein modeling methods .
FasL
Fas
1
Although the cytotoxic activity of mutant Y218D was unaltered , mutant Y218R was inactive , correlating with the prediction that Tyr-218 of $T1$ interacts with a cluster of three basic amino acid side chains of $T2$ .
FasL
Fas
1
The death-inducing receptor Fas is activated when cross-linked by the type II membrane protein $T1$ ligand ( $T2$ ) .
Fas
FasL
1
Based on the structure of the closely related $T1$-$T2$ complex , a molecular model of the FasL homotrimer bound to three Fas molecules was generated using knowledge-based protein modeling methods .
lymphotoxin alpha
tumor necrosis factor receptor I
1
The death-inducing receptor $T1$ is activated when cross-linked by the type II membrane protein $T2$ ( FasL ) .
Fas
Fas ligand
1
The death-inducing receptor $T1$ is activated when cross-linked by the type II membrane protein Fas ligand ( $T2$ ) .
Fas
FasL
1
Characterization of Fas ( $T1$ , CD95 ) -$T2$ interaction .
Apo-1
Fas ligand
1
Characterization of Fas ( Apo-1 , $T1$ ) -$T2$ interaction .
CD95
Fas ligand
1
Characterization of $T1$ ( Apo-1 , CD95 ) -$T2$ interaction .
Fas
Fas ligand
1
Characterization of $T1$ ( Apo-1 , $T2$ ) -Fas ligand interaction .
Fas
CD95
0
Characterization of $T1$ ( $T2$ , CD95 ) -Fas ligand interaction .
Fas
Apo-1
0
Characterization of $T1$ ( Apo-1 , CD95 ) -$T2$ ligand interaction .
Fas
Fas
0
Characterization of Fas ( $T1$ , $T2$ ) -Fas ligand interaction .
Apo-1
CD95
0
Characterization of Fas ( Apo-1 , $T1$ ) -$T2$ ligand interaction .
CD95
Fas
0
Characterization of Fas ( $T1$ , CD95 ) -$T2$ ligand interaction .
Apo-1
Fas
0
The death-inducing receptor $T1$ is activated when cross-linked by the type II membrane protein $T2$ ligand ( FasL ) .
Fas
Fas
0
The death-inducing receptor Fas is activated when cross-linked by the type II membrane protein $T1$$T2$ ( FasL ) .
Fas
Fas ligand
0
Characterization of Fas ( Apo-1 , CD95 ) -$T1$$T2$ interaction .
Fas
Fas ligand
0
When human soluble $T1$ ( sFasL , containing the extracellular portion ) was expressed in human embryo kidney 293 cells , the three N-linked glycans of each $T2$ monomer were found to be essential for efficient secretion .
FasL
FasL
0
Based on the structure of the closely related $T1$-tumor necrosis factor receptor I complex , a molecular model of the $T2$ homotrimer bound to three Fas molecules was generated using knowledge-based protein modeling methods .
lymphotoxin alpha
FasL
0
Based on the structure of the closely related $T1$-tumor necrosis factor receptor I complex , a molecular model of the FasL homotrimer bound to three $T2$ molecules was generated using knowledge-based protein modeling methods .
lymphotoxin alpha
Fas
0
The death-inducing receptor Fas is activated when cross-linked by the type II membrane protein $T1$ ( $T2$ ) .
Fas ligand
FasL
0
Based on the structure of the closely related lymphotoxin alpha-$T1$ complex , a molecular model of the $T2$ homotrimer bound to three Fas molecules was generated using knowledge-based protein modeling methods .
tumor necrosis factor receptor I
FasL
0
Based on the structure of the closely related lymphotoxin alpha-$T1$ complex , a molecular model of the FasL homotrimer bound to three $T2$ molecules was generated using knowledge-based protein modeling methods .
tumor necrosis factor receptor I
Fas
0
Mutants P206R , P206D , and P206F displayed reduced cytotoxicity toward $T1$-positive cells with a concomitant decrease in the binding affinity for the recombinant $T2$-immunoglobulin Fc fusion proteins .
Fas
Fas
0
Unlabeled $T1$ and TNF-beta were equally effective at displacing the binding of labeled $T2$ to TNF-R expressing cells .
TNF-alpha
TNF-alpha
0
Unlabeled TNF-alpha and $T1$ were equally effective at displacing the binding of labeled $T2$ to TNF-R expressing cells .
TNF-beta
TNF-alpha
0
Unlabeled $T1$ and $T2$ were equally effective at displacing the binding of labeled TNF-alpha to TNF-R expressing cells .
TNF-alpha
TNF-beta
0
The extracellular cysteine-rich domain of the TNF-R is homologous to the nerve growth factor receptor and the $T1$ $T2$ .
B cell activation protein
Bp50
0
Scatchard analysis of in vitro binding between Raf/330 and G beta gamma revealed an affinity of interaction ( Kd = 163 +/- 36 nM ) , similar to that seen between $T1$ and $T2$ ( Kd = 87 +/- 24 nM ) .
G beta gamma
beta ARK
1
In vivo complexes of $T1$ and $T2$ were isolated from human embryonic kidney 293-T cells transfected with epitope-tagged G beta 2 .
Raf-1
G beta gamma
1
In competition experiments , the carboxyl terminus of beta-adrenergic receptor kinase ( beta ARK ) blocked the binding of G beta gamma to Raf/330 ; however , the $T1$-binding proteins , $T2$ and 14-3-3 , had no effect .
Raf-1
Ras
1
Scatchard analysis of in vitro binding between $T1$ and $T2$ revealed an affinity of interaction ( Kd = 163 +/- 36 nM ) , similar to that seen between G beta gamma and beta ARK ( Kd = 87 +/- 24 nM ) .
Raf/330
G beta gamma
1
In vitro , purified $T1$ subunits specifically bound to a GST fusion protein encoding amino acids 1-330 of Raf-1 ( $T2$ ) .
G beta gamma
Raf/330
1
In competition experiments , the carboxyl terminus of beta-adrenergic receptor kinase ( beta ARK ) blocked the binding of $T1$ to $T2$ ; however , the Raf-1-binding proteins , Ras and 14-3-3 , had no effect .
G beta gamma
Raf/330
1
Using a yeast two-hybrid strategy to identify other proteins that interact with and potentially regulate $T1$ , we isolated a clone encoding the carboxyl-terminal half of the $T2$ of heterotrimeric G-proteins .
Raf-1
G beta 2 subunit
1
In vitro , purified $T1$ subunits specifically bound to a GST fusion protein encoding amino acids 1-330 of $T2$ ( Raf/330 ) .
G beta gamma
Raf-1
1
A direct interaction between $T1$ subunits and the $T2$ .
G-protein beta gamma
Raf-1 protein kinase
1
Raf-1 is a serine/threonine protein kinase positioned downstream of $T1$ in the $T2$ cascade .
Ras
mitogen-activated protein kinase
0
$T1$ is a serine/threonine protein kinase positioned downstream of $T2$ in the mitogen-activated protein kinase cascade .
Raf-1
Ras
0
$T1$ is a serine/threonine protein kinase positioned downstream of Ras in the $T2$ cascade .
Raf-1
mitogen-activated protein kinase
0
In vivo complexes of Raf-1 and $T1$ were isolated from human embryonic kidney 293-T cells transfected with epitope-tagged $T2$ .
G beta gamma
G beta 2
0
In vivo complexes of $T1$ and G beta gamma were isolated from human embryonic kidney 293-T cells transfected with epitope-tagged $T2$ .
Raf-1
G beta 2
0
In vitro , purified G beta gamma subunits specifically bound to a GST fusion protein encoding amino acids 1-330 of $T1$ ( $T2$ ) .
Raf-1
Raf/330
0
The formation of native heterotrimeric $T1$ complexes , as measured by pertussis toxin ADP-ribosylation of G alpha , could be disrupted by increasing amounts of $T2$ , with an EC50 of approximately 200 nM , in close agreement with the estimated binding affinity .
G alpha beta gamma
Raf/330
0
Scatchard analysis of in vitro binding between Raf/330 and $T1$ revealed an affinity of interaction ( Kd = 163 +/- 36 nM ) , similar to that seen between G beta gamma and $T2$ ( Kd = 87 +/- 24 nM ) .
G beta gamma
beta ARK
0
Scatchard analysis of in vitro binding between $T1$ and G beta gamma revealed an affinity of interaction ( Kd = 163 +/- 36 nM ) , similar to that seen between G beta gamma and $T2$ ( Kd = 87 +/- 24 nM ) .
Raf/330
beta ARK
0
Scatchard analysis of in vitro binding between Raf/330 and $T1$ revealed an affinity of interaction ( Kd = 163 +/- 36 nM ) , similar to that seen between $T2$ and beta ARK ( Kd = 87 +/- 24 nM ) .
G beta gamma
G beta gamma
0
Scatchard analysis of in vitro binding between $T1$ and G beta gamma revealed an affinity of interaction ( Kd = 163 +/- 36 nM ) , similar to that seen between $T2$ and beta ARK ( Kd = 87 +/- 24 nM ) .
Raf/330
G beta gamma
0
Binding assays with truncation mutants of GST-$T1$ indicate that the region located between amino acids 136 and 239 is a primary determinant for interaction with $T2$ .
Raf
G beta gamma
0
In competition experiments , the carboxyl terminus of $T1$ ( $T2$ ) blocked the binding of G beta gamma to Raf/330 ; however , the Raf-1-binding proteins , Ras and 14-3-3 , had no effect .
beta-adrenergic receptor kinase
beta ARK
0
In competition experiments , the carboxyl terminus of $T1$ ( beta ARK ) blocked the binding of $T2$ to Raf/330 ; however , the Raf-1-binding proteins , Ras and 14-3-3 , had no effect .
beta-adrenergic receptor kinase
G beta gamma
0
In competition experiments , the carboxyl terminus of $T1$ ( beta ARK ) blocked the binding of G beta gamma to $T2$ ; however , the Raf-1-binding proteins , Ras and 14-3-3 , had no effect .
beta-adrenergic receptor kinase
Raf/330
0
In competition experiments , the carboxyl terminus of $T1$ ( beta ARK ) blocked the binding of G beta gamma to Raf/330 ; however , the $T2$-binding proteins , Ras and 14-3-3 , had no effect .
beta-adrenergic receptor kinase
Raf-1
0
In competition experiments , the carboxyl terminus of $T1$ ( beta ARK ) blocked the binding of G beta gamma to Raf/330 ; however , the Raf-1-binding proteins , $T2$ and 14-3-3 , had no effect .
beta-adrenergic receptor kinase
Ras
0
In competition experiments , the carboxyl terminus of beta-adrenergic receptor kinase ( $T1$ ) blocked the binding of $T2$ to Raf/330 ; however , the Raf-1-binding proteins , Ras and 14-3-3 , had no effect .
beta ARK
G beta gamma
0
In competition experiments , the carboxyl terminus of beta-adrenergic receptor kinase ( $T1$ ) blocked the binding of G beta gamma to $T2$ ; however , the Raf-1-binding proteins , Ras and 14-3-3 , had no effect .
beta ARK
Raf/330
0
In competition experiments , the carboxyl terminus of beta-adrenergic receptor kinase ( $T1$ ) blocked the binding of G beta gamma to Raf/330 ; however , the $T2$-binding proteins , Ras and 14-3-3 , had no effect .
beta ARK
Raf-1
0
In competition experiments , the carboxyl terminus of beta-adrenergic receptor kinase ( $T1$ ) blocked the binding of G beta gamma to Raf/330 ; however , the Raf-1-binding proteins , $T2$ and 14-3-3 , had no effect .
beta ARK
Ras
0
In competition experiments , the carboxyl terminus of beta-adrenergic receptor kinase ( beta ARK ) blocked the binding of $T1$ to Raf/330 ; however , the $T2$-binding proteins , Ras and 14-3-3 , had no effect .
G beta gamma
Raf-1
0
In competition experiments , the carboxyl terminus of beta-adrenergic receptor kinase ( beta ARK ) blocked the binding of $T1$ to Raf/330 ; however , the Raf-1-binding proteins , $T2$ and 14-3-3 , had no effect .
G beta gamma
Ras
0
In competition experiments , the carboxyl terminus of beta-adrenergic receptor kinase ( beta ARK ) blocked the binding of G beta gamma to $T1$ ; however , the $T2$-binding proteins , Ras and 14-3-3 , had no effect .
Raf/330
Raf-1
0
In competition experiments , the carboxyl terminus of beta-adrenergic receptor kinase ( beta ARK ) blocked the binding of G beta gamma to $T1$ ; however , the Raf-1-binding proteins , $T2$ and 14-3-3 , had no effect .
Raf/330
Ras
0
These data show that $T1$ and $T2$ physically and functionally interact demonstrating that cross-talk occurs between factors of distantly related transcription families .
USF
Fra1
1
Both the bHLHZip and the N-terminal regions of $T1$ are required for efficient interaction with $T2$ .
Fra1
USF
1
In vivo association between $T1$ and $T2$ has been demonstrated by co-immunoprecipitation .
USF
Fra1
1
A bZip protein , $T1$ , was found to efficiently interact with $T2$ .
Fra1
USF
1
$T1$ specifically interacts with $T2$ but not with other closely related family members , c-Fos , Fra2 , FosB , or with c-Jun .
USF
Fra1
1
Cross-family interaction between the bHLHZip $T1$ and bZip $T2$ proteins results in down-regulation of AP1 activity .
USF
Fra1
1
Cross-family interaction between the bHLHZip $T1$ and bZip Fra1 proteins results in down-regulation of $T2$ activity .
USF
AP1
0
Cross-family interaction between the bHLHZip USF and bZip $T1$ proteins results in down-regulation of $T2$ activity .
Fra1
AP1
0
To further examine the function of the bHLHZip protein , $T1$ , we screened for cellular proteins which could directly interact with $T2$ using the yeast two-hybrid system .
USF
USF
0
USF specifically interacts with Fra1 but not with other closely related family members , $T1$ , $T2$ , FosB , or with c-Jun .
c-Fos
Fra2
0
USF specifically interacts with Fra1 but not with other closely related family members , $T1$ , Fra2 , $T2$ , or with c-Jun .
c-Fos
FosB
0
$T1$ specifically interacts with Fra1 but not with other closely related family members , $T2$ , Fra2 , FosB , or with c-Jun .
USF
c-Fos
0
USF specifically interacts with Fra1 but not with other closely related family members , $T1$ , Fra2 , FosB , or with $T2$ .
c-Fos
c-Jun
0
USF specifically interacts with $T1$ but not with other closely related family members , $T2$ , Fra2 , FosB , or with c-Jun .
Fra1
c-Fos
0
USF specifically interacts with Fra1 but not with other closely related family members , c-Fos , $T1$ , $T2$ , or with c-Jun .
Fra2
FosB
0
$T1$ specifically interacts with Fra1 but not with other closely related family members , c-Fos , $T2$ , FosB , or with c-Jun .
USF
Fra2
0
USF specifically interacts with Fra1 but not with other closely related family members , c-Fos , $T1$ , FosB , or with $T2$ .
Fra2
c-Jun
0
USF specifically interacts with $T1$ but not with other closely related family members , c-Fos , $T2$ , FosB , or with c-Jun .
Fra1
Fra2
0
$T1$ specifically interacts with Fra1 but not with other closely related family members , c-Fos , Fra2 , $T2$ , or with c-Jun .
USF
FosB
0
USF specifically interacts with Fra1 but not with other closely related family members , c-Fos , Fra2 , $T1$ , or with $T2$ .
FosB
c-Jun
0
USF specifically interacts with $T1$ but not with other closely related family members , c-Fos , Fra2 , $T2$ , or with c-Jun .
Fra1
FosB
0
$T1$ specifically interacts with Fra1 but not with other closely related family members , c-Fos , Fra2 , FosB , or with $T2$ .
USF
c-Jun
0
USF specifically interacts with $T1$ but not with other closely related family members , c-Fos , Fra2 , FosB , or with $T2$ .
Fra1
c-Jun
0
Expression of exogenous $T1$ led to a decrease in $T2$-dependent transcription in F9 cells .
USF
AP1
0
Co-expression of exogenous $T1$ restored the $T2$ activity in a dose-dependent manner .
Fra1
AP1
0
When transfected into COS cells the cloned cDNA directed the expression of a $T1$ showing a single class of affinity ( KD = 2 ( -8 ) nM ) and specificity for human $T2$ but not interleukin-3 .
GM-CSF-R
GM-CSF
1
Two cDNA clones encoding a receptor for human $T1$ ( $T2$ ) were isolated by expression screening of a library made from human placental mRNA .
granulocyte-macrophage colony-stimulating factor
hGM-CSF-R
1
It does not contain a tyrosine kinase domain nor show homology with members of the immunoglobulin super gene family , but does show some significant sequence homologies with receptors for several other haemopoietic growth factors , including those for $T1$ , erythropoietin and $T2$ ( beta-chain ) and also to the prolactin receptor .
interleukin-6
interleukin-2
0
It does not contain a tyrosine kinase domain nor show homology with members of the immunoglobulin super gene family , but does show some significant sequence homologies with receptors for several other haemopoietic growth factors , including those for interleukin-6 , $T1$ and $T2$ ( beta-chain ) and also to the prolactin receptor .
erythropoietin
interleukin-2
0
When transfected into COS cells the cloned cDNA directed the expression of a $T1$ showing a single class of affinity ( KD = 2 ( -8 ) nM ) and specificity for human GM-CSF but not $T2$ .
GM-CSF-R
interleukin-3
0
It does not contain a tyrosine kinase domain nor show homology with members of the immunoglobulin super gene family , but does show some significant sequence homologies with receptors for several other haemopoietic growth factors , including those for $T1$ , $T2$ and interleukin-2 ( beta-chain ) and also to the prolactin receptor .
interleukin-6
erythropoietin
0
When transfected into COS cells the cloned cDNA directed the expression of a GM-CSF-R showing a single class of affinity ( KD = 2 ( -8 ) nM ) and specificity for human $T1$ but not $T2$ .
GM-CSF
interleukin-3
0
Association of $T1$ with both $T2$ and HSP90 may also imply a mechanistic link between the functions of CDC37 and HSP90 .
CDK4
CDC37
1
Association of $T1$ with both CDC37 and $T2$ may also imply a mechanistic link between the functions of CDC37 and HSP90 .
CDK4
HSP90
1
A physical interaction between $T1$ and $T2$ suggests that CDC37 may regulate the mammalian cell cycle through a direct effect on CDK4 .
CDC37
CDK4
1
A physical interaction between CDC37 and CDK4 suggests that $T1$ may regulate the mammalian cell cycle through a direct effect on $T2$ .
CDC37
CDK4
1
We have detected a specific association of $T1$ with the molecular chaperon $T2$ and a 44-kDa protein that we identify as mammalian CDC37 .
CDK4
HSP90
1
We have detected a specific association of $T1$ with the molecular chaperon HSP90 and a 44-kDa protein that we identify as mammalian $T2$ .
CDK4
CDC37
1
Physical interaction of mammalian $T1$ with $T2$ .CDC37 was originally identified as a Start gene in budding yeast and has been shown to be required for association of CDC28 with cyclins .
CDC37
CDK4
1
Physical interaction of mammalian $T1$ with CDK4 $T2$ was originally identified as a Start gene in budding yeast and has been shown to be required for association of CDC28 with cyclins .
CDC37
.CDC37
0
Physical interaction of mammalian $T1$ with CDK4 .CDC37 was originally identified as a Start gene in budding yeast and has been shown to be required for association of $T2$ with cyclins .
CDC37
CDC28
0
Physical interaction of mammalian CDC37 with $T1$ $T2$ was originally identified as a Start gene in budding yeast and has been shown to be required for association of CDC28 with cyclins .
CDK4
.CDC37
0
Physical interaction of mammalian CDC37 with CDK4 $T1$ was originally identified as a Start gene in budding yeast and has been shown to be required for association of $T2$ with cyclins .
.CDC37
CDC28
0
Physical interaction of mammalian CDC37 with $T1$ .CDC37 was originally identified as a Start gene in budding yeast and has been shown to be required for association of $T2$ with cyclins .
CDK4
CDC28
0
$T1$ is a $T2$ that controls progression through G1 of the mammalian cell cycle .
CDK4
cyclin D-dependent kinase
0
We have detected a specific association of CDK4 with the molecular chaperon $T1$ and a 44-kDa protein that we identify as mammalian $T2$ .
HSP90
CDC37
0
A physical interaction between $T1$ and CDK4 suggests that $T2$ may regulate the mammalian cell cycle through a direct effect on CDK4 .
CDC37
CDC37
0
A physical interaction between $T1$ and CDK4 suggests that CDC37 may regulate the mammalian cell cycle through a direct effect on $T2$ .
CDC37
CDK4
0
A physical interaction between CDC37 and $T1$ suggests that $T2$ may regulate the mammalian cell cycle through a direct effect on CDK4 .
CDK4
CDC37
0
A physical interaction between CDC37 and $T1$ suggests that CDC37 may regulate the mammalian cell cycle through a direct effect on $T2$ .
CDK4
CDK4
0
Association of $T1$ with both CDC37 and HSP90 may also imply a mechanistic link between the functions of $T2$ and HSP90 .
CDK4
CDC37
0
Association of $T1$ with both CDC37 and HSP90 may also imply a mechanistic link between the functions of CDC37 and $T2$ .
CDK4
HSP90
0
Association of CDK4 with both $T1$ and $T2$ may also imply a mechanistic link between the functions of CDC37 and HSP90 .
CDC37
HSP90
0
Association of CDK4 with both $T1$ and HSP90 may also imply a mechanistic link between the functions of $T2$ and HSP90 .
CDC37
CDC37
0
Association of CDK4 with both $T1$ and HSP90 may also imply a mechanistic link between the functions of CDC37 and $T2$ .
CDC37
HSP90
0
Association of CDK4 with both CDC37 and $T1$ may also imply a mechanistic link between the functions of $T2$ and HSP90 .
HSP90
CDC37
0
Association of CDK4 with both CDC37 and $T1$ may also imply a mechanistic link between the functions of CDC37 and $T2$ .
HSP90
HSP90
0
Association of CDK4 with both CDC37 and HSP90 may also imply a mechanistic link between the functions of $T1$ and $T2$ .
CDC37
HSP90
0
Comparison of the two crystallographically distinct protein-DNA complexes show that the coiled-coil is flexibly joined to the basic regions and that the $T1$-$T2$ heterodimer does not recognize the asymmetric 5'-TGAGTCA-3 ' recognition element in a unique orientation .
Fos
Jun
1
The $T1$ and $T2$ families of eukaryotic transcription factors heterodimerize to form complexes capable of binding 5'-TGAGTCA-3 ' DNA elements .
Fos
Jun
1
We have determined the X-ray crystal structure of a heterodimer of the bZIP regions of $T1$ and $T2$ bound to DNA .
c-Fos
c-Jun
1
Crystal structure of the heterodimeric bZIP transcription factor $T1$-$T2$ bound to DNA .
c-Fos
c-Jun
1
Moreover , mutation of $T1$ residues 143-145 impairs binding of 14-3-3 , but not $T2$ , to the Raf-CRD .
Raf-1
Ras
1
Moreover , mutation of $T1$ residues 143-145 impairs binding of 14-3-3 , but not Ras , to the $T2$ .
Raf-1
Raf-CRD
1
We recently reported that $T1$ interaction with the Raf-1 cysteine-rich domain ( $T2$ , residues 139-184 ) may be required for Raf-1 activation .
Ras
Raf-CRD
1
In the present study , we demonstrate that $T1$ binds directly to the isolated $T2$ .
14-3-3 zeta
Raf-CRD
1
$T1$ negatively regulates raf-1 activity by interactions with the $T2$ cysteine-rich domain .
14-3-3 zeta
Raf-1
1
We recently reported that $T1$ interaction with the $T2$ ( Raf-CRD , residues 139-184 ) may be required for Raf-1 activation .
Ras
Raf-1 cysteine-rich domain
1
$T1$ negatively regulates $T2$ activity by interactions with the Raf-1 cysteine-rich domain .
14-3-3 zeta
raf-1
1
Although Raf-1 is a critical effector of Ras signaling and transformation , the mechanism by which $T1$ promotes $T2$ activation is complex and remains poorly understood .
Ras
Raf-1
0
Although $T1$ is a critical effector of Ras signaling and transformation , the mechanism by which $T2$ promotes Raf-1 activation is complex and remains poorly understood .
Raf-1
Ras
0
Although Raf-1 is a critical effector of $T1$ signaling and transformation , the mechanism by which $T2$ promotes Raf-1 activation is complex and remains poorly understood .
Ras
Ras
0
Although $T1$ is a critical effector of Ras signaling and transformation , the mechanism by which Ras promotes $T2$ activation is complex and remains poorly understood .
Raf-1
Raf-1
0
Although Raf-1 is a critical effector of $T1$ signaling and transformation , the mechanism by which Ras promotes $T2$ activation is complex and remains poorly understood .
Ras
Raf-1
0
Although $T1$ is a critical effector of $T2$ signaling and transformation , the mechanism by which Ras promotes Raf-1 activation is complex and remains poorly understood .
Raf-1
Ras
0
Thus , 14-3-3 interaction with the Raf-CRD may serve in negative regulation of Raf-1 function by facilitating dissociation of 14-3-3 from the NH2 terminus of $T1$ to promote subsequent events necessary for full activation of $T2$ .
Raf-1
Raf-1
0
Thus , 14-3-3 interaction with the Raf-CRD may serve in negative regulation of $T1$ function by facilitating dissociation of 14-3-3 from the NH2 terminus of Raf-1 to promote subsequent events necessary for full activation of $T2$ .
Raf-1
Raf-1
0
Thus , 14-3-3 interaction with the $T1$ may serve in negative regulation of Raf-1 function by facilitating dissociation of 14-3-3 from the NH2 terminus of Raf-1 to promote subsequent events necessary for full activation of $T2$ .
Raf-CRD
Raf-1
0
Thus , 14-3-3 interaction with the Raf-CRD may serve in negative regulation of $T1$ function by facilitating dissociation of 14-3-3 from the NH2 terminus of $T2$ to promote subsequent events necessary for full activation of Raf-1 .
Raf-1
Raf-1
0
Thus , 14-3-3 interaction with the $T1$ may serve in negative regulation of Raf-1 function by facilitating dissociation of 14-3-3 from the NH2 terminus of $T2$ to promote subsequent events necessary for full activation of Raf-1 .
Raf-CRD
Raf-1
0
We recently reported that $T1$ interaction with the $T2$ cysteine-rich domain ( Raf-CRD , residues 139-184 ) may be required for Raf-1 activation .
Ras
Raf-1
0
We recently reported that $T1$ interaction with the Raf-1 cysteine-rich domain ( Raf-CRD , residues 139-184 ) may be required for $T2$ activation .
Ras
Raf-1
0
Thus , 14-3-3 interaction with the $T1$ may serve in negative regulation of $T2$ function by facilitating dissociation of 14-3-3 from the NH2 terminus of Raf-1 to promote subsequent events necessary for full activation of Raf-1 .
Raf-CRD
Raf-1
0
We recently reported that Ras interaction with the $T1$$T2$ ( Raf-CRD , residues 139-184 ) may be required for Raf-1 activation .
Raf-1
Raf-1 cysteine-rich domain
0
We recently reported that Ras interaction with the $T1$ cysteine-rich domain ( $T2$ , residues 139-184 ) may be required for Raf-1 activation .
Raf-1
Raf-CRD
0
We recently reported that Ras interaction with the $T1$ cysteine-rich domain ( Raf-CRD , residues 139-184 ) may be required for $T2$ activation .
Raf-1
Raf-1
0
Moreover , mutation of Raf-1 residues 143-145 impairs binding of 14-3-3 , but not $T1$ , to the $T2$ .
Ras
Raf-CRD
0
14-3-3 zeta negatively regulates $T1$ activity by interactions with the $T2$ cysteine-rich domain .
raf-1
Raf-1
0
We recently reported that Ras interaction with the $T1$ ( $T2$ , residues 139-184 ) may be required for Raf-1 activation .
Raf-1 cysteine-rich domain
Raf-CRD
0
We recently reported that Ras interaction with the $T1$ ( Raf-CRD , residues 139-184 ) may be required for $T2$ activation .
Raf-1 cysteine-rich domain
Raf-1
0
We recently reported that Ras interaction with the Raf-1 cysteine-rich domain ( $T1$ , residues 139-184 ) may be required for $T2$ activation .
Raf-CRD
Raf-1
0
The $T1$ is located in the NH2-terminal negative regulatory domain of $T2$ and is highly homologous to cysteine-rich domains found in protein kinase C family members .
Raf-CRD
Raf-1
0
Recent studies indicate that the structural integrity of the $T1$ is also critical for $T2$ interaction with 14-3-3 proteins .
Raf-CRD
Raf-1
0
However , whether 14-3-3 proteins interact directly with the $T1$ and how this interaction may mediate $T2$ function has not been determined .
Raf-CRD
Raf-1
0
This protein , designated $T1$ ( VRP ) , specifically binds to the extracellular domain of $T2$ , stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells , and promotes the mitogenesis of human lung endothelial cells .
VEGF-related protein
Flt4
1
This protein , designated VEGF-related protein ( $T1$ ) , specifically binds to the extracellular domain of $T2$ , stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells , and promotes the mitogenesis of human lung endothelial cells .
VRP
Flt4
1
Flt1 and $T1$ have been shown to play key roles in vascular development ; these two receptors bind and are activated by $T2$ ( VEGF ) .
Flk1
vascular endothelial growth factor
1
Flt1 and $T1$ have been shown to play key roles in vascular development ; these two receptors bind and are activated by vascular endothelial growth factor ( $T2$ ) .
Flk1
VEGF
1
$T1$ and Flk1 have been shown to play key roles in vascular development ; these two receptors bind and are activated by $T2$ ( VEGF ) .
Flt1
vascular endothelial growth factor
1
$T1$ and Flk1 have been shown to play key roles in vascular development ; these two receptors bind and are activated by vascular endothelial growth factor ( $T2$ ) .
Flt1
VEGF
1
$T1$ : a ligand and specific activator of the tyrosine kinase receptor $T2$ .
Vascular endothelial growth factor-related protein
Flt4
1
$T1$-related protein : a ligand and specific activator of the tyrosine kinase receptor $T2$ .
Vascular endothelial growth factor
Flt4
0
$T1$$T2$ : a ligand and specific activator of the tyrosine kinase receptor Flt4 .
Vascular endothelial growth factor
Vascular endothelial growth factor-related protein
0
The tyrosine kinases Flt4 , Flt1 , and $T1$ ( or $T2$ ) constitute a family of endothelial cell-specific receptors with seven immunoglobulin-like domains and a split kinase domain .
Flk1
KDR
0
The tyrosine kinases $T1$ , Flt1 , and $T2$ ( or KDR ) constitute a family of endothelial cell-specific receptors with seven immunoglobulin-like domains and a split kinase domain .
Flt4
Flk1
0
The tyrosine kinases Flt4 , $T1$ , and $T2$ ( or KDR ) constitute a family of endothelial cell-specific receptors with seven immunoglobulin-like domains and a split kinase domain .
Flt1
Flk1
0
The tyrosine kinases $T1$ , Flt1 , and Flk1 ( or $T2$ ) constitute a family of endothelial cell-specific receptors with seven immunoglobulin-like domains and a split kinase domain .
Flt4
KDR
0
The tyrosine kinases Flt4 , $T1$ , and Flk1 ( or $T2$ ) constitute a family of endothelial cell-specific receptors with seven immunoglobulin-like domains and a split kinase domain .
Flt1
KDR
0
The tyrosine kinases $T1$ , $T2$ , and Flk1 ( or KDR ) constitute a family of endothelial cell-specific receptors with seven immunoglobulin-like domains and a split kinase domain .
Flt4
Flt1
0
Flt1 and Flk1 have been shown to play key roles in vascular development ; these two receptors bind and are activated by $T1$ ( $T2$ ) .
vascular endothelial growth factor
VEGF
0
$T1$ and $T2$ have been shown to play key roles in vascular development ; these two receptors bind and are activated by vascular endothelial growth factor ( VEGF ) .
Flt1
Flk1
0
This protein , designated $T1$$T2$ ( VRP ) , specifically binds to the extracellular domain of Flt4 , stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells , and promotes the mitogenesis of human lung endothelial cells .
VEGF
VEGF-related protein
0
This protein , designated $T1$-related protein ( $T2$ ) , specifically binds to the extracellular domain of Flt4 , stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells , and promotes the mitogenesis of human lung endothelial cells .
VEGF
VRP
0
This protein , designated $T1$-related protein ( VRP ) , specifically binds to the extracellular domain of $T2$ , stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells , and promotes the mitogenesis of human lung endothelial cells .
VEGF
Flt4
0
This protein , designated $T1$-related protein ( VRP ) , specifically binds to the extracellular domain of Flt4 , stimulates the tyrosine phosphorylation of $T2$ expressed in mammalian cells , and promotes the mitogenesis of human lung endothelial cells .
VEGF
Flt4
0
This protein , designated $T1$ ( $T2$ ) , specifically binds to the extracellular domain of Flt4 , stimulates the tyrosine phosphorylation of Flt4 expressed in mammalian cells , and promotes the mitogenesis of human lung endothelial cells .
VEGF-related protein
VRP
0
This protein , designated $T1$ ( VRP ) , specifically binds to the extracellular domain of Flt4 , stimulates the tyrosine phosphorylation of $T2$ expressed in mammalian cells , and promotes the mitogenesis of human lung endothelial cells .
VEGF-related protein
Flt4
0
This protein , designated VEGF-related protein ( $T1$ ) , specifically binds to the extracellular domain of Flt4 , stimulates the tyrosine phosphorylation of $T2$ expressed in mammalian cells , and promotes the mitogenesis of human lung endothelial cells .
VRP
Flt4
0
This protein , designated VEGF-related protein ( VRP ) , specifically binds to the extracellular domain of $T1$ , stimulates the tyrosine phosphorylation of $T2$ expressed in mammalian cells , and promotes the mitogenesis of human lung endothelial cells .
Flt4
Flt4
0
$T1$ fails to bind appreciably to the extracellular domain of Flt1 or $T2$ .
VRP
Flk1
0
VRP fails to bind appreciably to the extracellular domain of $T1$ or $T2$ .
Flt1
Flk1
0
$T1$ fails to bind appreciably to the extracellular domain of $T2$ or Flk1 .
VRP
Flt1
0
